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Abstract 
 
Proteins are often regulated through the addition of chemical modifications that 
modulate localization, activity, and interactions. Protein S-palmitoylation describes the 
attachment of long-chain fatty acids to cysteine residues in proteins to promote 
membrane association, which contributes to the regulation of a number of cellular 
processes. Altered S-palmitoylation contributes to the pathogenesis of neurological 
disorders, cancer, and many other diseases. Importantly, dynamic S-palmitoylation is 
required to modulate the activity of proteins in response to various extracellular 
signaling events. This includes various membrane-associated or membrane proteins 
such as G proteins, small GTPases, receptors, scaffold proteins, cytoskeletal proteins, 
and kinases. These observations suggest that enzymes catalyzing the removal of 
palmitate must also play a critical role in modulating the activity of hundreds of essential 
proteins. Therefore, it is important to characterize how S-palmitoylation is regulated, 
which will provide a more complete molecular picture of how cells adjust to various 
signaling events. Over the last decade, potent inhibitors of depalmitoylases have been 
developed, yet the basic mechanisms and the cellular functions of depalmitoylases 
remain poorly characterized. Since depalmitoylation can modulate select cell signaling 
events, I hypothesized that depalmitoylase enzymes have dedicated substrates and 
differentially contribute to the global dynamic S-palmitoylation regulation. My 
dissertation addresses this hypothesis by focusing on the structure, function, and 
inhibition of the depalmitoylating enzymes APT1 and APT2. The first chapter of this 
thesis provides an overview of depalmitoylating enzymes. Second, I used isoform-
selective inhibitors to understand the structure, substrate engagement and selectivity of 
APT1 and APT2. Third, I validated the selectivity of the APT2 inhibitor ML349 by affinity 
enrichment and proteomics. Finally, I explore the dynamic rate of palmitoylation 
regulated by depalmitoylases in cells. Overall, my research has clarified the mechanism 
and function of protein de-palmitoylation in cell regulation. 
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Chapter 1 : Protein Depalmitoylases* 
 
Abstract 
Protein depalmitoylation describes the removal of thioester-linked long chain fatty acids 
from cysteine residues in proteins. For many S-palmitoylated proteins, this process is 
promoted by acyl protein thioesterase enzymes, which catalyze thioester hydrolysis to 
solubilize and displace substrate proteins from membranes (Figure 1.1). The closely 
related enzymes acyl protein thioesterase 1 (APT1; LYPLA1) and acyl protein 
thioesterase 2 (APT2; LYPLA2) were initially identified from biochemical assays as G 
protein depalmitoylases, yet later were shown to accept a number of S-palmitoylated 
protein and phospholipid substrates. Leveraging the development of isoform-selective 
APT inhibitors, several studies report distinct roles for APT enzymes in growth factor 
and hormonal signaling. Recent crystal structures of APT1 and APT2 reveal convergent 
acyl binding channels, suggesting additional factors beyond acyl chain recognition 
mediate substrate selection. In addition to APT enzymes, the ABHD17 family of 
hydrolases contributes to the depalmitoylation of Ras-family GTPases and synaptic 
proteins. Overall, enzymatic depalmitoylation ensures efficient membrane targeting by 
balancing the palmitoylation cycle, and may play additional roles in signaling, growth, 
and cell organization. In this chapter, we provide a perspective on the biochemical, 
structural, and cellular analysis of protein depalmitoylases, and outline opportunities for 
future studies of systems-wide analysis of protein depalmitoylation. 
                                             
* This chapter presents a published peer-reviewed review article. Won S. J. et al Crit Rev Biochem Mol Biol. 2018 
53(1):83-98 
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Figure 1.1 Graphical abstract showing depalmitoylation event mediated by a thioesterase. 
(A) A cartoon showing localization of palmitoylated substrate before and after hydrolysis by a thioesterase. (B) A 
generic chemical mechanism of serine hydrolase in action. 
 
Introduction 
S-Palmitoylation describes the addition of a long-chain fatty acid to a cysteine 
residue via a thioester linkage.1 This hydrophobic post-translational modification 
promotes the membrane tethering, trafficking, and localization of a significant fraction of 
membrane-associated proteins. While the term “S-palmitoylation” implies exclusive 
modification by 16:0 fatty acids, the cellular profile of fatty acylated cysteine residues 
likely includes a variety of long chain fatty acids with differing unsaturation,2-4 and is 
interchangeably used with the term “S-acylation”. Protein S-palmitoylation is catalyzed 
by a family of protein acyl transferases, termed zDHHC enzymes due to their predicted 
Zn2+-binding and conserved Asp-His-His-Cys motif.5-7 These multipass transmembrane 
proteins catalyze acyl transfer from long chain fatty acyl-CoAs to cysteine residues in 
proteins. Humans express 23 zDHHC enzymes that influence many diverse cellular 
pathways. For example, zDHHC5 deletion blocks neuronal stem cell differentiation,8 
and along with its close homologue zDHHC8, localize to synapses in neurons9 where 
they influence activity-dependent endocytic trafficking, excitability, and synaptic 
connectivity.10 In addition, zDHHC2 palmitoylates Src-family kinases,11 while inhibition 
of close homologue zDHHC20 prevents EGFR S-palmitoylation and enhances the 
action of EGFR inhibitors.12 zDHHC9 is reported to S-palmitoylate Ras,13, 14 and is 
 3 
genetically linked to X-linked mental retardation.15 Across dozens of publications, 
zDHHC enzymes have emerged as critical regulators of protein S-palmitoylation and 
membrane targeting.1, 16  
Perhaps the most intriguing aspect S-palmitoylation is its reversibility, since 
thioester hydrolysis eliminates the fatty acyl anchor to modulate membrane localization 
and/or function. For example, cycles of acylation and deacylation are required for the 
plasma membrane association of Ras-family small GTPases and G proteins,17-19 
establishing a distinct mode of peripheral membrane protein directionality dependent on 
a continuous palmitoylation cycle.20, 21 Indeed, pharmacological inhibition with 
promiscuous inhibitors of either zDHHC PATs or depalmitoylases block the plasma 
membrane targeting of Ras and G proteins.20, 22, 23 Microinjection of semi-synthetic 
fluorescently-labeled S-palmitoylated Ras rapidly redistributes to the golgi, which is 
established as the destination of depalmitoylated Ras.21 Based on these findings, 
peripheral membrane protein S-palmitoylation requires a balanced cycle of both zDHHC 
enzymes and depalmitoylating enzymes for efficient transport along the flux of the 
secretory pathway towards the plasma membrane.20 Furthermore, both Ras and G 
proteins are rapidly depalmitoylated in their GTP-bound state,24-26 which coincides, but 
is not required for agonist dependent-internalization to internal membranes.23 Based on 
these examples, constitutive protein S-palmitoylation is required for proper trafficking of 
many peripheral membrane proteins, but may also function as a reversible signal 
analogous to protein phosphorylation (Figure 1.2). For example, serum, growth factor, 
or phorbol ester addition triggers deacylation of a 64 kD protein in [3H]-palmitate labeled 
mouse BH3C1 cells,27 which in light of more recent proteomics studies,28 likely 
corresponds to depalmitoylation of Metadherin, a major driver of cancer and 
metastasis.29 Therefore, external stimuli trigger either direct activation of 
depalmitoylases, or facilitate conformational changes that enhance depalmitoylase 
accessibility, which then tip the balance of the palmitoylation cycle to reorganize 
membrane distribution and signaling outputs. 
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Figure 1.2 Cellular pathways of protein depalmitoylation.  
Protein depalmitoylation can proceed by either non-enzymatic hydrolysis, inducible depalmitoylation, or constitutive 
depalmitoylation during trafficking. zDHHC enzymes are shown as transmembrane proteins. 
 
While this model is appealing, a number of fundamental questions remain, such 
as 1) what enzymes catalyze depalmitoylation of different S-palmitoylated proteins, 2) 
what, if anything, triggers their activation, and 3) is there a coincident dysregulation of 
protein acyl transferase enzymes to block re-palmitoylation? In addition to peripheral 
membrane proteins, many integral membrane proteins such as channels, receptors, 
and adhesion proteins also require S-palmitoylation for proper activation, sensitization, 
or microdomain localization. Given the ever-expanding number of bona fide S-
palmitoylated proteins,30 how broad is the role for depalmitoylases in regulating S-
palmitoylation stability? What is the scope of enzymatic depalmitoylation compared with 
the intrinsic hydrolysis of the high-energy thioester linkage? Through the development 
of new methods and model systems, these questions are central to understanding the 
role of dynamic S-palmitoylation in physiological systems. 
Assays for depalmitoylation 
Protein S-palmitoylation was first reported nearly 40 years ago,31 but even the 
most basic experiments were hindered by the limitations of [3H]-palmitate labeling. The 
low radioactivity and incorporation efficiency typically required weeks to return results 
for a single experiment.32 Furthermore, assaying [3H]-palmitate incorporation requires 
immunoprecipitation of a single protein, limiting the scope of the analysis to only specific 
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hypotheses. Nonetheless, [3H]-palmitate metabolic labeling is the most accepted 
method for studying S-palmitoylation, particularly for measuring stability in pulse-chase 
assays. In this approach, cells are labeled with [3H]-palmitate for a fixed amount of time, 
followed by washes and incubation in media supplemented with excess unlabeled 
palmitic acid.32 After immunoprecipitation and SDS-PAGE, the rate of palmitate turnover 
on a specific protein can be quantified by autoradiography. Through such analysis, the 
rate of protein S-palmitoylation turnover is generally faster than the rate of protein 
turnover, establishing that multiple S-palmitoylation and depalmitoylation events occur 
throughout the lifetime of an S-palmitoylated protein.28 Thus, different PATs and APT 
enzymes may function at different stages of protein trafficking to promote plasma 
membrane delivery and residency. 
The recent development of non-radioactive detection methods has rejuvenated 
interest in S-palmitoylation, providing simple methods that accelerate the identification 
and quantitation of S-palmitoylated proteins.33, 34 The primary method for biochemical 
analysis of S-palmitoylation uses hydroxylamine to hydrolyze all thioesters across the 
proteome, followed by capture of the newly liberated thiols.35-37 These hydroxylamine-
switch methods begin with reduction of disulfides with tris(2-carboxyethyl)phosphine 
(TCEP), followed by treatment with maleimide to alkylate all reduced thiols. Next, 
neutral hydroxylamine is added to hydrolyze thioesters, which coincidentally hydrolyzes 
other mechanistic protein-linked thioesters including ubiquitin ligases and lipoamide-
dependent dehydrogenases. Any hydroxylamine sensitive thiols are then captured using 
a pyridyl-disulfide biotin conjugate for streptavidin-resin enrichment (biotin-exchange) or 
captured directly with pyridyl-disulfide resin (Acyl-resin assisted capture; Acyl-RAC) for 
further analysis.38 Pyridyl-disulfide resin capture has at least three advantages. First, it 
limits capture to hydroxylamine-sensitive thioesters, and does not capture products from 
other ester or other functional groups. Second, the captured disulfide adduct is easily 
reversible by TCEP, allowing simple elution for gel-based or proteomic analysis of site-
specific S-palmitoylation. Finally, since these methods avoid metabolic labeling, primary 
tissues can be readily analyzed to provide a snapshot of the steady state levels of S-
palmitoylation. Most importantly, biotin-exchange and acyl-RAC have enabled mass 
spectrometry-based discovery and analysis across hundreds of S-palmitoylated 
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proteins, allowing correlated annotation of the exact sites of S-palmitoylation.38 Such 
large-scale profiling efforts provide long lists of putative S-palmitoylated proteins, which 
warrant additional biochemical validation. This is somewhat mitigated by the S-
palmitoylation database SwissPalm,30 which provides a searchable platform to qualify 
candidates across published datasets and compare data from distinct experimental 
systems, enrichment methods, and laboratories. 
The commercially available alkynyl fatty acid derivative 17-octadecynoic acid (17-
ODYA) provides a second non-radioactive approach for detecting S-palmitoylation.34, 39, 
40 After addition to the cell culture media, cells process the free alkynyl fatty acid to form 
the coenzyme A (CoA) conjugate, which then serves as a substrate for enzymatic 
transfer to endogenous sites of S-palmitoylation. Cells collected at different time points 
are then lysed and conjugated by copper-catalyzed azide alkyne cycloaddition (CuAAC) 
to reporter-linked azides (fluorophores or biotin) for gel-based or mass spectrometry 
analysis. Saturated incorporation typically occurs in a few hours, although shorter time 
points can probe more rapid acylation events. For mass spectrometry-based analysis, 
lysates are conjugated to biotin-azide for streptavidin enrichment, and comparative 
mass spectrometry is performed using hydroxylamine-treated or palmitic acid treated 
samples as controls. Additional precautions are necessary to prevent thioesterase 
hydrolysis during sample preparation, including addition of generic esterase inhibitors, 
limited total sample processing time, and careful monitoring of the pH of all reagents.41 
Several proteomic studies report bioorthogonal alkynyl-fatty acid labeling for profiling S-
palmitoylation, including analyses in immune cells,8, 28, 42 epithelial cells,43 and 
protozoa.44, 45 Importantly, alkynyl-fatty acid labeling provides a natural complement to 
hydroxylamine-switch methods, establishing two distinct enrichment methods for more 
confident analysis. 
Alkynyl-fatty acid metabolic labeling has opened new opportunities for non-
radioactive profiling of dynamic changes in S-palmitoylation. For example, Lck S-
palmitoylation turnover in Jurkat T-cells was assayed using alkynyl-fatty acid pulse-
chase methods and quantified by in-gel fluorescence.46 Surprisingly, Lck 
depalmitoylation was accelerated after treatment with the phosphatase inhibitor 
pervanadate, yet stabilized by incubation with the non-selective hydrolase inhibitor 
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methyl arachidonyl fluorophosphonate (MAFP). Thus, activated T-cells increase Lck S-
palmitoylation cycling, which is dependent on one or more MAFP-sensitive thioesterase 
enzymes.  
Using similar pulse-chase methods, proteome-wide S-palmitoylation dynamics 
were profiled by quantitative proteomics in a mouse B-cell line.28 Using stable isotope 
labeling with amino acids in cell culture (SILAC) methods, matched “light” and “heavy” 
replicates were labeled with 17-ODYA over a 2 hr pulse. One of the samples was then 
further incubated with 10-fold excess palmitic acid in the presence of the translation 
inhibitor cycloheximide. After combining the two samples together, the pooled lysates 
were conjugated to biotin-azide for enrichment and quantitative proteomic analysis. 
While most S-palmitoylated proteins cycled palmitate at a uniform rate in the pulse-
chase assay, a subset of proteins demonstrated accelerated turnover, including G 
proteins, Ras-family GTPases, and a number of cell polarity proteins. Furthermore, 
treatment with the non-selective lipase inhibitor hexadecylfluorophosphonate (HDFP) 
stabilized the same subset of dynamically S-palmitoylated proteins, confirming direct 
enzymatic contribution to S-palmitoylation dynamics on key signaling and polarity 
scaffolding proteins. Based on these results, the majority of S-palmitoylated proteins 
undergo basal hydrolysis, while a small subset of S-palmitoylated proteins are rapidly 
depalmitoylated by HDFP-sensitive lipases. 
Alkynyl fatty acid labeling has several inherent limitations, primarily the direct 
incorporation of the labeled fatty acid across a variety of phospholipids. Longer 
incubation times lead to more extensive alkynyl-fatty acid incorporation into 
phospholipid pools,47 reducing the effectiveness of any later chase with free palmitate. 
This pulse-chase suppression potentially excludes a number of proteins from dynamic 
analyses. Furthermore, addition of palmitate has major effects on cellular metabolism. 
For instance, addition of 500 M palmitate to human primary melanocytes expressing 
the variants of the melanocortin 1 receptor (MC1R) increased cAMP levels by almost 3-
fold, potentially through direct enhancement of GPCR S-palmitoylation.48 Exogenous 
fatty acids also increase cellular acyl-CoA levels,4 which may enhance S-palmitoylation 
levels by driving zDHHC activity or by non-enzymatic thioester exchange with 
accessible cysteine residues. For example, 17-ODYA in the presence of 2-
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bromopalmitate (a non-selective palmitoylation inhibitor) only partially reduces 
incorporation of the 17-ODYA.49 Therefore, non-enzymatic palmitoylation levels may be 
enhanced by 17-ODYA incubation, elevating acyl-CoA pools to driving non-
physiological thioester exchange to enhance levels of S-acylation.  
Another major caveat is metabolic labeling can only occur at accessible, reduced 
cysteines. Thus, stable S-palmitoylated cysteines are essentially invisible, since they do 
not turnover to present a free thiol substrate for zDHHC PAT enzymes. Accordingly, the 
more stable S-palmitoylation site, the more challenging it is to assay by metabolic 
labeling. In addition, high palmitate levels can induce oxidative stress,50 which may trap 
depalmitoylated thiols as oxidized disulfides or glutathione adducts. Different zDHHC 
enzymes have also been shown to prefer different fatty acyl-CoAs,4 suggesting an 
additional level of diversity that could select against a single alkynyl fatty acid species to 
bias probe incorporation. Varying the acyl length of the alkynyl reporter revealed 
different acyl preferences, particularly since terminal azide conjugates surprisingly have 
little influence on zDHHC acyl specificity.4 Moreover, any differential turnover rates 
between distinct sites in the same protein are effectively averaged in shotgun 
proteomics experiments, since there are no robust mass spectrometry methods to 
broadly profile fatty S-acylated peptides. [3H]-palmitate can be elongated or shortened 
by ß-oxidation, further diversifying the labeled acyl species. This is particularly 
problematic when 17-ODYA is shortened to 15-pentadecynoic acid, which is 
enzymatically incorporated into N-myristoylation sites.34 Despite these pitfalls, metabolic 
labeling remains the only approach to profile S-palmitoylation dynamics, on select 
proteins or across the proteome.  
Palmitoyl protein thioesterase 1 
Several early reports demonstrated enhanced depalmitoylation upon hormonal 
stimulation, suggesting activation of specific depalmitoylases might regulate intracellular 
signaling pathways.25, 26, 51 For example, both Ras and G proteins are more rapidly 
depalmitoylated after activation, which was believed to contribute to more efficient 
internalization. Several candidate depalmitoylating enzymes were later identified by 
activity-guided fractionation and purification from soluble tissue homogenates.52, 53 
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While technically feasible, this approach ignored the presence of any membrane-bound 
depalmitoylating enzymes.  
Nonetheless, the lysosomal hydrolase PPT1 was identified as the most robust H-
Ras depalmitoylase in vitro.52 PPT1 was later found to localize exclusively in lysosomes 
and late endosomes,54 functionally separating PPT1 from depalmitoylase activity in the 
cytosol or on plasma membrane. PPT1 is one of 14 genes genetically linked to the 
family of human neuronal ceroid lipofuscinosis (NCL) lysosomal storage diseases, 
characterized by accumulation of lysosomal autofluorescent storage material, 
neurodegeneration, and childhood mortality.55 Interestingly, while not localized in the 
lysosome, mutations in cysteine string protein alpha gene (CSP) also lead to NCL.56 
CSP is multiply S-palmitoylated, and functions as a HSC70 interacting J-protein 
important for protein folding and synaptic vesicle function. In CSP mutant cells, PPT1 
is highly over-expressed.57 Furthermore, PPT1 can depalmitoylate CSP in vitro, which 
is reported to lead to the formation of insoluble aggregates. Acyl-RAC analysis of CSP 
mutant cells revealed decreased S-palmitoylation of several synaptic proteins and 
neuronal signaling proteins. Overall, PPT1 is likely not contributing to plasma 
membrane depalmitoylation, but could play a role in vesicular depalmitoylation and 
lysosomal degradation of S-palmitoylated proteins. 
Acyl protein thioesterases 
The reported lysophospholipase LYPLA1 was identified by screening soluble 
tissue homogenates for G protein depalmitoylase activity,53 and subsequently renamed 
acyl protein thioesterase 1 (APT1). In addition to its depalmitoylase activity, APT1 
hydrolyzes a broad profile of lysophospholipids and other long-chain mono-acyl glycerol 
esters, albeit at a lower catalytic efficiency than high-energy S-palmitoylated 
substrates.58, 59 Since APT1 was first reported before the development of RNAi 
methods, much of the first decade of depalmitoylase research relied on in vitro 
biochemistry or over-expression studies. Over-expression of APT1 enhances the 
depalmitoylation of small GTPases,60, 61 endothelial nitric oxide synthase,62 and a 
number of other peripheral membrane proteins in transfected cells. Such over-
expression could lead to a number of potential artifacts, either by disruptive fusion of 
epitope tags or fluorescent proteins, or through saturation of binding partners at non-
 10 
physiological expression levels. If the enzyme concentration increases much beyond 
physiological levels, the rate of substrate hydrolysis will also increase, and potentially 
promote depalmitoylation of non-physiological substrates. In addition, over-expression 
could also impart non-physiological depalmitoylase activity to otherwise dedicated lipid 
modifying enzymes, particularly since thioesters are high energy bonds readily 
hydrolyzed by even weak nucleophiles. Over-expressing candidate S-palmitoylated 
substrates is also problematic, since high expression levels can approach the enzyme 
Km, further promoting APT1-dependent depalmitoylation of non-native substrates. Even 
so, APT1 can depalmitoylate a number of proteins in cells. In fact, the neuronal 
microRNA mi138 modulates APT1 levels in synaptic spines, reportedly affecting spine 
volume through modulation of G13 S-palmitoylation.63 
In addition to APT1, vertebrates express the highly similar depalmitoylase APT2, 
(68% identical, 81% similar). APT2 also hydrolyzes lysophospholipids,64 but in contrast 
to APT1, it also hydrolyzes prostaglandin glycerol esters.65 Both APT1 and APT2 act as 
efficient depalmitoylases in vitro,59 and are presumed to broadly regulate S-
palmitoylation and trafficking of peripheral membrane proteins in cells. Unfortunately, 
there are no quality commercial sources of APT1 and APT2 antibodies, since they are 
likely poorly immunogenic due to nearly exact conservation across most mammals, 
including mice, rabbits, and humans. Thus, most studies on APT1 and APT2 
localization have used GFP or epitope fusions for subcellular analysis. The literature 
consensus reveals both enzymes are primarily cytoplasmic, although partially localized 
on internal membranes66 or in some instances on the plasma membrane.60, 67 Both 
APT1 and APT2 share a cysteine at the second position immediately following the 
initiator methionine, and are reportedly both S-palmitoylated.60, 66, 68 After removal of the 
initiator methionine, if the N-terminus is not acetylated, it may readily undergo N-acyl 
transfer to form a stable amide linkage. Interestingly, APT1 S-palmitoylation has been 
reported in only one proteomics experiments using hydroxylamine switch methods, but 
never by alkynyl fatty acid labeling.30, 68 APT1 and APT2 are expressed and active 
across nearly all tissues,69, 70 yet their absence in most large-scale profiling efforts 
suggests they may not be stoichiometrically S-palmitoylated. This low-level S-
palmitoylation could be caused by an alternative translational start site (potentially Met-
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6) or through auto-depalmitoylation. Nonetheless, knockdown of either APT1 or APT2 
promotes plasma membrane association of the other APT enzyme, suggesting an 
interdependent S-palmitoylation cycle.60 
Based on their predicted role in regulating peripheral membrane protein 
localization, peptidomimetic inhibitors of APT1 were developed that upon microinjection 
could mislocalize N-Ras away from the plasma membrane.71 Based on these studies, 
derivatives of the generic natural product lipase inhibitor tetrahydrolipstatin were 
identified that potently inhibited both APT1 and APT2.61 The -lactone mechanism-
based inhibitors Palmostatin B and the choline-derivative Palmostatin M 59 were 
developed as dual inhibitors of both APT enzymes. Palmostatin B treatment led to 
accumulation of N-Ras on internal membranes, as well as partial rescue of E-Cadherin 
membrane localization.61 Interestingly, knockdown of APT1 was not sufficient to 
reproduce the pharmacological effects to statistical significance, demonstrating possible 
compensatory mechanisms, either by APT2 or by other unannotated depalmitoylating 
enzymes. Single cell studies revealed altered trafficking dynamics of over-expressed N-
Ras fluorescent protein fusions and microinjection of semi-synthetic, fluorescently 
labeled N-Ras. Upon growth factor stimulation, Palmostatin B treated cells showed 
reduced Ras activation on the golgi. Later studies demonstrated selective growth 
inhibition of N-Ras, but not K-Ras driven growth of myeloid progenitors.72 Accordingly, 
Palmostatin B directly modulates N-Ras localization and activity by disrupting the Ras 
palmitoylation cycle.73 
While Palmostatin B demonstrates high potency against both APTs (IC50 < 5 
nM),59 phenotypic effects typically require > 20 µM.61, 74, 75 Early studies suggested that 
Palmostatin derivatives are highly unstable in serum, requiring repeated cycles of 
inhibitor addition to maintain inactivation.63 Nevertheless, this compound has been used 
in numerous studies to profile APT1 and APT2 function. For instance, Palmostatin B 
addition accelerated the incorporation of the 17-ODYA in Lck in unstimulated T-cells.76 
However, the compound failed to block depalmitoylation once the cells were stimulated 
with Fas ligand. The authors suggested that there may be distinct pools of 
depalmitoylases once the receptors are activated. In addition, the neuronal RGS-
binding protein R7BP accelerates the deactivation of Gi/o proteins. Inhibition with 
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Palmostatin B or HDFP both redistributed R7BP from the plasma membrane to 
endomembranes, disrupted association with G protein-regulated inwardly rectifying 
potassium (GIRK) channels, and slowed GIRK channel closure.77 Importantly, 
knockdown of both APT1 and APT2 had no effect on GIRK inactivation, suggesting the 
presence of additional depalmitoylated enzymes. Chronic lymphocytic leukemia (CLL) 
B-cells express nearly 10-fold more APT2 and 2-fold more APT1. Palmostatin B 
treatment or APT knockdown increased CD95-mediated apoptosis.78 Activity-based 
protein profiling (ABPP) studies later demonstrated that Palmostatin B is not exclusive 
for APT1/APT2, and inactivates a number of other lipid processing serine hydrolases 
with somewhat weaker potency, including ABHD6, ABHD16A, ABHD17A-C, PNPLA6, 
and FASN.79 Accordingly, Palmostatin B should be used only as a generic 
depalmitoylase inhibitor, with a clear understanding that multiple enzymes are blocked 
at concentrations required for sustainable depalmitoylase inhibition, and the biological 
outcomes may reflect polypharmacology summed across many enzymes. 
Despite these issues, Palmostatin B remains a popular tool for blocking 
depalmitoylase activity, and even attenuates depalmitoylation in vivo after 
intraperitoneal injection.48 The MC1R G-protein-coupled receptor triggers melanin 
production and enhances DNA repair after ultraviolet irradiation. Mice with red hair 
MC1R variants have reduced MC1R S-palmitoylation, weaker cAMP stimulation, and 
are more susceptible to developing melanoma. Remarkably, intraperitoneal injection of 
Palmostatin B (10 mg kg-1) prior to UV irradiation increased MC1R S-palmitoylation and 
clearance of DNA photoproducts while reducing tumor growth. While Palmostatin B is 
promiscuous, at this relatively low-dose, APTs are likely to be the primary targets. APT 
inhibition also prevents melanoma tumor cell invasion by regulating the S-palmitoylation 
of the polarity organizing protein MCAM.51 Wnt5a stimulation promotes APT1-
dependent depalmitoylation of MCAM, inducing asymmetric MCAM localization to 
promote a more invasive state. Taken together, APT inhibitors may be valuable 
prophylactics in topical sunscreens to prevent melanoma. Nonetheless, the APT1 and 
APT2 inhibitors ML348 and ML349 had no effect on MAPK signaling or growth across 
several N-Ras-dependent melanoma cell lines,80 demonstrating APT activity is not 
essential across all cancers types or stages. 
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A number of more selective APT inhibitors have been developed with more drug-
like properties. Isoform-selective inhibitors of APT1 (ML348, Ki = 280 nM) and APT2 
(ML349, Ki = 120 nM) were identified by high throughput screening in a competitive 
fluorescence polarization assay.81-83 These inhibitors share a common piperazine-amide 
scaffold, but diverge through additional modifications to impart isoform selectivity. For 
example, APT1 inhibitor, ML348 has piperazine amide adjacent to a furanyl group but 
APT2 inhibitor, ML349 has a thiophene conjugated to thiochromane 1,1-dioxide. These 
isoform-selective inhibitors are active in vivo following intraperitoneal injection, and 
engage their respective targets across all major tissues.83 Furthermore, chemical 
proteomics analysis of biotin-conjugated ML349 confirmed largely selective inhibition 
across the proteome at low micromolar concentrations.84 Other covalent APT1/APT2 
dual inhibitors have been reported, including the commercially available triazole urea 
ML21185, 86 and the commercially available N-hydroxyhydantoin carbamate ML378.87, 88 
ML211 is more potent, yet the higher reactivity reflects a smaller selectivity window 
limiting in vivo applications. ML378 also inhibits ABHD6 and FAAH in mouse brain 
homogenates, yet selective inhibitors to ABHD6 and FAAH can be used as anti-target 
controls. Based on our studies, we highly recommend ML348 and ML349 as probes for 
exploring APT function in cells and model organisms (Figure 1.3). 
 
Figure 1.3 APT inhibitor selectivity index.  
All listed inhibitors are commercially available, except the promiscuous lipase inhibitor HDFP. HDFP 
(fluorophosphonate), Palmostatin B (b-lactone), ML378 (N-hydroxyhydantoin carbamate), and ML211 (triazole urea) 
are covalent inhibitors, although the covalent Palmostatin B adduct is slowly reversible. ML211 inhibits ABHD1186 and 
PPT1 (unpublished). ML378 inhibits ABHD6, FAAH, and PPT1 at higher doses.87 
 
Arguably, the development of APT inhibitors has outpaced detailed biochemical analysis 
of APT function in cells. According to pulse-chase S-palmitoylation proteomics studies, the 
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tumor suppressor Scribble (Scrib) demonstrated the fastest S-palmitoylated turnover in 
aggressive B-cell hybridoma cells.28 Importantly, this turnover was completely blocked by 
treatment with the non-selective lipase inhibitor HDFP. Originally identified in Drosophila, the 
cell polarity tumor suppressor Scrib has emerged as a central regulator of cell growth, invasion, 
and malignancy.89-91 While Scrib is not widely mutated in cancers, its mislocalization and 
amplification are clinically correlated with high-grade cervical carcinomas,92, 93 as well as 
malignant colon,94 prostate,95 breast cancers,95, 96 and other epithelial cancers 97 (Figure 1.4A-
B). In addition, Scrib+/- heterozygous male mice develop widespread epithelial hyperplasia,95 
and MMTV-driven conditional knockout of Scrib in female mice induces breast hyperplasia and 
widespread tumor formation.91 
 
Figure 1.4 APT2 inhibition restores Scribble plasma membrane localization in Snail-expressing cells.  
(A) Scribble (Scrib) moves from the plasma membrane to the cytosol in the more malignant cells. (B) Scrib is 
localized at the plasma membrane in MDCK polarized epithelial cells. (C) APT2 inhibition significantly rescues Scrib 
plasma membrane localization in Snail expressing MDCK cells. Adapted from Hernandez et al.75 
 
  In order to explore the mechanism of Scrib membrane mislocalization in cancer, 
we engineered cells to over-express the epithelial to mesenchymal transition 
transcription factor (EMT-TF) Snail. Snail reprograms cells to transform to a more stem 
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cell-like state, which eliminates basolateral polarity and leads to Scrib translocation from 
membrane to the cytosol 98 (Figure 1.4C). Importantly, Scrib fusion to a C-terminal 
CAAX prenylation motif is reported to rescue plasma membrane localization and 
reduces levels of activated TAZ,98 the central transducer of the Hippo signaling 
pathway. Without its plasma membrane localization, Scrib no longer represses 
Ras/MAPK-driven cell invasion and EMT phenotypes, yet retains the ability to suppress 
anchorage-independent growth.99 Interestingly, Snail expression in either MDCK or 
MCF10A cells led to the repression of select zDHHC protein acyl transferases and 
increased expression of the depalmitoylase APT2, suggesting Snail initiates a 
transcriptional program that directly targets the S-palmitoylation cycle.43, 75 When Snail 
over-expressing cells are treated with the APT2 inhibitor ML349 or APT2 siRNAs, Scrib 
localization is largely restored to the plasma membrane, rescuing markers of cell 
polarity and suppressing MAPK signaling 75 (Figure 1.4C). ML349 had no effect on 
Ras-GTP levels, but markedly reduced Raf and MEK activation, suggesting S-
palmitoylated Scrib organizes a signaling complex that regulates Raf activation 
downstream of Ras. Importantly, overnight incubation with Palmostatin B also rescued 
Scrib membrane localization, but required 100-times higher concentrations than ML349. 
Surprisingly, the APT1 inhibitor ML348 had no effect on Scrib localization, confirming 
isoform-selective depalmitoylase regulation of S-palmitoylation. Altogether, this data 
demonstrates that APT2, but not APT1, participates in an altered S-palmitoylation cycle 
that becomes imbalanced to promote pathways that drive malignancy. Furthermore, this 
work established a unique biochemical pathway that reverts certain malignant 
phenotypes in cancer through pharmacological perturbation of the Scrib palmitoylation 
cycle, without directly affecting Ras activation or signaling. 
 Beyond their role as protein depalmitoylases, APT enzymes can also hydrolyze a 
variety of other esters and thioester metabolites.100 APT1 and APT2 were originally 
characterized as lysophospholipase enzymes, yet later studies demonstrated enhanced 
catalytic efficiency towards acyl-thioester-linked proteins. Interestingly, APT2 was 
identified as the primary prostaglandin glycerol esterase, while APT1 had no significant 
activity.65 Both APT1 and APT2 accelerate the deacylation of octanoyl-ghrelin in serum, 
suggesting these enzymes may also be secreted from cells.101 Lipopolysaccharide 
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treatment increased in APT1 serum levels, potentially through release from liver. 
Furthermore, the intracellular APT1 mRNA and protein levels were reduced after LPS 
stimulation, yet APT2 levels were unaffected. Overall, APTs likely hydrolyze a number 
of more soluble acyl-esters and thioesters, and may have broader functional roles in 
vivo beyond depalmitoylation.  
To add spatial and temporal resolution to depalmitoylation enzymes, a series of 
mechanism-based octanoyl-thioester fluorogenic probes were developed for live cell 
imaging.102 Approximately half of the probe fluorescence in HEK293T cells was blocked 
by ML348 or Palmostatin B, and APT1 siRNA knockdown reduced probe fluorescence 
by 25%. Interestingly, EGF stimulation reduced probe fluorescenbce by about 10% in 
live cells, suggesting some growth factor regulation of deacylase activity. While 
intriguing, further evidence is needed to establish if such reductions affect steady-state 
cellular S-palmitoylation levels, particularly of S-palmitoylated growth signaling 
mediators. Given the large number of candidate octanoyl-thioesterases, these probes 
provide a useful cell-based platform to explore deacylase activity in live cells, and 
measure contributions across different candidate enzymes.  
Structural insights to APT enzymes 
In order to explain the functional differences between APT1 and APT2, the first 
high-resolution structures bound to their respective inhibitors103 were recently solved. 
The structures of these enzymes will be further discussed in the next chapter. While the 
structure of apo-APT1 was reported,104 there were no additional studies to analyze the 
structure of APT1 or any structures of APT2 for comparison. Before solving the 
structures of each enzyme, we profiled the thermostability of APT1 and APT2 bound to 
different ligands. APT1 was more thermostable than APT2 (5ºC), suggesting previous 
efforts to crystalize APT2 were likely stymied by additional flexibility or disorder. 
Compared to free enzyme, APT1 binding to ML348 or APT2 binding to ML349 
increased the thermostability by 4ºC, which confirms thermodynamically favorable 
inhibitor engagement. Furthermore, incubation with HDFP led to a surprising 10ºC 
stabilization. Accordingly, APT enzymes were predicted to harbor an acyl-binding 
pocket to stabilize the enzyme upon substrate binding. Based on these observations, 
we identified co-crystallization conditions and solved the structures of both 
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APT1•ML348 (1.55 Å; 5SYM) and APT2•ML349 (1.64 Å; 5SYN) by x-ray 
crystallography (Figure 1.5). 
 
Figure 1.5 Divergence in APT1 and APT2 structures.  
Blue regions signify divergence between APT1 and APT2. Adapted from Won et al., 2016.103 
 
APT1 and APT2 feature unusual  / serine hydrolase fold where the first 1 
strand in the ‘canonical’ fold is missing and the fourth -helix is replaced by a short -
helical segment termed G3. These enzymes include unique insertions, which add the 
short 4-5 sheet and the 5-2 loop. This loop contributes to forming a relatively long 
channel flanking the catalytic triad of both enzymes. Comparison of apoAPT1, 
APT1•ML348, and APT2•ML349 revealed this loop has varying degrees of openness, 
suggesting dynamic movement may engage various substrates. This feature 
functionally replaces the ‘cap’ or ‘lid’ domain found in many lipases, contributing to 
substrate engagement and providing thermodynamically stable environment for the 
catalysis. Both ML348 and ML349 make unique interactions with the divergent residues 
along this channel (Figure 1.6). However, these residues are either protruding away 
from the core of the protein (I76/M79, Q83/P86) or are similar in characteristics (eg. 
I75/L78). Importantly, mutational analysis identified a single residue I75/L78 
(APT1/APT2) that establishes steric constraints to impart isoform selective inhibition. 
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Similarly, the residues within the loop of the catalytic D174/176 does not show obvious 
differences. Other divergent residues in the G3 helix show marginal contributions to 
inhibitor selectivity, potentially by constraining the dynamics of the 5-2 loop. 
 
Figure 1.6 Isoform-selective inhibitor binding in APT1 and APT2.  
Alignment demonstrates inhibitor engagement spanning along a hydrophobic channel towards the catalytic triad. 
Select residues are highlighted with sequence divergence between APT1 and APT2. Adapted from Won et al., 
2016.103 
 
The 5-2 loop and the surrounding residues around the active site form a 
hydrophobic channel, that may enhance the entry and engagement of hydrophobic 
substrates. While it is tempting to think that peptide component of substrates might 
occupy the channel, docking simulations further support exclusive acyl chain 
occupancy. As further evidence, ML349-fluorescein binding to APT2 is blocked by pre-
treatment with palmitic acid. Together with the observed 10ºC thermal stabilization upon 
HDFP engagement, we hypothesize long chain fatty acyl substrates bind in the channel, 
locking the substrate to promote ester hydrolysis. The channel and residues in proximity 
are probably not involved in the selectivity of the enzymes towards palmitoylated 
substrates, but rather select for acyl chain length through stabilization of the 5-2 loop. 
Of note, the structures of both APT1•ML348, and APT2•ML349 lack the first few N-
terminal residues. Since APT enzymes may be S-palmitoylated themselves at the N-
terminus, it remains unclear how this may influence hydrophobic channel orientation 
and engagement of palmitoylated substrates. However, APT enzymes are largely 
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soluble present in the cytosol, so we predict APTs may only be fractionally S-
palmitoylated. 
Our structural analysis of APT1 and APT2 reveal strikingly similar substrate 
binding regions and surface polarity, and only conservative mutations across the 
enzyme active site (Figure 1.7). ML348 and ML349 are isoform selective apparently by 
coincidence and not by evolutionary selection in substrate discrimination. Therefore, 
any specific biological roles for each enzyme may be due to distinct protein-protein 
interactions, post-translational processing, differential expression, or distinct subcellular 
localizations. This raises several questions, such as why would evolution keep two 
isoforms of APT enzymes? What imparts the functional divergence between APT 
enzymes? Although these enzymes share nearly 70% identity, overexpression and 
knockdown studies clearly show preferences for specific palmitoylated substrates. One 
explanation could be the large difference in melting temperatures between isoforms, 
which suggest APT2 is more flexible and may be able to accept more diverse 
substrates than APT1. Furthermore, the single acyl binding channel explains the 
reduced activity towards diacylated substrates, and emphasizes a potential role for APT 
enzymes as general esterases for long-chain monoacylated substrates, including 
lysophospholipids, S-palmitoylated proteins, and prostaglandin glycerol esters. Overall, 
structural analysis of APT1 and APT2 do not provide a definitive explanation of how 
these enzymes are functionally divergent. 
 
Figure 1.7 Surface polarity of APT1 and APT2. 
Both APT1 and APT2 have similar surface polarity, with similar distributions of polar and hydrophobic surfaces. 
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ABHD17 family thioesterases 
Until recently, APT1 was recognized as the primary depalmitoylase in cells, yet 
mutants in yeast, Drosophila, and C. elegans have no reported phenotypes. Given that 
APT1 was initially described as the primary depalmitoylase regulating N-Ras activity, 
this was quite puzzling. Cracks in this model began to appear throughout a number of 
publications, most strikingly from evidence that H-Ras depalmitoylase activity was 
exclusively in insoluble cell fraction (P100), and not with APT1 in the soluble fraction 
(S100).105 Later, APT1/2 knockdown was shown to have no effect on R7BP 
depalmitoylation, while treatment with Palmostatin B or HDFP both blocked activity.77 
This was followed by detailed activity-based profiling of Palmostatin B targets, and the 
realization that Palmostatin B is broadly reactive across a number of candidate 
depalmitoylases.79 Clearly other depalmitoylase activities beyond APT1/APT2 are 
present in cells, and likely contribute to the depalmitoylation of plasma membrane 
localized targets, including Ras. 
In order to identify these additional depalmitoylases, Palmostatin B targeted 
hydrolases were over-expressed and S-palmitoylation turnover was assayed using 17-
ODYA pulse-chase methods. This led to the identification of ABHD17 enzymes as 
candidate N-Ras depalmitoylases in COS-7 cells.79 Over-expression of catalytic dead 
enzyme or N-terminal truncated mutants did not affect the N-Ras palmitoylation cycle, 
confirming ABHD17 enzymes are functional depalmitoylases in cells. ABHD17 
hydrolases (ABHD17A, ABHD17B, and ABHD17C) are broadly expressed in all 
vertebrates, and harbor multiple conserved cysteines near their N-termini (Figure 1.8A). 
The N-terminal cysteine rich domain is essential for both S-palmitoylation and plasma 
membrane association.34 Thus, ABHD17 enzymes are themselves S-palmitoylated, 
which is necessary for plasma membrane association and proximity to other S-
palmitoylated proteins (Figure 1.8B). Importantly, deletion of the N-terminal cysteine 
rich domain has no effect on ABHD17 reactivity with fluorophosphonate activity-based 
probes, suggesting the palmitoylation motif is primarily responsible for directing 
membrane localization and does not influence enzyme activity. ABHD17A over-
expression shifted N-Ras localization from the plasma membrane to internal 
membranes, indicative of more rapid S-palmitoylation turnover. Triple ABHD17 (A-C) 
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knockdown stabilized N-Ras 17-ODYA labeling, while APT1/APT2 inhibition with ML348 
and ML348 had no effect. Accordingly, ABHD17 enzymes (but not APT1/APT2) 
contribute to N-Ras depalmitoylation in cells. 
 
Figure 1.8 ABHD17 enzymes are palmitoylated and localize to the plasma membrane.  
(A) ABHD17A-C are S-palmitoylated in a conserved N-terminal cysteine-rich motif separate from alpha-beta 
hydrolase domain. (B) ABHD17A-GFP localization in HeLa cells demonstrates predominant plasma membrane 
localization. 
 
The synaptic protein PSD-95 is rapidly de-palmitoylated after depolarization. In 
order to identify the PSD-95 depalmitoylase, a panel of serine hydrolases were 
individually co-expressed with PSD-95 in 293T and COS-7 cells.74, 106 Over-expressed 
ABHD17 enzymes efficiently depalmitoylated PSD-95 in 293T, COS-7, and primary 
neuronal cultures, while other Palmostatin B targets ABHD12, ABHD13, APT1, and 
APT2 had only fractional reductions in PSD-95 S-palmitoylation (Figure 1.9). ABHD17 
over-expression reduced the synaptic clusters of PSD-95 and AMPA receptors in 
neurons, while ABHD17A/ABHD17B/ABHD17C knockdown stabilized palmitoylated 
PSD-95 and prevented the decrease in synaptic PSD-95 clustering. In addition, 
ABHD17 overexpression in primary neurons reduces the S-palmitoylation of 
microtubule-associated protein 6 (MAP6), causing MAP6 retention in axons and 
microtubule stability.106 Recently the international knockout mouse consortium identified 
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ABHD17A as one of the top suppressors of distal cancer metastasis in mice107 
suggesting it may play a role in immune cell activation or surveillance. 
 
Figure 1.9 Homology, depalmitoylase activity, and Palmostatin B inhibition of HDFP-sensitive serine 
hydrolases. 
HDFP-sensitive serine hyrolases reported from mouse B-cell hybridoma cells28 are shown based on active-site 
anchored homology. Palmostatin B targets are highlighted in red. 79, 108 Enzymes that reduced PSD-95 S-
palmitoylation after over-expression are labeled with a red star.74 
 
Despite this growing number of cell-based ABHD17 studies, there is no 
biochemical evidence demonstrating in vitro depalmitoylation, enzyme kinetics, 
substrate specificity, or other functional properties of each ABHD17 enzyme. ABHD17 
enzymes may hydrolyze other lipid substrates, particularly since their plasma 
membrane association delivers them in proximity to a number of potential substrates. A 
reported biochemical high throughput screen identified moderately potent inhibitors of 
an N-terminal truncated ABHD17B protein, yet these inhibitors failed to inhibit full-
length, mammalian cell expressed protein (National Center for Biotechnology 
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Information. PubChem BioAssay Database; AID=2200). Structural studies are clearly 
necessary to understand if the N-terminal 100 amino acids before the conserved /-
hydrolase domain function solely as a platform for S-palmitoylation and membrane 
tethering, or if they impart additional structural features important for substrate 
engagement. Clearly future efforts are needed to explore the substrate profile, 
redundancy between isoforms, and physiological roles for each ABHD17 enzymes.  
Conclusions 
Cycles of S-palmitoylation and depalmitoylation provide a mechanism for 
membrane sampling and trafficking of peripheral membrane proteins to the plasma 
membrane. Such directional palmitoylation cycles are demonstrated for G proteins, Ras, 
Scrib, and other central regulators of cell growth and organization. G protein 
internalization occurs even in the presence of generic depalmitoylation inhibitors, 
demonstrating that while depalmitoylation may be necessary for plasma membrane 
trafficking, agonist-dependent internalization occurs independent of depalmitoylation.23 
Based on these findings, many peripheral membrane proteins require cycles of S-
palmitoylation and depalmitoylation for plasma membrane delivery, but there are no 
definitive examples of post-translational regulation of depalmitoylation activity. Rather, 
depalmitoylation appears to depend more on sub-cellular localization and regulated 
expression. ABHD17 enzymes localize to the plasma membrane, where they have 
direct access to neuronal scaffolding proteins and growth regulators. APT enzymes are 
soluble, and largely cytoplasmic, and play active roles in maintaining the directional 
palmitoylation cycle important for peripheral membrane protein trafficking. 
Future efforts to understand regulation of depalmitoylation will continue to 
leverage emerging chemical and genetic technologies. While Palmostatin B and HDFP 
are useful generic inhibitors of depalmitoylases, selective inhibitors of APT enzymes 
should now be routinely used to individually perturb each APT isoform. These reagents 
will be valuable for parsing how APT1 and APT2 function either independently or in 
conjunction to influence distinct cellular outcomes. Future efforts are needed to validate 
APT1 and APT2 localization, interaction partners, and modifications to fully understand 
the divergent phenotypes. This would be greatly accelerated by knockout animal 
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models, allowing detailed biochemical and phenotypic analysis for each APT enzyme in 
their native physiological environments. 
Similarly, ABHD17 enzymes are largely unannotated, and without biochemical 
analysis, it is not clear if each of the three enzymes are bona fide depalmitoylases or if 
each isoform carries out unique cellular functions. Clearly, ABHD17A plays a major role 
in suppressing growth of distal metastases, which likely reflects a role in immune 
regulation. Surely there are additional depalmitoylating enzymes, whether as their 
primary biochemical role or through non-specific acyl-thioester hydrolysis. Furthermore, 
Palmostatin B and HDFP likely act though polypharmacology, inhibiting a number of 
depalmitoylase (or lipase) enzyme activities to affect global depalmitoylation dynamics. 
Further functional studies of other hydrolases are likely to add to the growing number of 
factors contributing depalmitoylation dynamics in cells. 
Finally, with the emergence of novel depalmitoylating enzymes, it is important to 
annotate the substrate profile and functional regulation by each enzyme. For example, 
cells could be treated with ML348 or ML349 to profile differential enrichment by mass 
spectrometry. Such experiments may be complicated by compensatory mechanisms, 
requiring simultaneous inhibition across a panel of depalmitoylases. Current enrichment 
and mass spectrometry detection methods are either indirect (Acyl-RAC) or require non-
physiological metabolic labeling (17-ODYA). Since current liquid chromatography 
methods are optimized for polar peptides, future efforts are needed to extend 
quantitative proteomics to more hydrophobic peptides, allowing direct analysis of the 
modified peptide and the specific acyl chain. This could readily be accomplished by 
changing the column resin or adapting the mobile phase composition. Investment in 
sample preparation methods to optimize acyl-thioester stability, separation, ionization, 
and fragmentation have not been explored outside of single peptide measurements. In 
addition, multiplexed quantitative proteomics has emerged as a promising approach for 
time-dependent analyses, providing multiple measurements in a single combined 
proteomics experiment. We anticipate that ongoing advances in sample preparation and 
analysis will ultimately resolve many unanswered questions, providing a direct approach 
to profile the hydrophobic proteome and enzyme regulation. 
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Chapter 2 : Molecular Mechanism for Isoform-selective Inhibition of Acyl Protein 
Thioesterases 1 and 2 (APT1 and APT2)† 
 
Abstract 
Post-translational S-palmitoylation directs the trafficking and membrane localization of 
hundreds of cellular proteins, often involving a coordinated palmitoylation cycle that 
requires both protein acyl transferases (PATs) and acyl protein thioesterases (APTs) to 
actively redistribute S-palmitoylated proteins toward different cellular membrane 
compartments. This process is necessary for the trafficking and oncogenic signaling of 
S-palmitoylated Ras isoforms, and potentially many peripheral membrane proteins. The 
depalmitoylating enzymes APT1 and APT2 are separately conserved in all vertebrates, 
suggesting unique functional roles for each enzyme. The recent discovery of the APT 
isoform-selective inhibitors ML348 and ML349 has opened new possibilities to probe 
the function of each enzyme, yet it remains unclear how each inhibitor achieves 
orthogonal inhibition. Herein, we report the high-resolution structure of human APT2 in 
complex with ML349 (1.64 Å), as well as the complementary structure of human APT1 
bound to ML348 (1.55 Å) (Figure 2.1). Although the overall peptide backbone structures 
are nearly identical, each inhibitor adopts a distinct conformation within each active site. 
In APT1, the trifluoromethyl group of ML348 is positioned above the catalytic triad, but 
in APT2, the sulfonyl group of ML349 forms hydrogen bonds with active site resident 
waters to indirectly engage the catalytic triad and oxyanion hole. Reciprocal 
mutagenesis and activity profiling revealed several differing residues surrounding the 
active site that serve as critical gatekeepers for isoform accessibility and dynamics. 
Structural and biochemical analysis suggests the inhibitors occupy a putative acyl-
binding region, establishing the mechanism for isoform-specific inhibition, hydrolysis of 
acyl substrates, and structural orthogonality important for future probe development. 
                                             
† This chapter presents a published peer reviewed article. Won S.J. et al ACS Chem Biol. 2017 Jan 19;24(1):87-97 
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Figure 2.1 Graphical abstract. 
 
 
Introduction 
 Post-translational S-palmitoylation anchors target proteins to membranes using a 
high-energy thioester, which can be readily hydrolyzed by enzymes or other cellular 
nucleophiles. In contrast, stable modifications like N-myristoylation and S-prenylation 
modify proteins via an amide or thioether linkage. Thus, while some proteins evolved as 
targets of stable lipidation, others use reversible membrane anchors for dynamic spatial 
regulation. Indeed, blocking Ras palmitoylation attenuates growth signaling and 
transformation in mutant cells.26 Similarly, G proteins are rapidly depalmitoylated 
following activation,25 potentially redistributing active signaling proteins to attenuate 
signaling. While such rapid depalmitoylation events may be enzyme-mediated, signal-
dependent conformational changes could still be necessary to expose the S-
palmitoylated cysteine to promote enzymatic hydrolysis.  
The first characterized cytosolic protein depalmitoylase, acyl protein thioesterase 
(APT1/LYPLA1), was identified biochemically from rat liver.58 Although it was previously 
annotated as a lysophospholipase,109 both rat and yeast APT1 exhibit >65-fold to 
>2000-fold greater catalytic efficiencies (kcat/Km) as a Gsα protein depalmitoylase,110,111 
respectively. Rat and yeast APT1 were each shown to catalyze the depalmitoylation of 
Giα1 (N-myristoylated and S-palmitoylated) 10-fold to 70-fold faster than Ras (S-
farnesylated and S-palmitoylated),111 respectively, demonstrating that the enzyme can 
discriminate between different S-palmitoylated substrates. Nevertheless, thioester 
hydrolysis is significantly more exergonic than ester hydrolysis, which likely accounts for 
the majority of rate acceleration. APT2 (LYPLA2) shares 68% protein sequence identity 
with APT164 and displays similar Ras depalmitoylase and lysophospholipase activity in 
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vitro.64,59 While APT1 and APT2 likely share many common substrates, in cellular 
assays only APT2 affects the palmitoylation of GAP-43,112 while only APT1 participates 
in the depalmitoylation of BK potassium channels113 and the melanoma adhesion 
molecule (MCAM).51 However, these observed isoform-specific activities could also 
represent differential overexpression, knockdown, or subcellular localization in each 
model. Overall, many studies of protein depalmitoylation rely on the dual APT1/APT2 
inhibitor Palmostatin B,61 which obscures the contributions from each individual enzyme. 
Nonetheless, dual APT1/APT2 inhibition disrupts overexpressed Ras trafficking and 
reverts certain malignant phenotypes.61  
Later screening efforts identified piperazine amide competitive inhibitors with 
exquisite selectivity for APT1 and APT282,81,83 (Figure 2.2 a). The APT1 inhibitor ML348 
and the APT2 inhibitor ML349 are isoform-selective and relatively potent (Ki ≤ 300 nM) 
and exhibit orthogonality beyond the solubility of each probe.83 Because both inhibitors 
incorporate a common piperazine amide linked to a five-membered hetero- cycle 
(thiophene or furan), each was hypothesized to occupy a similar position in the active-
site.100 Since there is no reported structure of APT2, the structural elements that impart 
inhibitor orthogonality and substrate selectivity have remained elusive. Here, we present 
the cocrystal structures of APT1 and APT2 binding to their respective selective 
inhibitors. Surprisingly, neither inhibitor directly hydrogen bonds to amino acid side 
chains but rather coordinates structural waters and occludes access to the catalytic 
residues. Mutagenesis along the β5-α2 loop and the G3 helix revealed the basis for 
inhibitor selectivity, which involves several residues that influence distinct loop 
conformations between APT1 and APT2. These elements engage each inhibitor, 
forming a hydrophobic fatty acyl-binding channel adjacent to the catalytic triad. Overall, 
these findings provide mechanistic insight into isoform-selective substrate specificity 
and reveal new directions for inhibitor optimization.  
 
Results 
Co-crystal Structures of APT1·ML348 and APT2· ML349. Differential scanning 
fluorimetry indicates a ∼5 °C higher melting temperature (Tm) in APT1 (59.2 °C) relative 
to APT2 (54.4 °C; Figure 2.2 b). Thus, crystallization could be disfavored by additional 
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disorder in APT2. Upon ligand binding, both APT1 and APT2 are stabilized by 
3.5−3.7 °C. Similar values were measured using a thermal shift assay, where heat 
denaturation and centrifugation are used to monitor protein solubility114 (Figure 2.2 C). 
Again, APT1 is more thermally stable than APT2 by 4 °C, and inhibitor engagement 
considerably impedes denaturation.  
 
Figure 2.2 Stabilization of APT1 and APT2 by isoform-selective inhibitors. 
(a) Chemical structures of ML348 and ML349. (b) ML348 and ML349 impart dose-dependent thermal stabilization of 
APT1 and APT2, respectively, by differential scanning fluorimetry. (c) Thermal shift assay corroborates thermal 
stabilization of APT enzymes by selective ligands.  
 
Using this information, we readily obtained cocrystals of both APT1·ML348 and 
APT2·ML349. The structure of APT2 has not been reported, and therefore obtaining this 
model was critical for understanding the origins of inhibitor selectivity. Atomic structures 
of APT1·ML348 and APT2·ML349 were subsequently determined at 1.55 Å and 1.64 Å 
resolution, respectively (Table 2.1). Although a previously reported APT1 structure 
implied formation of a weak dimer,104 both APT1·ML348 and APT2·ML349 form distinct 
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dimer interfaces in each respective asymmetric unit, suggesting that oligomerization is 
likely an artifact of crystallization.  
 
Table 2.1 Crystallography data collection and refinement statistics 
 
aStatistics for highest resolution bin of reflections in parenthesis. bIntensity signal-to-noise ratio. cCompleteness of the 
unique diffraction data.  
 
 
Each APT structure adopts an atypical α/β hydrolase fold featuring a central, 
seven-stranded, mostly parallel β-sheet, corresponding to strands β1−β3 and β6−β9, 
surrounded by variable lengths of loops, helices, and strands (Figure 2.3 a, b). In both 
enzymes, the nucleophilic serine (APT1-Ser199/APT2- Ser122) assumes the typical 
strained conformation at the apex of the elbow between β6 and α3, whereas the 
histidine base (APT1-His209/APT2-His210) and aspartate (APT1-Asp174/ APT2-
Asp176) are positioned on nearby extended loops between β9 and α5 and β8 and α4, 
respectively. APT1 and APT2 include noncanonical insertions of an antiparallel β4−β5 
sheet, the corresponding β5−α2 loop, and a short G1 helix. Furthermore, both enzymes 
replace the fourth α-helix of the canonical fold with a short helical segment, termed G3,  
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which is structurally divergent between the APT1·ML348 and APT2·ML349 structures, 
and an additional short helix in APT2, termed G4. 
 
Figure 2.3 Conformational changes induced upon ligand binding revealed by co-crystal structures of 
APT1•ML348 and APT2•ML349. 
(a) Co-crystal structure of APT1·ML348. A 2 σ omit map is shown for ML348. The catalytic triad is indicated in sticks, 
and the noncanonical β4-β5 sheet, the G1 helix, and the β5-α2 loop are colored purple (b) Co-crystal structure of 
APT2·ML349. A 2 σ omit map is shown for ML349, where the catalytic triad is indicated in sticks. Other features 
highlighted in APT1·ML348 are colored in purple. (c) Structure alignment of APT1·ML348 and APT2·ML349. Regions 
of significant conformational differences are shown in red-dotted circles. (d) Structural variance of APT1 (PDB: 1FJ2) 
in orange and APT1· ML348 in dark blue. Significant conformation changes are observed for the G1 helix, β4−β5 
stands, and β5−α2 loop.  
 
Unlike other α/β hydrolase lipases, APT homologues lack a distinctive “cap” 
domain important for substrate binding and a flexible “lid” that protects the active site 
from solvent. Instead, APTs may use the β5−α2 loop, which is flanked on one side by a 
G1/β8−α4 loop and a G3 helix on the other to form a relatively long (∼20 Å) putative 
acyl-binding channel wherein both ML348 and ML349 reside. This hydrophobic channel 
shows varying degrees of openness between APT1, APT1· ML348, and APT2·ML349 
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(Figures 2.3 c,d and 2.4). In the distant bacterial homologue FTT258 (PDB: 4F21), the 
analogous loop domain demonstrates dynamic conformational changes proposed to 
define the active and inactive states, suggesting the loop closes upon substrate binding 
to initiate hydrolysis.115 However, this substrate driven conformational change could 
differ among APTs, especially because the shorter G1 helix and the noncanonical 
β4−β5 sheet replace this loop in all vertebrate APTs (Figure 2.5 a, b). Although part of 
β4 and G1 pack with the β5−α2 loop to form one end of the channel, the overall 
functional role of the β4−β5 sheet and G1 motif remains speculative. The resulting 
hydrophobic channel has sufficient space and polarity to accommodate long chain fatty 
acyl chains. Because APT enzymes are more active toward long chain fatty acyl 
substrates,116 shorter acyl chains may not provide enough free energy to counteract the 
entropic penalty of binding (increasing Km) or bind too deep in the channel. Either would 
impede substrate orientation and activity. In comparison to the unbound structure, 
ML348 binding pushes out the β5−α2 loop, suggesting loop flexibility in this 
noncanonical region likely contributes to inhibitor engagement.  
 
 
Figure 2.4  APT1 (PDB: 1FJ2) alignment with APT2•ML349. 
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Figure 2.5 Sequence alignment and conservation across vertebrate APT enzymes. 
(a) Sequence and secondary structure alignment of APT enzymes. Human APT1·ML348 and human APT2·ML349 
were used to define secondary structures. (b) Cartoon model of APT enzymes rendered using UCSF-Chimera to 
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determine the degree of conservation. Blue regions signify divergence between APT1 and APT2, highlighting APT1-
L176M and APT2-M178L (in sticks) in the β8/α4 region.  
 
Structural Features of ML348 and ML349 Engagement. In the structure of 
APT1·ML348, two waters form hydrogen bonds to the anilide carbonyl, whereas in 
APT2 the same waters interact with the piperazine amide carbonyl (Figures 2.6 a,d). 
Clearly, the piperazine amide carbonyls of ML348 and ML349 motifs interact differently 
in each enzyme, showing no clear structure−activity relationship shared between APT1 
and APT2.81-83 Regardless, the bulk of both ML348 and ML349 molecules occupy the 
hydrophobic channel where their water-coordinated carbonyl groups are superimposed. 
One of these waters forms a hydrogen bond to the backbone carbonyl of APT1-
Gln83/APT2-Pro86 and the backbone amide of APT1-Gly77/APT2-Met79, whereas the 
second forms hydrogen bonds to APT1-Glu84/APT2-Glu87. In addition, APT1-
Trp145/APT2-Trp148 forms putative π−π stacking interactions with the aromatic anilide 
of ML348 and the thiophene of ML349. On the other end, APT1-Phe181/ APT2-Phe183 
also forms a π−π stacking interaction between the ML348 furanyl group and ML349 
anisole group.  
 The G3 helix has weak sequence similarity between APT1 and APT2, suggesting 
it may be a site of functional divergence (Figure 2.5 a, b). In APT1, Arg149 of G3 forms 
a hydrogen bond with a water molecule that coordinates the ML348 piperazinyl amide 
carbonyl and the Pro80 backbone carbonyl in the β5−α2 loop (Figure 2.7 a). In 
contrast, His152 in the APT2 G3 helix forms a π−π stacking with the ML349 anisole 
group, and Arg153 forms a hydrogen bond with the Asp84 side chain of the β5−α2 loop 
(Figure 2.7 b). Most importantly, both the anilide ring of ML348 and the thiochromene 
heterocycle of ML349 are positioned directly above the catalytic triad, blocking substrate 
access. The ML348 trifluoromethyl substituent passively blocks the catalytic triad 
through a series of hydrophobic contacts, including those with Leu30, Leu176, and the 
hinge residue Ile75. In contrast, the ML349 sulfone group participates in a hydrogen 
bond network with water molecules, making indirect contacts with both the oxyanion 
hole and the catalytic triad (Figures 2.6 a−d).  
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Figure 2.6 Inhibitor binding in APT1 and APT2 promoted by distinct binding modes. 
(a) The hydrophobic channel of the APT1·ML348 complex from different perspectives. Side chains of residues within 
3.5 Å of ML348 (green) are shown as gray sticks. Water molecules are shown as red spheres and hydrogen bonds 
by red dotted lines. (b) The hydrophobic channel of the APT2·ML349 complex from different perspectives. Side 
chains of residues within 3.5 Å of ML349 (orange) are shown in gray sticks, with similar notation for waters and 
hydrogen bonds. (c) Two-dimensional ligand plot of ML348 interactions with APT1. Red dashed lines represent 
hydrogen bonds, and gray dashed lines indicate π−π stacking interactions. Chemical features are color coded and 
labeled. (d) Two-dimensional ligand plot of ML349 with corresponding labels as described in c.  
 
Figure 2.7 The G3 helix interacts with the β5-α2 loop. 
(a) The APT1 G3 helix interacts with ML348 and the β5-α2 loop. (b) The APT2 G3 helix interacts with ML349 and β5-
α2 loop, through both hydrogen bonding (red dashed lines) and a π−π stacking (black dashed lines) 
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At first glance, we initially hypothesized the ML349 sulfone might act as a 
tetrahedral transition state inhibitor since the sulfonyl group of ML349 is in proximity to 
the catalytic residues Ser122, His210, and the oxyanion hole backbone carbonyl 
oxygens of Gln123 and Leu33 (Figure 2.6 b, d). On closer analysis, ML349 appears to 
form indirect hydrogen bonds to APT2 via two intervening water molecules, each 
tethered by hydrogen bonds to the catalytic machinery in the active site. One water 
molecule forms a hydrogen bond to an oxyanion hole amide through its oxygen lone 
pair, while also serving as a hydrogen bond donor to an ML349 sulfone oxygen. The 
other water molecule is positioned near the histidine base (His210) where it would 
normally become polarized to participate in acyl-intermediate hydrolysis but instead 
forms a hydrogen bond to the other ML349 sulfone oxygen.  
 Next, we examined if the formation of the enzyme−inhibitor complex depends on 
the presence of the sulfonyl oxygens. A racemic ML349−sulfoxide derivative 
demonstrated some residual inhibition, but ML349−thioether completely lost any ability 
to bind APT2 (Figures 2.8 b and 2.9 a, b and Table 2.2). In order to test whether the 
serine nucleophile participates in ML349 binding, we synthesized an ML349−fluorescein 
(ML349−FL) conjugate to probe active site binding by fluorescence polarization, 
independent of substrate hydrolysis (Figure 2.8 a). Interestingly, both ML349 and the 
ML349−FL bind the catalytic dead APT2−S122A mutant with similar affinity (Figures 
2.8 a, b), confirming Ser122 does not engage the thiochromene sulfone. Pretreatment 
with either ML349 or hexadecylfluorophosphonate (HDFP) blocked ML349-FL 
polarization with APT2, ruling out any alternative binding mechanisms while confirming 
overlap between HDFP and ML349 binding sites. Furthermore, both activity-based and 
fluorescence polarization competition studies confirmed that ML349 has at least 20-fold 
lower Kd than the racemic ML349−sulfoxide toward APT2, and no significant binding by 
ML349−thioether (Figures 2.8 b and Table 2.2).  
 
 
 37 
 
Figure 2.8 Catalytic triad and oxyanion hole of APT2 indirectly engaged by ML349. 
(a) ML349−FL exhibits APT2-dependent fluorescence polarization. (b) Chemical structures of ML349 derivatives are 
shown above the dose-dependent ML349−FL displacement by ML349 derivatives in APT2 and APT2−S122A. (c) 
Structural representation of the S and R oxygen atoms comprising the ML349 sulfone group in APT2. Atomic 
distances are shown with dotted lines corresponding to the color schemes used to present the molecular dynamics 
simulations. Blue represents the distance from the His210 τ- nitrogen to ML349-S-oxygen. Brown represents the 
distance from the ML349-S-oxygen to Q123 backbone amide nitrogen. Red represents the distance from the ML349-
S-oxygen to S122 oxygen. Green represents the distance from His210 τ-nitrogen to the ML349-R- oxygen. Black 
represents the distance from the ML349-R-oxygen to the Q123 backbone amide nitrogen. Purple represents the 
distance from the ML349-R-oxygen to the S122 oxygen. (d) Molecular dynamic simulation of APT2·ML349 
demonstrates little active site fluctuation between the sulfone oxygens and catalytic triad. (e) Bound (S)-ML349-
sulfoxide promotes flexibility of His210 to destabilize the active site. (f) Bound (R)-ML349-sulfoxide promotes even 
greater flexibility of His210, and similarly destabilizes the active site.  
 
 
Figure 2.9 ML349 engagement with APT2 requires the thiochromene sulfone. 
(a) FP-PEG-TAMRA competitive assay with ML349 derivatives. (b) APT2 binds sulfone variants with lower affinity, 
measured by ResOAc substrate hydrolysis assay. 
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Table 2.2 Binding affinity of ML349 derivatives determined from competitive ML349-FL fluorescent 
polarization 
 
 
Molecular Dynamics Simulations. To complement the characterization noted above, 
we carried out molecular dynamics simulations of the enzyme−ligand complexes to 
investigate how each sulfonyl oxygen of ML349 interacts in the presence of active site 
resident waters to stabilize the enzyme−inhibitor complex in comparison with sulfoxide 
variants. In order to monitor enzyme−inhibitor interactions, we constructed the distance 
between two designated atoms throughout the course of the simulated trajectories. 
These distances were displayed graphically over 50 ns periods from separate 
simulations for ML349 and the two in silico generated enantiomers (S)-ML349 sulfoxide 
(oxygen atom pointing toward His210) and (R)-ML349 sulfoxide (oxygen pointing toward 
oxyanion hole; Figure 2.8c). Whereas, the sulfonyl containing ML349 showed 
essentially no motion in the active site during our simulations, both (S)-ML349-sulfoxide 
and (R)- ML349-sulfoxide−enzyme simulations displayed increased fluctuations at 
His210 (Figures 2.8d−f). The (R)-ML349- sulfoxide showed significantly more 
fluctuation than the (S)- ML349-sulfoxide, suggesting the pro-(S) sulfone oxygen may 
play a more significant role in active site stabilization. All together, these simulations 
demonstrate how both sulfone oxygens of ML349 minimize disorder in the active site by 
indirectly engaging the catalytic residues through water- mediated hydrogen bonds and 
are consistent with the findings from the thermal denaturation and kinetic analysis.  
The β5−α2 Loop and G3 Helix Are Responsible for Inhibitor Selectivity. APT1 and 
APT2 have only a few divergent residues in the ligand-binding region (Figure 2.10a). In 
order to examine whether these positions are responsible for functional discrimination 
between ML348 and ML349, we performed reciprocal site-directed mutagenesis 
between APT1 and APT2 at these sites and carried out steady-state kinetic assays with 
the fluorogenic substrate resorufin acetate (ResOAc)83 (Table 2.3 and Figure 2.11). As 
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confirmation of proper fold, essentially every reciprocal mutant displayed similar Km 
values except for APT1-L176M, which might be explained by its position close to the 
catalytic triad (Figures 2.5b and 2.11a). APT1-Ile75 (Leu78 in APT2) introduces a 
steric clash with the thiophene group of ML349 (Figure 2.10b) and may disrupt ML349 
binding. Indeed, the APT1-I75L variant introduces a steric clash with the ML348 
trifluoromethyl group. This clash reduces ML348 binding almost 10-fold (Ki = 2.2 μM) 
and enhances binding to ML349 (Ki = 370 nM). The analogous APT2−L78I mutant only 
partially mirrored the reversal observed in APT1−I75L, yielding measurable ML348 
binding (Ki = 5.8 μM), but introduces a new steric clash at the ML349 thiophene sulfur to 
weaken ML349 binding. Thus, Ile75 and Leu78 play important roles in dictating 
selectivity, but these roles are distinct with each inhibitor.  
 
Figure 2.10 Inhibitor selectivity imparted by the divergent β5−α2 loop. 
a) Structural view of divergent residues near the ligand-binding region. APT1 (dark blue) is shown bound to ML348 
(green), and APT2 (teal) is shown bound to ML349 (orange). Homologous vertebrate sequences near the β5−α2 loop 
and G3 helix are shown, highlighting highly divergent (yellow) and less divergent (gray) residues that were selected 
for mutagenesis. (b) APT1-I75 and APT2-L78 contribute to inhibitor selectivity caused by isoform-selective steric 
clashes, high- lighted in black dashed lines.  
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Table 2.3 Summary of kinetic and inhibition parameters of APT reciprocal mutants using ResOAc substrate 
hydrolysis. 
 
 
 
Figure 2.11 Reciprocal mutant sensitivity to ML348 and ML349. 
(a) Steady-state ResOAc hydrolysis rates for APT1 mutants. (b) Reciprocal mutagenesis and inhibition of APT1 by 
ML348 and ML349. (c) Steady-state ResOAc hydrolysis rates for APT2 mutants. (d) Reciprocal mutagenesis and 
inhibition of APT2 by ML348 and ML349. 
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Since the reciprocal mutations at APT1-I75L/APT2-L78I do not fully reconstitute 
the observed potency and orthogonality of the wild type enzymes, synergistic residues 
were profiled by combining several reciprocal mutations. The triple APT1-I75L/ 
S82A/Q83P mutant completely abolished ML348 inhibition but showed weaker ML349 
potency (Ki = 1.2 μM) compared to just the single I75L mutant (Ki = 370 nM). Since the 
APT1- Q83P mutation alone had no effect on selectivity, we examined if APT1-S82 
cooperates with APT1-I75 to impart inhibitor orthogonality. Interestingly, the double 
mutant APT1-I75L/ S82A slightly improved ML348 and ML349 inhibition compared to 
APT1-I75L alone. The triple mutant APT1- I75L/S82A/Q83P no longer binds ML348 and 
loses significant potency for ML349. Taken together, these data demonstrate that the 
selectivity effect cannot be isolated to a single mutation, and S82A synergizes with 
Q83P to impact ML348 selectivity. Alternatively, the single APT2-P86Q and the double 
mutant APT2-L78I/A85S have essentially the same Ki values as either wild-type APT2 
or APT2-L78I. Since the APT2 triple mutant L78I/A85S/P86Q improved ML348 potency, 
neither A85S nor P86Q by itself has much effect on preventing ML348 binding. As 
shown for APT1, the synergetic effect is observed when both residues are mutated 
together. Ultimately, switching the G3 helix between APT1 and APT2 led to the most 
robust selectivity reversal, where APT1-I75L/S82A/Q83P/R149H/A150R/S151A was 
potently inhibited by ML349 (Ki = 180 nM) and lost all potency for ML348. The reciprocal 
mutant APT2-L78I/A85S/P86Q/H152R/R153A/A154S was similarly inhibited by ML348 
(Ki = 430 nM) and had no residual inhibition by ML349. Clearly, the G3 helix influences 
β5−α2 loop dynamics to differentially engage ML348 and ML349, through interactions 
with the ML348 piperazinyl amide and the ML349 methoxyphenyl ring. Altogether, these 
structural features form the basis for orthogonal inhibition through a combination of 
differential flexibility and steric constraints.  
Substrates and Selective Inhibitors Engage a Common Acyl-Binding Pocket. On 
the basis of the arrangement of hydrophobic residues, we predict the acyl chain of 
native substrates lies in the same channel as ML348 and ML349. Interestingly, HDFP 
increased the Tm of each APT enzyme by over 10 °C (Figure 2.12), suggesting lipid 
engagement provides a major source of energetic stabilization that decreases the Kd for  
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long chain acyl substrates. To explore acyl engagement more directly, we performed 
product competition studies with ML349−FL. While oleic acid is competitive with 
ML349−FL binding, the observed IC50 value (9.9 ± 0.6 μM) is above the 6 μM critical 
micelle concentration (CMC) for the lipid (Figure 2.13).117 Incubation with 1-oleoyl-2-
hydroxy-sn-glycero-3-phosphocholine produced slightly more potent ML349−FL 
competition (IC50 = 4.3 ± 0.4 μM), although it also serves as a substrate and releases 
oleic acid. Interestingly, the catalytic dead APT2-S122A mutant showed no ML349−FL 
competition with 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine. Thus, any 
competition is likely driven by released oleic acid upon lysophosphatidylcholine 
hydrolysis, and subject to the same potential micellar affects. To overcome this 
experimental obstacle, we directly assayed acyl binding using the environmentally 
sensitive acyl-fluorophore BODIPY-FL-C16, which exhibits increased fluorescence in 
nonpolar environments.118 A constant, submicellar concentration of BODIPY-FL-C16 
was incubated with increasing concentrations of each enzyme, reporting dose-
dependent, saturable fluorescence enhancement with APT1 (Kd =2.5 ±0.5 μM) and 
APT2 (Kd =2.8 ±0.5 μM; Figure 2.14a). Furthermore, BODIPY-FL-C16 exhibited a dose-
dependent reduction in fluorescence after the addition of ML348 in APT1 or ML349 in 
APT2, further supporting competition for the enclosed acyl-binding pocket (Figure 2.14 
b, c). Although the precise BODIPY-FL-C16 orientation and binding mode are unknown, 
this assay confirms BODIPY engagement to a nonpolar site displaced selectively in 
each APT isoform by its corresponding competitive inhibitor.  
 
Figure 2.12  Thermal stabilization of APT1 and APT2 by HDFP. 
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(a) Structure of the covalent lipase inhibitor HDFP. (b) APT1 and APT2 pre-incubated with HDFP stabilizes each 
protein (∆Tm >10 °C) by differential scanning fluorimetry (thermofluor). Further titration of ML348 or ML349 had no 
additive effect on the observed ∆Tm. Stabilization of APT1 by ML348 (green) and APT2 by ML349 (orange) are 
shown as a reference. 
 
 
Figure 2.13  ML349-FL fluorescence polarization with APT2 is attenuated by fatty acid 
APT2 fluorescence polarization with ML349-FL was measured after equilibration for 30 minutes with oleic acid or 
(18:1) lysophosphatidylcholine (Lyso PC). APT2-S122A was not affected by lyso PC, suggesting oleic acid product 
binding. 
 
 
Figure 2.14 Isoform-selective inhibitors displace submicellar fluorescent lipids.  
(a) APT enzymes enhance BODIPY-FL-C16 fluorescence. (b) BODIPY- FL-C16 competition with ML348 and ML349 
against APT1. (c) BODIPY- FL-C16 competition with ML348 and ML349 against APT2. 
 
Discussion 
APT1 and APT2 are broadly invoked whenever describing the dynamic turnover 
of S-palmitoylation on proteins.100 While ML348 and ML349 superficially share a 
common piperazinyl amide chemotype, our high-resolution structural analyses reveal 
distinct binding modes that block access to the catalytic triad and occlude the putative 
acyl-binding pocket. Ligand engagement by a hydrophobic channel is not surprising, 
since APT1 and APT2 react exceptionally fast with aliphatic fluorophosphonate probes 
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and HDFP, and much slower with polar, PEG-fluorophosphonate probes.28, 83 The 
potent dual APT1/APT2 inhibitor Palmostatin B also incorporates a 10-carbon chain,61 
reinforcing the benefit conferred by an acyl binding element.  
On the basis of structural and sequence alignment of APTs across vertebrates, 
any determinants promoting functional orthogonality between APT1 and APT2 are not 
immediately obvious (Figure 2.5). Several studies suggest that APT1 and APT2 harbor 
intrinsic substrate preferences,112, 113 and clearly APT1 and APT2 possess sufficient 
structural variance to enable isoform-selective inhibition. Herein we carried out 
reciprocal mutagenesis at divergent residues distal from the catalytic triad, revealing 
functional differences affecting inhibitor engagement. Although definitive evidence 
supporting the precise mode of acyl group engagement will require further 
crystallographic analysis, our current biochemical competition data demonstrate that 
each isoform-selective inhibitor occludes acyl engagement across the nonpolar channel, 
which likely forms upon substrate engagement by the closure of the β5−α2 loop. 
Alternatively, the acyl group could potentially occupy the shallow groove contiguous 
along the catalytic site and acyl-binding pocket (Figure 2.15). Since this groove is 
largely solvent exposed with mixed polarity, it more likely helps dock lysophospholipid 
head groups or the palmitoylated protein domains. While this model is intuitive, any 
functional role for the adjacent groove will require further biochemical studies, 
potentially after HDFP inactivation. However, part of the β8/α4 region also features 
several divergent residues closer to the active site. These additional residues could 
cooperate in substrate acquisition, supporting additional investigation to dissect further 
functional divergence. Overall, the observed inhibitor orthogonality is solely derived from 
the acyl-binding channel, thus any substrate selectivity beyond acyl-chain selection is 
more likely promoted through distal sites not engaged by either ML348 or ML349.  
On the basis of the structural models presented, we speculate that APT enzymes 
primarily hydrolyze substrates with reduced membrane partitioning, including 
lysophospholipids, prostaglandin esters, or singly S-palmitoylated substrates. Further S- 
acylation of each APT enzyme likely localizes the enzyme in close proximity to 
membrane-bound substrates, thereby enhancing substrate acquisition and relative 
activity. Following substrate recruitment and acyl engagement, we propose that the 
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β5−α2 loop closes to encapsulate the nonpolar acyl chain, providing significant enzyme 
stabilization to drive polar coordination of the acyl thioester. Additional interactions may 
further align the peptide, culminating in the thioester hydrolysis and subsequent release 
of product. This model readily accommodates S-palmitoylated sites near the protein 
termini or disordered regions, allowing the peptide and acyl chain to thread along the 
contiguous groove. Dually lipidated proteins, such as N-myristoylated and S-
palmitoylated Lck and Giα1, may require additional rearrangements to engage the active 
site. Here, the N-myristoyl group could expand the binding pocket by shifting the flexible 
β5−α2 loop to accommodate both lipids, or one acyl group could remain engaged in the 
membrane and thread next to the β4−β5 sheets and G1 helix. Deciphering the precise 
mechanism of substrate engagement will likely require additional structural analysis, 
potentially capturing native substrates with a catalytic dead enzyme, or through the 
design of tailored fluorophosphonate probes to mimic acylated peptide substrates.  
Overall, the structures of APT1·ML348 and APT2·ML349 show highly similar 
active sites with distinct inhibitor conformations despite a related chemotype. Inhibitor 
selectivity depends on distinct residues lining a divergent flexible loop, reminiscent of 
the lid domain of related bacterial hydrolases.115 More potent inhibitors may be 
optimized to directly engage each protein, potentially by displacing active site waters, or 
through extended engagement of the shallow proximal groove. Furthermore, we report 
the unique sulfonyl-engagement of ML349 by APT2, suggesting further exploration of 
sulfonyl functional groups when optimizing active site-directed reversible hydrolase 
inhibitors. Ultimately, this structural analysis highlights the subtle differences between 
APT1 and APT2 leveraged by ML348 and ML349, which will provide value in future 
studies profiling the physiological function and substrates of each enzyme across both 
lipidated peptides and metabolites.  
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Figure 2.15  ML348 and ML348 are adjacent to a contiguous groove. 
Surface rendering of APTs reveal a shallow groove contiguous from the active site. The opening of the channel and 
the residues that line the center in both structures are formed by hydrophobic residues (black font). Polar residues 
that line the groove are highlighted in blue.  
 
 
Materials and Methods 
Protein Expression, Purification, and Crystallization. APT1 and APT2 genes were 
amplified from human 239T cell cDNA and inserted into pMCSG7 to introduce an in-
frame N-terminal polyhistidine tag for expression. BL21 (DE3) E. coli (Novagen) cultures 
(OD600 = 0.6) were induced with 0.5 mM IPTG for 16 h at 25 °C. Cell pellets were 
resuspended in 50 mM HEPES at pH 7.8, 300 mM NaCl, and 10% glycerol; sonicated; 
and centrifuged at 35000g for 30 min. Talon cobalt affinity beads (Clontech) were 
incubated with the cleared supernatant for 1 h and then washed with 50 mM HEPES at 
pH 7.8, 150 mM NaCl, and 1 mM imidazole buffer. The proteins were eluted with 50 mM 
HEPES, 150 mM NaCl, and 150 mM imidazole buffer. The eluted samples were 
dialyzed overnight in the presence of TEV protease to remove excess imidazole and to 
cleave the HisTag, yielding ∼10 mg mL−1 of protein. Protein samples were 
supplemented with 20% glycerol and stored at −80 °C. For crystallization, protein stock 
solutions preincubated with inhibitors were prepared at 8 mg mL−1 and supplemented 
with 5 mM dithiothreitol (DTT). APT1 was incubated with 3 mM ML348, and APT2 was 
incubated with 1 mM ML349 for at least 1 h at 4 °C before setting crystal trays for 
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incubation at 20 °C. Crystals were produced by sitting drop vapor diffusion with drops 
containing 2 μL of enzyme− inhibitor complex and 2 μL of reservoir solution. For 
APT1·ML348, the best-diffracting crystals were formed from reservoir solution 
containing 0.1 M sodium citrate at pH 5.5, 22−24% PEG 3350, and 200 mM MgCl2. For 
APT2·ML349, the best-diffracting crystals were formed from reservoir solution 
containing 0.1 mM sodium citrate at pH 5.5 and 20−24% PEG 3350. Larger, better 
diffracting crystals were formed by microseeding 1 day after setup. After 1−2 weeks, 
thin plate crystals formed. Reservoir solution was supplemented with 25% ethylene 
glycol for cryopreservation.  
Data Collection and Structure Determination. Diffraction data for APT1·ML348 and 
APT2·ML349 were collected on the Advanced Photon Source LS-CAT beamlines 21-ID-
D and 21-ID-G, respectively. The data were processed with MOSFLM119 and scaled 
with SCALA.120 APT1·ML348 was solved to 1.55 Å resolution by molecular replacement 
using MOLREP121 with the A chain of APT1 (PDB ID: 1FJ2) as the search model. The 
structure of APT2·ML349 was solved to 1.64 Å resolution by molecular replacement via 
Balbes,122 which also used the APT1 structure as the search model. Both structures 
went through iterative rounds of manual electron density fitting and structural refinement 
in Coot123 and Buster.124 Difference electron density maps contoured at 2σ showed the 
presence of an inhibitor associated with each protein chain. Coordinates and restraint 
files for each ligand were created by grade124 with the mogul+qm option. Data collection 
and refinement statistics for each structure are listed in Table 2.1. Figures were 
generated using the PyMol Molecular Graphics system (Schrödinger). Atomic 
coordinates for APT1·ML348 and APT2·ML349 have been deposited in the PDB as 
entries 5SYM and 5SYN, respectively.  
General chemical synthesis and purification procedure. 
Can be found in Appendix A. 
Thermal denaturation assays. For thermal shift assays, 0.25 mg / mL of recombinant 
protein in Phosphate Buffered Saline (PBS) was incubated with 200 µM ligand for 30 
minutes, heated to desired temperature for 3 minutes using a thermocycler (Bio-Rad), 
and incubated on ice. The tubes were spun at 20,000 x g for 20 minutes at 4 °C. The 
concentration of soluble protein was quantified with the DC Protein Assay kit (Bio-Rad). 
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For differential scanning fluorimetry assays, 0.2 mg / mL of protein in PBS was 
incubated with varying amounts of ligand for 30 minutes, followed by the addition of 1-
anilinonaphthalene-8-sulfonic acid (ANS, ThermoFisher) to a final concentration of 0.2 
mM. Samples were transferred to a black 384-well PCR plate (Axygen, 384-55-BK) and 
1.5 µL of silicon oil was added on top of each well. Plates were heated from 25 °C to 85 
°C at 1 minute intervals and each condition was measured in quadruplicate using a 
ThermoFluor plate reader (Johnson & Johnson). The melting curves were analyzed by 
fitting to a Boltzmann model to determine Tm using ThermoFluor Acquire 3.0 software. 
Steady-state kinetic assays. Assays were performed as previously described with 
modifications83. The Km for resorufin acetate was determined for different APT mutants 
using resorufin acetate (Sigma). Assays were performed side-by-side with catalytic-
dead enzyme (APT1-S119A, APT2-S122A) to subtract any spontaneous hydrolysis. 
Enzymes were diluted to 10 nM in PBS pH 6.5 (adjusted with sodium acetate) 
supplemented with 0.1 g / L pluronic F127 (Sigma). Varying concentrations of resorufin 
acetate (Sigma) in DMSO were added as 5 µL aliquots to clear-bottom 96-well plates 
(Greiner bio-one). Using a multi-channel pipette, 95 µL of enzyme was added to each 
well and quickly mixed by pipetting up and down several times. Each enzyme was 
assayed in 2 separate runs, each with 4 replicates per substrate concentration and 4 
replicates of catalytic-dead enzyme. Fluorescence was measured every 35 seconds for 
15 minutes on a Tecan F500 plate reader (525/35 nm excitation filter, 600/10 nm 
emission filter, and a 560 LP dichroic filter). Initial reaction velocities were calculated 
from the slope of the background-subtracted (catalytic dead) fluorescence in the first 5 
minutes, and processed in Graphpad Prism 6 to derive Km and Vmax. Steady-state 
inhibitors IC50 values were calculated using a similar experimental scheme, starting by 
pre-incubating 10 nM enzyme with varying inhibitor concentrations for 30 minutes at 
room temperature. A fixed concentration of substrate (50 µM final) was aliquoted into 
each well and the reaction was initiated by the addition of the enzyme-inhibitor mixture 
and initial rates were measured. The data containing 8 replicates per inhibitor 
concentration was imported to Graphpad Prism 6 and a standard non-logarithmic 
sigmoidal dose response curve was fitted to each enzyme experiment. Each Ki value 
was calculated using Cheng-Prusoff equation. 
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Fluorophosphonate-TAMRA competitive assays. APT2 (200 nM) was incubated with 
varying concentrations of inhibitor in PBS pH 7.4 at room temperature for 30 minutes, 
and then mixed with 1 µM of FP-PEG-TAMRA for 10 minutes. The reaction was 
quenched by addition of Laemmli sample buffer and incubation at 90 °C for 5 minutes. 
The samples were resolved on 12% SDS-PAGE and visualized by Azure C600 imager. 
Computational methods. Molecular dynamics simulations were performed using the 
CHARMM macromolecular modeling program125, version c39b2, for APT2·ML349, 
APT2·ML349 (R-sulfoxide), and APT2·ML349 (S-sulfoxide). Dynamics were performed 
using the Leapfrog Verlet/Langevin integrator with a 2 fs timestep. A non-bonded cutoff 
range of 10-12 Å was used with a van der Waals switching function, where the non-
bonded list was generated using a 15 Å cutoff. Long range electrostatic interactions 
were treated using the particle-mesh Ewald method126, with a κ = 0.56 and an 
interpolation spline order of 4. Each simulation was heated to 310 K utilizing a Langevin 
heat bath for 100 ps, equilibrated for 100 ps, followed by a production run of 50 ns. In 
each simulation, the APT systems were simulated as a monomer. The CHARMM22 all-
atom force field for proteins with CMAP correction127 was used for the APT2 ML349 
systems, and the CHARMM36 all-atom force field was used for the sulfoxide systems. 
Each system was solvated in a 13,793 TIP3P128 water molecule box with periodic 
boundary conditions in a cubic volume of edge length 36 Å. Eighteen sodium chloride 
pairs and an additional sodium ion were added to the APT2 enzyme to give a net zero 
charge and an excess salt concentration of 0.1 M for each system. For ligand 
parameterization, ML349, ML349 (R-sulfoxide) and ML349 (S-sulfoxide) were assigned 
parameters and partial charges consistent with the CHARMM General Force Field 
(CGenFF)129-132 using the CGenFF interface for ParamChem129-132. The most recent 
extension of the CGenFF force field covers sulfonyl-containing compounds with good 
agreement with experimental IR/NMR data, allowing for the assignment of parameters 
to ML349, and was implemented into MATCH Analysis. The distance between two 
defined atoms was calculated in VMD133 and graphed using MATLAB. 
Fluorescence binding assays. Varying amounts of enzyme were diluted in PBS 
supplemented with 0.5 g / L pluronic F127 and incubated with 500 nM ML349-FL for 30 
minutes at room temperature. The fluorescent polarization from each well was 
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measured using a Tecan F500 plate reader using 485/20 nm excitation and 535/25 nm 
emission polarization filters. Each concentration was measured in 2 replicates. The 
background signal was subtracted to obtain ∆ mP at each protein concentration and 
imported to Graphpad Prism 6.0 for one site-specific binding analysis. For dose-
response fluorescent polarization, 1 µM of protein and 500 nM ML349-FL were 
incubated with varying amounts of ML349 derivatives for 30 minutes at room 
temperature. The standard non-logarithmic sigmoidal dose-response curve was used to 
derive IC50. Ki was calculated using the online IC50 to Ki converter134. For BODIPY-FL-
C16 binding assays, 1 µM of BODIPY FL C16 (ThermoFisher) was incubated with 
various concentrations of enzyme in PBS for 30 minutes. The relative fluorescence was 
performed as two independent replicates, and measured using Tecan F500 plate reader 
(485/20 nm excitation filter, 535/25 nm emission filter). After background subtraction, 
the data was processed in Graphpad Prism 6 for single site binding analysis. For 
competition assays, 5 µM APT, 1 µM BODIPY-FL-C16, and varying concentration of 
ML348 or ML349 were incubated for 30 minutes in PBS and data was fit to a non-
logarithmic sigmoidal dose response curve. 
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Chapter 3 : Affinity-based Selectivity Profiling of an In-class Selective 
Competitive Inhibitor of Acyl Protein Thioesterase 2§ 
 
Abstract 
Activity-based protein profiling (ABPP) has revolutionized the discovery and 
optimization of active-site ligands across distinct enzyme families, providing a robust 
platform for in-class selectivity profiling. Nonetheless, this approach is less 
straightforward for profiling reversible inhibitors and does not access proteins outside 
the ABPP probe’s target profile. While the active-site competitive acyl protein 
thioesterase 2 (APT2) inhibitor ML349 (Ki = 120 nM) is highly selective within the serine 
hydrolase enzyme family, it could still interact with other cellular targets. Here we 
present a chemoproteomic workflow to enrich and profile candidate ML349-binding 
proteins. In human cell lysates, biotinylated-ML349 enriches a recurring set of proteins, 
including metabolite kinases and flavin-dependent oxidoreductases that are potentially 
enhanced by avidity-driven multimeric interactions. Confirmatory assays by native mass 
spectrometry and fluorescence polarization quickly rank-ordered weak off-targets, 
providing justification to explore ligand interactions and stoichiometry beyond ABPP. 
 
 
Figure 3.1 Graphical abstract 
                                             
§ This chapter presents a published peer reviewed work. Won S. J. et al ACS Med Chem Lett. 2016 Dec 9;8(2):215-
220 
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Introduction 
Medicinal chemistry efforts primarily focus on achieving the highest potency 
ligands, which in the best-case scenario obviates any off-target engagement. In 
practice, many lead inhibitors have suboptimal potency, leaving open the possibility of 
off-target binding to other enzymes. In order to validate selectivity, medicinal chemistry 
campaigns typically assess inhibition against related enzymes that share the same 
catalytic mechanism. Particularly for kinases, hydrolases, and proteases, this workflow 
can induce active-site competitive assays with reporter-linked covalent inhibitors.135 For 
example, fluorophosphonate probe labeling is occluded when an inhibitor covalently 
modifies or otherwise occupies an active site. Such competitive activity-based protein 
profiling (ABPP) methods enable evaluation of both potency and in-class selectivity 
either by in-gel fluorescence or affinity purification for mass spectrometry profiling. 
Across the serine hydrolase enzyme family, ABPP methods have supported the 
development of several mechanism-based covalent scaffolds, including N-heterocyclic 
ureas,86 β-lactones,61 and activated carbamates.87, 136, 137 Since these scaffolds 
covalently modify their target enzymes, the competitive fluorophosphonate assay 
requires only enough probe and time to achieve complete labeling. Profiling reversible 
inhibitors is more complicated since each enzyme has a different rate of inactivation 
(Kinact), as well as different rates of inhibitor displacement (koff).83 Under such conditions, 
selectivity profiling is most representative of inhibition for enzymes with relatively slower 
Kinact constants, providing a kinetic window to profile target engagement. For example, 
the fluorophosphonate-TAMRA reacts extremely rapidly with acyl protein thioesterase 2 
(APT2), which overwhelms much of the observable competition by the reversible active 
site inhibitor ML349.83 This can be addressed by tailoring the reactivity of the ABPP 
probe, such as using a less reactive N-heterocyclic urea. In this example, intraperitoneal 
injection of ML349 was chased with an alkynyl N-heterocyclic urea probe in living mice, 
allowing assessment of in vivo target engagement and partial in-class selectivity from 
isolated tissue homogenates.83  
Due to these limitations, in-class selectivity profiling can also be carried out using 
reversible ligands linked to an affinity resin. Such affinity purification approaches have 
been used for decades for target enrichment and identification, particularly when 
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coupled with quantitative shotgun proteomics methods. When adapted for on-bead 
competitive displacement assays, inhibitor selectivity can be quantitatively profiled for 
any enriched proteins. For example, a resin-linked kinase inhibitor cocktail (or kinome 
beads) allows multiplexed dose−response analysis of ligand selectivity across more 
than 200 enriched kinases.138 In addition, such native enrichment approaches also 
capture accessory proteins, or in some cases totally orthogonal enzyme classes. Using 
this approach, imatinib was found to bind the oxidoreductase NQO2 6-fold stronger than 
BCR-ABL, establishing unanticipated off-targets outside the targeted kinase family.138, 
139 More recently, cellular thermal shift assays (CETSA),114 drug affinity responsive 
target stability (DARTS),140 or CRISPR genome-wide approaches141 provide orthogonal 
routes to target discovery independent of affinity enrichment.  
Here we evaluated the selectivity of the APT2 inhibitor ML349, comparing 
reported ABPP selectivity to traditional affinity-based target identification methods. 
APT2 is a widely expressed serine hydrolase with several reported substrates, including 
lysophospholipids,64 prostaglandin esters,65 and S-palmitoylated proteins.61 The active 
site competitive APT2 inhibitor ML349 was first identified from a high-throughput 
competitive activity-based fluorophosphonate assay in collaboration with the NIH 
Molecular Libraries Production Centers Network.81 Out of the 3 ×105 compounds tested, 
ML349 was identified as a promising competitive inhibitor with high selectivity across 
the serine hydrolase enzyme family. Even without further optimization, ML349 achieves 
target engagement and hydrolase selectivity in living mice.83, 100  
ML349 was later validated to modulate protein S-palmitoylation in cells. The S-
palmitoylated tumor suppressor Scribble (Scrib) localizes to the plasma membrane in 
polarized epithelial cells to attenuate growth signals and promote contact inhibition.142 
When polarized epithelial cells are induced to undergo epithelial-to-mesenchymal 
transition, Scrib relocates to the cytosol and is less S-palmitoylated.75Treatment with 
submicromolar concentrations of ML349 increase the S-palmitoylation and membrane 
localization of Scrib, restoring plasma membrane localization to attenuate growth 
signals.75As reported, ML349 only suppresses cell proliferation at significantly higher 
concentrations (100 × Ki), suggesting engagement of other potential off-target 
proteins.75In the crystal structure of APT2 bound to ML349 (1.6 Å), ML349 binds to a 
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hydrophobic channel extending across the enzyme active site, leaving only a solvent-
exposed p-methoxy substituent to tether a reporter group.103 Since cell proliferation is 
only inhibited at concentrations well beyond concentrations required for APT2 inhibition, 
we set out to functionalize ML349 at the p-methoxy position for affinity-guided off-target 
identification. 
Using an affinity purification strategy, we annotated a reproducible series of 
enriched targets by mass spectrometry. Some of these target proteins were individually 
profiled by native mass spectrometry, providing a direct assessment of ligand 
stoichiometry and affinity,143 particularly since several targets exist as homodimers. 
Confirmatory polarization assays with ML349-fluorescein ruled out other enriched 
targets, suggesting that resin avidity might enhance enrichment of otherwise low affinity 
targets. Overall, we report the target landscape of ML349, which includes APT2 and 
other weak cellular targets. Accordingly, while ABPP methods are streamlined for in-
class selectivity of covalent inhibitors, classic ligand affinity purification methods access 
diverse cellular targets and circumvent potential false negatives missed in time-
dependent competitive ABPP assays.  
 
Results 
Previous structure−activity analysis demonstrated that interchanging the ML349 
methoxy group from the para to ortho position abolished APT2 inhibition.83 Accordingly, 
we synthesized both p- and o-propargyl-ML349 derivatives and conjugated each to 
biotin-azide by copper catalyzed azide−alkyne cycloaddition (CuAAC) (Figure 3.2a). In 
a biochemical fluorogenic esterase assay, the p-substituted ML349-PEG3- biotin probe 
(ML349-biotin) lost approximately 9-fold affinity (Ki = 1100 nM), while the o-substituted 
probe (o-ML349- biotin) or the azide-PEG3-biotin linker alone were completely inactive 
(Figure 3.2b). Despite this reduction in affinity, we continued to explore if ML349-biotin 
could enrich APT2 or APT2-interacting proteins or reveal other protein targets. ML349-
biotin was preassociated with streptavidin beads to decrease the sample processing 
time and limit dissociation of weak interacting proteins. The ML349-biotin/streptavidin 
resin was then incubated with HEK-293T whole cell lysate for 60 minutes and quickly 
transferred to spin columns for rapid washes. Since ML349 is a competitive inhibitor, 
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incubation with fluorophosphonate-TAMRA displaces any ML349-bound serine 
hydrolases from the resin (Figure 3.3). By in-gel fluorescence, ML349-biotin exclusively 
enriches a ∼25 kDa hydrolase, corresponding to the molecular weight of APT2. Both o-
ML349-biotin and unconjugated azide-PEG3-biotin did not enrich any hydrolases, 
providing two distinct controls to quantify ML349-binding proteins in cell lysates.  
 
 
Figure 3.2 ML349 affinity probes inhibit APT2 
(a) Chemical structures of ML349 and derivatives. (b) APT2 inhibition by ML349 and functionalized derivatives 
measured by resorufin acetate hydrolysis, reporting Ki values.  
 
 
 
Figure 3.3 In-class selective APT2 enrichment by ML349-biotin 
Elution of ML349-biotin enriched serine hydrolases from HEK-293T lysate and detection by FP-TAMRA in-gel 
fluorescence. A labeled band corresponding to the molecular weight of APT2 is highlighted with a black arrow. FT = 
flow through, W = wash.  
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Next, proteome-wide ML349-interacting proteins were eluted with excess ML349 
and digested with trypsin for label- free mass spectrometry analysis. In our approach, 
we employed a data-independent acquisition workflow to maximize reproducibility, 
extracting precursor (MS1) peak area across replicates at high resolution (± 10 ppm), 
aligned retention times, and matched ion mobility drift times.144 In this method, once a 
peak is annotated in one data set, it can be cross-extracted to populate data across 
replicates. Each biological replicate was analyzed with three technical replicates for 
each probe, providing a dense data set for precise statistical analysis. In pairwise 
comparisons, ML349-biotin significantly enriched about 10 proteins (>5-fold) compared 
to o-ML349-biotin or azide-PEG3-biotin (Figure 3a,b and Tables 3.1, 3.2). This list  
includes APT2 (LYPA2), as well as the metabolite kinases ADK, DCK, and PDXK, the 
oxidoreductase NQO2, and the flavin adenine dinucleotide synthase FAD1.  
 
 
Figure 3.4 Label-free profiling of ML349-biotin enriched proteins. 
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(a) ML349-biotin enrichment relative to o-ML349-biotin. (b) ML349- biotin enrichment relative to azide-PEG3-biotin. 
(c) o-ML349-biotin enrichment relative to azide-PEG3-biotin reports few o-ML349-biotin enriched proteins. (d) ML349-
biotin enrichment with or without (control) APT2 covalent inhibition by HDFP. Protein identifiers (Uniprot accession 
code) are shown for significantly enriched proteins quantified by at least three peptides. Dotted lines indicate a 
minimum 5-fold change and p-value less than 0.05. Enriched binding proteins from HEK-293T cell lysates are shown.  
 
Table 3.1 List of significantly enriched proteins by ML349-biotin relative to o-ML349-biotin 
 
 
Table 3.2 List of significantly enriched proteins by ML349-biotin relative to Biotin-PEG3-Azide 
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Interestingly, NQO2 and ADK were both identified as binding proteins for active 
S-crizotinib stereoisomer,145 although the antiproliferative phenotype comes solely from 
inhibiting the oxidized nucleotide phosphatase MTH1. NQO2 is also inhibited by the 
BCR-ABL inhibitors imatinib (IC50 = 82 nM) and nilotinib (IC50 = 381 nM) in steady-state 
substrate assays.139 Additionally, the clinical PARP inhibitor niraparib inhibits DCK, 
preventing phosphorylation the chemotherapeutic nucleotide analogue cytarabine.146 
Based on these reported examples, several ML349-binding proteins may be general 
targets of many drug-like molecules. Other enriched proteins include the small GTPase 
Rab1A, the secreted acetylcholinesterase binding protein CutA, and the mitochondrial 
tRNA ligase SYLM. Importantly, o-ML349-biotin showed only marginal ∼3-fold 
enrichment of NQO2 and FAD1 compared to azide-PEG3-biotin alone, confirming its 
use as an orthogonal control probe (Figure 3.4c). Similar experiments were performed 
in MDCK cells lysates, where ML349 modulates Scrib S-palmitoylation.75 This analysis 
returned a similar profile of binding partners, recapitulating ML349-biotin enrichment of 
APT2, as well as multimeric nucleotide kinases and flavin-dependent oxidoreductases. 
Pretreatment with the generic lipase inhibitor hexadecylfluorophosphonate (HDFP)28 
occludes the APT2 active site and blocks enrichment of APT2 (Figure 3.4d and Table 
3.3). Since HDFP had no effect on ML349-binding protein enrichment, other enriched 
proteins are likely direct targets of ML349- biotin or ML349, and not APT2-interacting 
proteins. 
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Table 3.3  Significantly Enriched proteins in the presence and absence of HDFP 
 
 
In contrast to ABPP, affinity enrichment only returns proteins with some affinity 
for the ligand and does not report the fraction of enriched enzyme. Therefore, many of 
the enriched proteins could have marginal affinity for ML349-biotin, possibly influenced 
by the resin-enrichment strategy. On closer inspection, several of the enriched proteins 
from HEK-293T cells form oligomers, including NQO2 and PDXK. Based on this partial 
preference for oligomeric proteins, we wondered if avidity interactions contribute to the 
enrichment of weak ML349-interacting proteins.  
Accordingly, we set out to validate and quantify ML349 binding to the recurring 
set of proteins. Recombinant APT2, NQO2, PDXK, and Rab1A were incubated with a 
fluorescein-conjugated ML349 to assay binding by fluorescence polarization.84 ML349-
fluorescein (ML349-FL) (Figure 3.5a) interacted similarly with APT2 (Kd = 900 nM) and 
PDXK (Kd = 1.4 μM), but failed to interact with NQO2 or Rab1A in solution (Figure 
3.5b). Either these interactions are disrupted by the conjugated fluorescein, or they 
derive some additional affinity from the PEG-biotin reporter group. In the competition 
experiments, ML349-FL was readily competed with ML349 for APT2 (IC50 = 1.1 μM) but 
showed marginal competition with PDXK (IC50 > 10 μM) (Figure 3.5c). Furthermore, 
ML349- biotin only weakly competed with ML349-FL for both APT2 and PDXK (IC50 > 
10 μM). Therefore, unlike APT2, PDXK does not discriminate between ML349 and 
ML349-biotin.  
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Figure 3.5 Competitive fluorescence polarization assay for ML349 binding. 
(a) Chemical structure of ML349-FL. (b) ML349-FL binding to candidate interacting proteins detected by fluorescence 
polarization. (c) Dose-dependent competition of ML349-FL binding to APT2 or PDXK by ML349 and ML349-biotin. 
 
Since the ML349-FL polarization experiments had limited target scope, we set 
out to evaluate ligand binding and stoichiometry by native mass spectrometry. Putative 
ML349-binding proteins were mixed in an equal ratio with ML349 and directly infused for 
electrospray ionization native mass spectrometry. Using nanoelectrospray ionization, 
proteins are transferred from native buffer into the gas-phase in a gentle fashion to 
maintain native-like conformations and noncovalent interactions with small molecules. 
The signals generated using this method have been shown to be reflective of solution-
phase equilibria, providing a direct assay to profile protein−protein and protein−ligand 
interactions.147 Since native MS analysis reports on electrosprayed protein−ligand 
complexes, we predict some deviation from solution-phase affinity measurements due 
to high local concentration of ligands within electrospray droplets. Nonetheless, this 
assay provides a direct measure of relative binding stoichiometry. As a proof of 
principle, ML349 and ML349-biotin did not form significant amounts of complex with the 
homologous hydrolase APT1, but formed a stoichiometric complex with APT2 with no 
observable dimer formation (Figure 3.6a,b). In agreement with 9-fold increase in Ki, 
ML349-biotin displayed substoichiometric binding to APT2 (Figures 3.6a and 3.7). This 
approach provides a rapid assessment of the relation between homodimerization and 
the stoichiometry of ML349 or ML349-biotin association (Figures 3.6a and 3.7). As 
expected, Rab1A was observed solely as a monomer, yet did not associate with ML349. 
PDXK and NQO2 were detected as homodimers, yet with sub- stoichiometrtic 
association with ML349 and ML349-biotin. NQO2 can associate with two ML349 ligands 
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per homodimer, yet ML349-biotin preferentially binds only one site per homodimer. 
Conversely, PDXK binds only one ML349 or ML349-biotin per dimer. Therefore, in 
contrast to NQO2, PDXK enrichment is unlikely biased by avidity effects. Nonetheless, 
on-resin interactions are likely quite different than those in solution or in the gas-phase. 
Overall, ML349 demonstrates significantly weaker affinity for Rab1A, NQO2, and PDXK, 
suggesting low-micromolar concentrations of ML349 achieve selective APT2 
engagement in cells.  
 
 
Figure 3.6 Native mass spectrometry profiling of inhibitor engagement and stoichiometry. 
(a) Graphical distribution of ligand−protein complexes derived from native mass spectrometry analysis. NQO2 and 
PDXK formed observable dimers, forming two potential ligand binding sites per complex. Red bars represent 
occupancy at both binding sites, representing two ML349 molecules per dimer. Gray bars represent complete 
occupancy of ML349-biotin in NQO2 and PDXK. Asterisks (*) indicate a p-value less than 0.05, as compared to the 
nonspecific binding to APT1 (n = 3, standard deviation). (b) Representative mass/charge spectra with three charge 
states used for quantitation of proteins binding to ML349 before (black trace) and after deconvolution (green = apo 
protein, orange = ML349 bound protein, red = 2 xML349 bound protein) are shown for each protein.  
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Figure 3.7 Native mass spectrometry analysis of ML349-biotin binding and stoichiometry. 
Representative mass / charge spectra for each recombinant protein are shown. 3 charge states were for the 
quantitation. (Green = apo protein, blue = ML349-biotin bound protein, orange = ML349 bound protein, white triangle 
= 2xML349-biotin bound protein). 
 
Discussion 
As chemical proteomics methods become widely adopted, it is increasingly 
recognized that small molecule inhibitors often have multiple unanticipated binding 
partners in cells. In contrast to biochemical affinity-based methods, photoaffinity groups 
provide another sensitive approach to identify ligand targets in living cells.148, 149 This 
approach retrieves a snapshot of live-cell engagement of putative interacting proteins, 
although quantifying the interaction affinity requires titrations, competitions, or additional 
biochemical validation. This becomes even more challenging for well-validated inhibitors 
like (+)-JQ1, where photoaffinity profiling identified an additional >100 additional cellular 
binding partners.149 Clearly ligand space for many inhibitors is broader than previously 
envisioned. Other emerging approaches that leverage thermal stabilization may also 
miss many relevant interactions when the target is not sufficiently stabilized. Overall, 
various target identification methods each have different caveats, and selectivity from 
one assay can present different targets from another assay. ML349 is highly selective 
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by competitive fluorophosphonate ABPP, yet still weakly binds several hydrolases by 
ML349-biotin enrichment. Therefore, affinity-enrichment is likely more sensitive for initial 
target discovery, but does not provide information on the relative level of target 
occupancy. Importantly, many of the ML349-enriched targets are common to other 
chemoproteomic analyses, implying that many drug-like molecules share common 
promiscuous protein targets. Future efforts combining different target enrichment 
strategies will provide the most robust approach for understanding ligand selectivity 
across the proteome and provide new starting points for lead discovery across putative 
off-targets.  
In summary, we present a detailed profile of the proteome-wide target landscape 
of the reversible APT2 inhibitor ML349. While fluorophosphonate ABPP was critical for 
the initial discovery and characterization of ML349, we now demonstrate that narrow in-
class ABPP can overlook the extent of ligand targets outside of the tailored enzyme 
family. In this example, ML349-biotin/streptavidin resin enriches about a dozen targets 
outside of the serine hydrolase enzyme family, although confirmatory experiments 
suggest many of these may reflect multivalent interactions and are unlikely valid cellular 
targets at working inhibitor concentrations. Nonetheless, these efforts present a new 
affinity probe for profiling ligand engagement across this series of targets, providing a 
path to future competitive biochemical screens for proteins beyond the serine hydrolase 
enzyme family. 
 
Materials and Methods 
ML349-biotin pull-downs. Human HEK-293T cells were resuspended in phosphate 
buffered saline supplemented with 0.01% (v / v) triton-X (PBST) and sonicated briefly. 
Streptavidin-Agarose beads (EMD Millipore) (100 µL slurry) were incubated with 50 µM 
of ML349-biotin, o-ML349-biotin, or azide-PEG3-biotin (Click Chemistry Tools) in PBST 
for 30 minutes at 4 °C, and washed three times. Next, 1 mg of cell lysate was added for 
1 hour at 4 °C, centrifuged at 1000 x g for 1 minute, and then quickly washed 3 times 
with PBS. The enriched beads were then resuspended in 50 µL of PBS supplemented 
with 10 µM of ML349 and incubated for 1 hour at 4 °C. After centrifugation at 1000x g 
for 1 minute, the supernatant was transferred to another tube and treated with either 1 
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µM of FP-TAMRA for in-gel fluorescence or further processed for mass spectrometry 
analysis, diluting the sample in 6 M urea (4-fold) for 20 minutes at room temperature. 
Next, the sample was reduced with 5 mM Tris(2-carboxyethyl)phosphine hydrochloride 
(TCEP) for 20 minutes at 37 °C, and alkylated with 20 mM iodoacetamide for 1 hour at 
37 °C in the dark. After 3-fold dilution in PBS, 2.5 µg of mass spectrometry-grade trypsin 
(Promega) was added and incubated overnight at 37 °C. Samples were desalted using 
Oasis HLB μElution plates (Waters), dried using the Savant SPD1010 SpeedVac 
(Thermo Scientific) and reconstituted in LC-MS buffer (3% acetonitrile in LC-MS grade 
water, 0.1% formic acid, and 10 fmol/μL Saccharomyces cerevisiae alcohol 
dehydrogenase (P00330) digest, Waters). 
LC-MS proteomic analysis and data processing. Tryptic peptides were injected onto 
a 1D Waters NanoAquity UPLC system UPLC system equipped with a 5 µM Symmetry 
C18 (180 µm x 20 mm) trap column and a 1.8 µm High Strength Silica (HSS-T3) 
analytical column (75 µm x 150 mm). Initial loading of tryptic peptides was performed 
over 3 minutes by loading onto a trap column, followed by analytical separation over a 
90-minute gradient (7% to 35% acetonitrile) coupled to a Waters Synapt G2S HDMS 
time-of-flight mass spectrometer with ion mobility separation using data independent 
acquisition methods (Waters Corp.). The nanoLC flow rate was 500 nl / min. Lock mass 
(Glu-fibronogen peptide, m/z = 785.8426) was collected every 30 seconds for internal 
reference mass calibration. The capillary voltage was set at 3.00 kV. The quadruple 
mass analyzer was manually set for mass 500, 600 and 700 and the sampling cone was 
set to operate at 32 eV. The nano flow gas was set to flow at 0.2 bar with the purge gas 
set to flow at 50 L / h and the source temperature was set at 70 °C. All measurements 
were collected with the mass spectrometer operating in resolution mode (resolving 
power of at least 20,000 FWHM (full-width at half maximum) in positive-mode ESI for 
400 m/z). For Ion Mobility Separation (IMS) wave height was set as 40 V and IMS wave 
velocity as 600 m/s, with the spectral acquisition time each mode being 0.5 s. Collision 
energy (CE) ramp from 16 eV to 60 eV during each 0.5 s-integration was used as 
standard setting for the elevated energy MS scan. Data was analyzed with Progenesis 
QI for proteomics software (Nonlinear dynamics). The false discovery rate (FDR) was 
set to 1% with 1 maximum missed cleavage. The minimum ion matching requirements 
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were set to 2 fragments / peptide, 5 fragments / protein and 2 peptides / protein. The 
Top3 (3 most intense peptides) method was used for quantitative analysis. Briefly, the 3 
most-intense peptides from each protein were used to quantify the 
average abundance of a protein.150 Proteins with a minimum of 5-fold enrichment, a p-
value less than 0.05, and at least 3 quantified peptides were assigned as putative 
ML349-biotin binding proteins. 
Recombinant protein expression and purification. Human LYPLA1 (APT1), LYPLA2 
(APT2), Rab1A, NQO2, and PDXK genes were amplified from HEK-239T cell cDNA and 
sub-cloned into the pTrcHis2A bacterial expression vector (Sigma), transformed into 
BL21(DE3) cells, and induced with 0.5 mM IPTG for 16 hours at 25 º C. Cell pellets 
were lysed in 50 mM HEPES pH 7.8, 300 mM NaCl, and 10 % glycerol by sonication 
and cleared by centrifugation at 35000 x g for 30 minutes. The supernatant was 
incubated with Talon cobalt affinity beads for 1 hour (Invitrogen), washed, and eluted 
with imidazole. The eluted samples were dialyzed overnight in 50 mM HEPES pH 7.8, 
150 mM NaCl and supplemented with 20 % glycerol before for storage at -80 º C. 
Steady-state kinetic analysis. Resorufin acetate (Sigma) hydrolysis assays were 
performed to characterize APT2 inhibition, subtracting any spontaneous hydrolysis from 
the catalytic-dead enzyme (APT2-S122A). Steady-state inhibitors IC50 values were 
calculated by pre-incubating 10 nM protein with varying inhibitor concentrations for 30 
minutes at room temperature. A fixed concentration of substrate (50 µM final) was 
aliquoted into each well and the reaction was initiated by the addition of the enzyme-
inhibitor mixture and initial rates were measured. The data containing 8 replicates per 
inhibitor concentration was imported to Graphpad Prism 6 and a standard non-
logarithmic sigmoidal dose response curve was fitted to each enzyme experiment. Each 
Ki value was calculated using Cheng-Prusoff equation, referencing previously reported 
Km values. Fluorescence polarization assays were performed as previously 
described.103  
Native mass spectrometry analysis. Native MS experiments were performed using a 
Synapt G2 ion mobility-mass spectrometer (Waters Corp.). Samples were buffer 
exchanged into 200 mM ammonium acetate using a Micro Biospin column (Bio-Rad, 
Inc. Hercules, California). Each protein was incubated at a final concentration of 10 µM 
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protein: 10 µM ligand (ML349 or ML349-biotin) in 5% DMSO for 5 min. Samples were 
electrosprayed from in-house gold-coated borosilicate capillaries. Instrument 
parameters were optimized for high transmission of protein-ligand ions with minimal 
gas-phase dissociation. The backing pressure was set to ~8 mBar and the capillary 
potential was set to 1.6 kV, with a sampling cone potential of 30 V. For monomeric 
species, the trap collision energy was set to 20 V for efficient transmission of ions with 
no observable unfolding or ligand dissociation. For dimeric species, the trap collision 
energy was set to 50 V for more efficient desolvation, with no apparent ligand 
dissociation. Spectra were acquired from 1000 to 10000 m/z for 1 minute. Other 
instrument parameters were set to those found described as optimal in previous 
literature.151 The resulting datasets were processed and deconvolved using Unidec152 to 
yield relative abundances of apo and bound proteins. Relative abundance ratios were 
also validated manually using background subtraction and integration tools mMass.153 
Ratios of manually integrated peak areas were compared with the relative intensities 
derived from Unidec and found to be within 5% error in all cases. 
General chemical synthesis and purification procedures.  
Can be found in Appendix B. 
 
Individual contributions 
Sang Joon Won and Fei San Chong synthesized compounds. Sang Joon Won 
performed affinity purification proteomic experiments. Sang Joon Won and Jaimeen 
Majmudar processed and analyzed LC/MS data. Sang Joon Won purified all proteins. 
Sang Joon Won and Sin Ye Hwang performed enzyme assays. Joseph Eschweiler and 
Brandon Ruotolo performed native mass spectrometry and interpreted the data. Sang 
Joon Won and Brent Martin designed experiments and wrote the paper. 
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Chapter 4 : Temporal Profiling Establishes a Dynamic S-palmitoylation Cycle§ 
 
Abstract 
S-palmitoylation is required for membrane anchoring, proper trafficking, and the normal 
function of hundreds of integral and peripheral membrane proteins. Previous 
bioorthogonal pulse-chase proteomics analyses identified Ras family GTPases, polarity 
proteins, and G proteins as rapidly cycling S-palmitoylated proteins sensitive to 
depalmitoylase inhibition, yet the breadth of enzyme regulated dynamic S-palmitoylation 
largely remains a mystery. Here we present a pulsed bioorthogonal S-palmitoylation 
assay for temporal analysis of S-palmitoylation dynamics (Figure 4.1). Low 
concentration hexadecylfluorophosphonate (HDFP) preferentially inactivates the APT 
and ABHD17 families of depalmitoylases, which dramatically increases alkynyl-fatty 
acid labeling and stratifies S-palmitoylated proteins into kinetically distinct subgroups. 
Surprisingly, HDFP treatment has no effect on steady-state S-palmitoylation levels, in 
agreement with S-palmitoylation profiling of APT1-/-/APT2-/- mouse brains. Thus, 
disrupting depalmitoylase activity enhances levels of incorporated probe, but does not 
significantly affect steady state S-palmitoylation across the proteome. 
                                             
§ This chapter presents a submitted manuscript by Sang Joon Won and Brent Martin (2018). 
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Figure 4.1 Graphical abstract 
Introduction 
     The palmitoylation / depalmitoylation machinery establishes a spatially directed flow 
of S-palmitoylated proteins along vesicular pathways towards the plasma membrane, 
effectively overriding entropy-driven random membrane distribution. 20 The complete 
cycle occurs within seconds, where proteins are dynamically palmitoylated and 
depalmitoylated to effectively restrict transport along the flux of vesicular traffic. Generic 
depalmitoylase inhibition blocks this cycle, distributing plasma membrane targeted 
peripheral membrane proteins, such as Ras-family small GTPases 61 and G-proteins23 , 
randomly across internal membranes. In contrast, inhibition of the depalmitoylase APT2 
corrects an imbalanced palmitoylation cycle in malignant cells to restore lateral 
membrane localization of the multi-domain polarity scaffolding protein SCRIB. 75 Across 
decades of study, protein depalmitoylation has emerged as a critical mechanism for 
dynamic membrane localization, trafficking, and functional regulation, yet the breadth of 
substrates and global dynamics remain poorly characterized on a global scale.154 
 The recent development bioorthogonal labeling strategies has transformed the 
analysis of dynamic S-palmitoylation. 155 Pulse-chase metabolic labeling with the 
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alkynyl-fatty acid reporter 17-octadecynoic acid (17-ODYA) and click chemistry 
conjugation to biotin-azide has enabled quantitative proteomics assignment of a 
proteins with accelerated turnover dynamics, including Ras-family small GTPases, G-
proteins, and cell polarity organizing proteins.28 This accelerated turnover is stabilized 
by treatment with hexadecylfluorophosphonate, a broad inhibitor of cellular lipases.28 
While identifying new targets of depalmitoylase regulation, this limited profile falls short 
of many historical biochemical analyses demonstrating widespread depalmitoylase 
action across S-palmitoylated substrates.156 This discrepancy is likely due to the poor 
sensitivity of the alkynyl-fatty acid pulse-chase assay, particularly since alkynyl fatty 
acids are incorporated broadly across lipid classes. 47 Once distributed across 
membrane lipids, addition of excess palmitate is not very efficient in pulse-chase 
experiments, and limits sensitive analysis of proteome-wide S-palmitoylation turnover 
rates. 
 Here we present a multiplexed pulse-labeling method for profiling the kinetics of 
alkynyl fatty acid incorporation. The resulting kinetic signatures corroborate previous 
pulse-chase analysis, and reveal the presence of a conserved S-palmitoylation kinetic 
profile between different cell lines. In addition, HDFP increases alkynyl fatty acid 
incorporation through covalent inactivation of lipid hydrolase and depalmitoylase 
enzymes, revealing a much broader role for depalmitoylase regulation. While metabolic 
labeling reveals significant dynamics, hydroxylamine-switch methods do not identify any 
major steady-state S-palmitoylation changes. Furthermore, steady-state profiling of 
mouse brain samples deficient in both acyl protein thioesterases (APT1 and APT2) 
similarly lacked any change in global S-palmitoylation. Accordingly, we propose 
metabolic labeling only accesses a dynamic fraction of modified proteins, and these 
changes are lost in bulk steady-state analyses. These studies corroborate the presence 
of a dynamic palmitoylation cycle, and demonstrate multiple depalmitoylases contribute 
to the global S-palmitoylation regulation. 
 
Results 
Quantitative proteomic analysis of alkynyl fatty acid pulse-chase labeling 
revealed a distinct subset of depalmitoylase-regulated S-palmitoylated proteins28 but 
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sensitivity is hampered by the high concentrations of alkynyl reporters required for in-gel 
or mass spectrometry analysis. To avoid these challenges, we focused our efforts on 
profiling the temporal dynamics of S-palmitoylation, since probe incorporation must 
reflect the rate of S-palmitoylation cycling in cycloheximide treated cells. Interestingly, 
treatment with the promiscuous lipase inhibitor HDFP stimulates a time-dependent 
increase in alkynyl fatty acid incorporation broadly across labeled proteins, even at 
relatively early time points across multiple cell lines (Figures 4.2A, 4.3A, and 4.3B). 
The effect was independent of 17-ODYA labeling concentrations (Figure 4.2B), and 
present even at sub-micromolar HDFP concentrations. Competitive activity-based 
protein profiling (ABPP) with fluorophosphonate-rhodamine (FP-TAMRA) confirmed 
inactivation of the depalmitoylase enzymes APT1 and APT2 at sub-micromolar HDFP 
concentrations sufficient to stimulate 17-ODYA incorporation (Figures 4.2C and 4.2D). 
Quantitative mass spectrometry analysis identified a subset privileged HDFP targets 
(Figure 4.2E) including APT and ABHD17 family depalmitoylase enzymes. More 
selective inhibition of APT1 and APT2 similarly had no significant effect on 17-ODYA 
incorporation, suggesting the enhanced label incorporation may require the inhibition of 
alternative depalmitoylases (Figures 4.4A-C). Further profiling of FASN, PPT1, ABHD6, 
CES3, and NCEH1 similarly failed to stimulate 17-ODYA incorporation (Figures 4.4D-
G). Nonetheless, HDFP is a potent modulator of S-palmitoylation useful for broadly 
profiling dynamic regulation. 
 72 
 
Figure 4.2 Depalmitoylase inhibition enhances 17-ODYA labeling 
A) HDFP enhances 17-ODYA incorporation at all time points during labeling. Neutralized 0.5 M hydroxylamine 
(NH2OH) hydrolyzes 17-ODYA labeling, demonstrating the presence of a thioester linkage. (B) Different 
concentrations of 17-ODYA do not affect HDFP-dependent enhanced probe incorporation. (C) Fluorophosphonate-
TAMRA (FP-TAMRA) competitive ABPP demonstrates APT enzymes are inactivated by sub-micromolar HDFP 
concentrations. (D) Dose-dependent profile of HDFP-dependent enhancement of 17-ODYA incorporation. (E) 
Competitive ABPP mass spectrometry analysis of HDFP inhibition across the serine hydrolase family. Error bars 
represent error propagated from standard errors at differing HDFP concentrations, quantified from multiplexed TMT 
isobaric reporter ions. N = 4. Serine hydrolases with >2 PSMs are shown. Analysis was performed in human 293T 
cells across these experiments. 
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Figure 4.3 HDFP augments 17-ODYA incorporation in multiple cell lines. 
(A) Kinetic profile of 17-ODYA labeling demonstrates HDFP-dependent enhancement in Hap1 cells. Competitive 
ABPP analysis of HDFP treatment in while cell lysates with FP-TAMRA confirms inhibition of APT enzymes and other 
HDFP-sensitive hydrolases. Hydroxylamine (NH2OH) addition eliminates 17-ODYA labeling, confirming thioacylation 
of cellular proteins by 17-ODYA. (B) Kinetic profile of 17-ODYA labeling in Jurkat cells is also stimulated by HDFP. 
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Figure 4.4 Pharmacological profiling of hydrolase-regulated 17-ODYA labeling in cells 
(A) Structures of acyl protein thioesterase and zDHHC inhibitors. (B) APT inhibition does not affect 17-ODYA 
incorporation levels in 293T cells. 1 M HDFP, 50 M 2BP, 10 M ML348, ML349, and PalmB, 1 M ABC44 and 
ML211 were used. Data represents the average and standard error of 3 independent replicates, shown in (C). Red 
boxes illustrate the 20 kD band used for quantitation, which represents the molecular weight of Ras-family small 
GTPases. Intensity in each lane is normalized to the alpha-tubulin loading control. (D) PPT1 inhibition has no effect 
on 17-ODYA incorporation. High concentrations of ABC44 also inhibit APT enzymes. (E) FASN inhibition (1 M TVB-
3166) has no effect on 17-ODYA incorporation. (F) Structures of reported carbamate inhibitors for other HDFP 
targets. (G). ABHD6, CES3, and NCEH1 inhibition has no effect on 17-ODYA incorporation. Inhibitors were added at 
15 M final concentration, except HDFP (1 M). 
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Figure 4.5 Schematic of multiplexed kinetic profiling of S-palmitoylation. 
Cells are incubated with 17-ODYA for various time points, followed by click chemistry to biotin-azide, streptavidin 
enrichment, trypsin digestion, and labeling with lysine reactive TMT reagents for quantitative mass spectrometry 
analysis. 
 
     Based on these observations, we designed a multiplexed mass spectrometry 
approach for temporal profiling of bioorthogonal S-palmitoylation (Figure 4.5). Human 
293T cells were incubated with cycloheximide to block protein synthesis and co-
translational N-myristolyation, followed by 17-ODYA incubation for varying times. After 
click chemistry conjugation to biotin-azide, streptavidin enrichment, and trypsin 
digestion, the eluted peptides we incubated with amine-reactive 6Plex-TMT isobaric 
labeling reagents and combined for quantitative mass spectrometry analysis. Data was 
filtered based to include proteins annotation by at least 3 peptide spectrum matches 
(PSMs) and with >2-fold enrichment over the control across the last 3 time points. This 
analysis yielded several hundred specifically enriched proteins in 293T cells (Table 4.1), 
and nearly twice as many in HAP1 cells (Table 4.2), both largely overlapping with 
previously published S-palmitoylation proteomics studies. 30 
Hierarchical cluster analysis classified S-palmitoylated proteins with different 
kinetic features. For example, NRAS, SCRIB, MTDH, and GNAS were all grouped 
together in the most rapidly S-palmitoylated sub-group (Figure 4.6A and Table 4.1), 
corroborating previous pulse-chase studies. 28 Within this accelerated group, 17-ODYA 
incorporation peaks within 90 minutes, followed by decay to a steady state equilibrium. 
Since the analysis relies on quantitation of tryptic peptides outside of the specific S-
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palmitoylation sites, proteins with multiple S-palmitoylation sites would be predicted to 
incorporate 17-ODYA at a faster rate than proteins with a single S-palmitoylation site. 
Despite this prediction, there is no clear correlation between multiply S-palmitoylated 
proteins and the rate of probe incorporation. For example, SNAP23 has at least 5 S-
palmitoylation sites 157, yet demonstrates relatively average probe incorporation kinetics. 
 
Figure 4.6 Time-dependent profiling of 17-ODYA incorporation identifies kinetic clusters of dynamic S-
palmitoylated proteins 
(A) Clustered heat map of enriched proteins from 293T cells labeled with 17-ODYA for increasing lengths of time. 
Clusters of “fast”, “medium”, and “slow” are highlighted. Branches are simplified for clarity. Proteins were identified by 
3 or more PSMs and demonstrate >2-fold enrichment over DMSO controls. (B) Hierarchical clustering of 17-ODYA 
enriched S-palmitoylated proteins across both control and HDFP-treated cells reveals distinct kinetic clusters in 293T 
cells. Proteins with >2-fold enrichment and at least 3 PSMs are shown. The heat map is normalized to the highest 
point along the labeling time course. Branches were simplified to highlight higher level grouping. (C) Representative 
labeling time course of select proteins from each subclass. 
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In the same multiplexed analyses, HDFP treatment accelerated the kinetics of 
17-ODYA labeling, defining different S-palmitoylated proteins with more or less 
sensitivity to depalmitoylase inhibition (Figure 4.6B, Figure 4.7A, Tables 4.1-4.2). 
Paired clustering of control and HDFP treated cells led to further kinetic segregation, 
producing 4 major categories, essentially stratifying proteins based on their kinetic 
response to depalmitoylase inhibition (Figure 4.6C and 4.7B). Cluster 1 represents 
enriched proteins with both fast incorporation and relatively high sensitivity to HDFP at 
all time points. Cluster 2 represents enriched proteins with mild sensitivity to HDFP 
during the early to middle time points (RHOA, SNAP23, etc.). Cluster 3 represents 
enriched proteins with high HDFP sensitivity in early time points (SCRIB, FLOT2, etc.). 
Cluster 4 includes proteins with reduced labeling upon HDFP addition, and includes 
many proteins reported across multiple S-palmitoylation proteomics datasets. 30 These 
proteins may represent common false positives or could be enriched via chemically 
distinct mechanisms of protein acylation. Interestingly, NRAS S-palmitoylation is initially 
stimulated in HDFP treated samples, but decays over time and eventually equilibrates 
to similar levels as control cells. In many instances, HDFP shifts proteins to a hyper S-
palmitoylated state (MTDH, GNAS, SLC38A1, etc.), presumably increasing the steady-
state stoichiometry of probe incorporation. These clusters are largely similar between 
293T cells and HAP1 cells, supporting a conserved program of temporal and enzymatic 
regulation (Figure 4.7B-C). 
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Figure 4.7 Multiplexed kinetic profiling of 17-ODYA incorporation in HAP1 cells 
(A)Clustered heat map of S-palmitoylated proteins from HAP1 cells labeled with 17-ODYA comparing the effects of 
depalmitoylase inhibition with HDFP. Proteins identified in both 293T and HAP1 cells are shown. Clusters correspond 
to the kinetic groups described for 293T cells in Figure 4.6. (B) Representative S-palmitoylation kinetics from HAP1 
cell analysis corresponds data in Figure 4.6 (C) Representative overlapping clusters from 293T and HAP1 define 
conserved S-palmitoylation labeling kinetics and depalmitoylation effects across cell types.  
 
Since HDFP promotes greater 17-ODYA labeling, we questioned whether this 
translates to an increase in steady-state S-palmitoylation levels. In contrast to 
bioorthogonal metabolic labeling, steady-state S-palmitoylation can be assayed by 
methods using hydroxylamine-dependent thioester hydrolysis, thiol capture, and 
enrichment.38 In the acyl-Resin-Assisted Capture (acyl-RAC) protocol, thiols are first 
reduced and alkylated, and hydroxylamine is added to hydrolyze thioesterified cysteines 
for capture on pyridyl-disulfide conjugated agarose resin. This method is agnostic to the 
nature of the acyl group, and captures both S-palmitoylated and endogenously 
thioesterified proteins, including lipoamide cofactor-dependent dehydrogenases and 
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ubiquitin ligases. Despite the prevalence of bioorthogonal metabolic labeling and 
hydroxylamine-switch assays for S-palmitoylation, there have been no direct 
comparison by mass spectrometry profiling. In-gel hydroxylamine-switch analysis 
demonstrated no obvious changes in steady-state S-palmitoylation after HDFP or both 
HDFP and 17-ODYA (Figure 4.8A). Analysis of HDFP or HDFP/17-ODYA treated cells 
by acyl-RAC enrichment and multiplexed mass spectrometry analysis confirmed that 
lipase inhibition has no major effect on global steady-state S-palmitoylation levels 
(Figures 4.8B, 4.9A-B, and Table 4.3-4.4). These results were corroborated by gel-
based analysis of RAS and SCRIB, which were selected based on their validated 
dynamic S-palmitoylation28, 75  and their rapid increase in 17-ODYA labeling after HDFP 
treatment. Following acyl-RAC enrichment, neither protein was significantly different in 
HDFP treated samples (Figures 4.8C-D and 4.9C-D). 
 
Figure 4.8 Depalmitoylase inhibition does not influence steady-state S-palmitoylation. 
(A) In-gel analysis of S-palmitoylation using the hydroxylamine-switch analysis reports equivalent labeling profiles 
after 17-ODYA and HDFP treatment. Iodoacetamide-rhodamine (IAM-TAMRA) labeling reports the presence of 
hydroxylamine sensitive thiols. (B) Equivalent enrichment of S-palmitoylated proteins by quantitative proteomic 
analysis of acyl-RAC enriched proteins from control (DMSO) and HDFP or HDFP+17-ODYA treated cells, N=4. 
Proteins with >2 PSMs, multiple annotations in SwissPalm are shown. (C) Confirmatory acyl-RAC analysis of pan-
RAS and SCRIB S-palmitoylation. (D) Quantitation of acyl-RAC enrichment relative to control (DMSO) across 
replicates after normalizing to input (Ras, N = 5 for all conditions except 17-ODYA, N = 3; Scrib, N = 3 for all 
conditions except 17-ODYA, N = 2, ±SEM) demonstrates no significant changes following HDFP treatment, but 
shows major reductions after 2BP treatment (two-tailed Student’s t-test with unequal variance). 
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Figure 4.9 Steady-state S-palmitoylation is not affected by depalmitoylase inhibition. 
(A) Hydroxylamine-switch assay in HAP1 cells. 4 replicates in each condition. (B) Fold-change correlation plot of 
Acyl-RAC enriched proteins in HAP1, N = 4. Proteins with >2 PSMs and multiple annotations in SwissPalm are 
shown. (C) Replicates of acyl-RAC blots as described in Figure 4.8C-D. (D) Acyl-RAC replicates of Ras and Scrib in 
293T cells. Cells were incubated with HDFP for 90 minutes. Quantitative enrichment relative to DMSO control is 
shown. N = 3 for Ras, N = 2 for Scrib. Error bars represent the standard deviation. Changes are not significant (p > 
0.05). 
 
Conversely, the broadly reactive S-palmitoylation inhibitor 2-bromo-palmitate 
(2BP)49 reduced both RAS and SCRIB steady-state S-palmitoylation, verifying sufficient 
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sensitivity to measure chemically modulated S-palmitoylation. Nonetheless, 2BP can 
directly modify depalmitoylases, including APT 158 and ABHD17 enzyme families49, and 
thus could affect both arms of the S-palmitoylation cycle. Importantly, gel-based 
analysis using standard image auto-thresholds demonstrates an apparent increase in 
Ras S-palmitoylation (Figure 4.9D). After loading control normalization, these effects 
are neither large nor significant, underscoring the importance of biological replicates for 
accurate and precise measurements. Overall, HDFP enhances the stoichiometry of 
alkynyl labeling, but does not greatly impact bulk steady-state S-palmitoylation levels in 
either 293T or HAP1 cells.  
 The protein depalmitoylases APT1 and APT2 are structurally similar /-
hydrolases103 and catalyze depalmitoylation across dozens of proteins both in vitro and 
in cells 156. Despite the predicted role for APT1 and APT2 in broad regulation of protein 
depalmitoylation, cell-based studies rely exclusively on inhibitors or RNA interference to 
probe cellular phenotypes. Even with an arsenal of APT1 and APT2 inhibitors100, there 
have not been any reported efforts to profile APT1 and/or APT2 dependent S-
palmitoylation. To address this gap, APT1 (Lypla1) and APT2 (Lypla2) knockout mice 
were acquired through commercial sources, and crossed to generate double knockout 
mice. The resulting mice double knockout mice were viable and fertile, yet were born at 
sub-Mendelian frequencies. Whole brains were harvested from 3-month old APT1-/-
/APT2-/- mice for S-palmitoylation analysis. Double knockout was confirmed by 
fluorophosphonate activity-based profiling (Figure 4.10A). As observed with HDFP-
treated cells, there was no visual change in the S-palmitoylation profile by in-gel 
hydroxylamine-switch analysis (Figure 4.10B). These observations were confirmed by 
multiplexed mass spectrometry, again reporting no obvious changes in S-palmitoylation 
levels by APT1 and APT2 deletion, with the exception of MAP6 (2.5-fold increase) 
(Figure 4.10C and Table 4.5). Interestingly, MAP6 was recently reported to require 
ABHD17 activity to maintain a dynamic S-palmitoylation necessary for synaptic 
trafficking 106. This suggests either an interplay between ABHD17 and APT enzymes or 
differential depalmitoylase regulation between cultured primary neurons and brain. 
Accordingly, APT1 and APT2 knockout does not affect steady-state S-palmitoylation 
levels in the mouse brain. 
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Figure 4.10 Steady-state S-palmitoylation is unaffected in APT1-/-/APT2-/- mouse brains. 
(A) FP-TAMRA labeling of active serine hydrolases in whole mouse brain homogenates confirms selective deletion of 
APT1 and APT2. Knockout was also confirmed by western blot. (B) Hydroxylamine-switch analysis of S-
palmitoylation in normal and knockout samples does not reveal major changes in S-acylation profiles. (C) Volcano 
plot analysis of acyl-RAC enrichment and multiplexed TMT mass spectrometry analysis of APT1-/-/APT2-/- whole 
mouse brain homogenates (N=3). Red lines represent p < 0.05 from two-tailed Student’s t-test with unequal variance 
(horizontal) and 2-fold change (vertical). 
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Discussion 
S-palmitoylation is widely presented as a dynamic modification, yet due to 
technical challenges, there has been little progress towards profiling proteome-wide 
dynamics. Here we establish a method for temporal profiling, and confirm a direct 
correlation between dynamic S-palmitoylation and the rate of fatty acid incorporation. 
We anticipate this multiplexed mass spectrometry approach will significantly impact the 
analysis of the S-palmitoylation cycle, including further annotation of select 
depalmitoylases, zDHHC protein acyl transferases, and signal-dependent regulation. 
Since zDHHC enzymes often share common substrates16, this approach could provide 
an opportunity to bypass steady-state compensatory effects and assign substrates 
based on kinetic signatures of fatty acid incorporation. Such analysis could be 
complicated by acyl-CoA substrate preferences among zDHHC enzymes4, but provides 
a platform to profile incorporation of different alkynyl fatty acid derivatives across the 
proteome. 
We recently demonstrated HDFP treatment redistributes Gs randomly across 
internal membranes, independent of GPCR activation. 23 This corresponds to similar to 
analysis of NRAS random distribution after treatment with the promiscuous 
depalmitoylase inhibitor Palmostatin B.61 Based on our comparative acyl-RAC and 17-
ODYA profiling, we propose a model where depalmitoylase inhibition can affect the rate 
of fatty acylation, yet maintain relatively constant steady state S-palmitoylation levels. 
Accordingly, when the S-palmitoylation cycle is stalled, the functional affect may not be 
a shift in steady-state S-acylation, but instead a release from the vesicular flux and 
random localization across internal membranes. Alternatively, metabolic labeling 
approaches may only access a limited fraction of the total S-palmitoylated protein, and 
diminish any affects measured by bulk analysis. Clearly, the profile of 17-ODYA labeled 
proteins appears quite different than gel-based analysis using hydroxylamine-switch 
methods. Furthermore, while HDFP treatment stimulates 17-ODYA incorporation, the 
fraction labeled may only represent a minor fraction of the bulk S-palmitoylated form. 
While several studies have reported changes in S-palmitoylation of select targets by 
acyl-RAC after APT inhibition 156, these effects may be cell line dependent.75 APT 
enzymes represent only a fraction of depalmitoylase activity in 293T cells, suggesting 
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significant compensation from other uncharacterized enzymes. 102 While clarifying the 
HDFP-sensitive enzymes involved in this effect is ongoing, this compensation may be 
linked to ABHD17 family depalmitoylases. The development of potent and selective 
ABHD17 inhibitors will begin to address these questions, while avoiding technical 
challenges in deriving ABHD17A, ABHD17B, and ABHD17C triple knockout cells, 
particularly when knockout of individual members reduces cell viability across many 
cancer cell lines. 159 Alternatively, addition of azido-fatty acids to cells stimulates 
biosynthesis of CoA conjugates. 4 The data presented here suggests steady-state S-
palmitoylation is not greatly affected by addition of bioorthogonal fatty acids, 
depalmitoylase inhibitors, or genetic deletion of depalmitoylases, whether or not they 
modulate acyl-CoA levels in cells. 
     APT enzymes have been studied nearly exclusively in cancer cell models, where 
APT1 and APT2 inhibition represses oncogenic signaling and stem cell-like features by 
modulating lateral polarity complexes75 and asymmetric cell division160. Surprisingly, 
APT1-/-/APT2-/- mice are viable and have no overt developmental defects. While detailed 
analysis of these mutant mice will require more focused effort, cursory analysis 
suggests APT enzymes may exclusively exert their effects only in specific cell contexts 
to support tumorigenesis. 43, 160 Since APT1-/-/APT2-/- mice have no measureable 
changes in steady-state S-palmitoylation, it is unclear how relevant these enzymes are 
to regulating S-palmitoylation dynamics over other lipid hydrolase activities. 65  
     Overall, the methods and analyses presented reveal the kinetic profile of S-
palmitoylation in cells, revealing new insights to proteins linked to dynamic S-
palmitoylation cycles. These methods reveal potential limitations of steady-state 
analysis while presenting new opportunities for temporal profiling of S-palmitoylation. 
 
Materials and Methods 
Cell Lines 
Human 293T cells were cultured in Dulbecco’s Modified Eagle Media (DMEM / 
Invitrogen) supplemented with 1 % (v / v) 10000 Units / mL penicillin-streptomycin 
(Invitrogen), 4.5 g / L D-Glucose, 2 mM L-Glutamine, 110 mg / L sodium pyruvate, and 
10 % (v / v) dialyzed fetal bovine serum (JR Scientific). HAP1 cells were a generous gift 
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from Gisou van der Goot (EPFL), and were cultured in Iscove′s Modified Dulbecco′s 
Medium (IMDM / Invitrogen) supplemented with 1 % (v / v) 10000 Units / mL penicillin-
streptomycin, and 10 % (v / v) dialyzed fetal bovine serum. Jurkat cells were grown in 
Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen) supplemented with 2.383 g / L 
HEPES buffer, 1.5 g / L sodium bicarbonate, 1 % (v / v) 10000 Units / mL penicillin-
streptomycin, 4.5 g / L D-glucose, 2 mM L-Glutamine, 110 mg / L sodium pyruvate, and 
5 % (v / v) dialyzed fetal bovine serum. There was no additional effort to authenticate 
these cell lines, since the morphological characteristics matched signatures for each cell 
line. 
Mice 
Lypla1 (APT1) knockout mice were generated by purchasing the cryopreserved TF1704 
model from Taconic Biosciences. C57BL/6NTac females were impregnated with 
cryopreserved sperm from a mixed C57BL/6-129/SvEv background harboring a gene-
trap (“gt”) cassette between Lypla1 exons 2 and 3. After intercrossing, western blot and 
gel- and mass-spec-based experiments with FP probes confirmed complete loss of 
APT1 protein in Lypla1gt/gt mice. Lypla2 (APT2) knockout mice were generated by 
acquiring cryopreserved sperm from the KOMP repository at UC Davis harboring the 
Lypla2tm1a(KOMP)Mbp “knockout-first” gene-trap cassette which was inserted between 
exons Lypla2 1 and 2. Homozygous Lypla2gt/gt mice were found to retain ~20% residual 
APT2 expression via gel- and mass-spec-based experiments with FP-probes. Complete 
ablation of APT2 protein was achieved by crossing Lypla2gt/gt mice with a C757BL/6 
mouse line with ubiquitous expression of Cre recombinase (Taconic #12524) which 
resulted in removal of Lypla2 exons 2-10 from the genome. The resulting Lypla2Cre/Cre 
mice were confirmed to have no residual APT2 protein expression, as measured by gel- 
and mass-spec based experiments with FP probes. Lypla1/Lypla2 (APT1/APT2) double 
knockout mice were generated by crossing Lypla1gt/gt mice with Lypla2gt/gt mice. The 
resulting Lypla1gt/gt;Lypla2gt/gt mice were then crossed with a ubiquitous Cre deleter line 
(Taconic #12524) to accomplish removal of Lypla2 exons 2-10 and complete ablation of 
APT2 expression. 
Metabolic labeling and inhibitor treatments 
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17-ODYA labeling was performed as described previously28. HDFP, ML348, and ML349 
syntheses were previously reported 28, 103. Other inhibitors were purchased from Sigma 
(2-bromohexadecanoic acid, TVB-3166, and ABC44) or Cayman (JW480, WWL229, 
and WWL70). At ~90 % confluency, the growth media was aspirated and the new media 
containing 25 µM cycloheximide (Sigma) and the inhibitor was added to the cells 
(Control = 0.1% v / v DMSO final). For ABPP and acyl-RAC proteomic experiments, 
cells were incubated with HDFP for 3 hours. After incubation, 20 µM 17-ODYA 
(Cayman) was added. At different time points, cells were washed with cold DPBS 
(Invitrogen) and scraped off the plate. The cell pellets were washed with DPBS and 
stored at -80 °C. 
17-ODYA click chemistry and enrichment 
17-ODYA detection in cell homogenates was performed as previously described28. 
Frozen cell-pellets were resuspended in DPBS and lysed by sonication. For in-gel 
fluorescence analysis, 50 µg of protein (quantified using the BCA protein assay kit; Bio-
Rad) was incubated with 1 mM tris(2-carboxyethyl)phosphine (TCEP;Sigma), 20 µM 
TAMRA azide (Click Chemistry Tools), 1 mM CuSO4, and 100 µM Tris((1-benzyl-1H-
1,2,3-triazol-4-yl)methyl)amine (TBTA; Cayman) for 1 hour at room temperature. The 
samples were resolved by 12 % SDS-PAGE (180 V;1 hr) and imaged using Azure C600 
(Azure Biosystems). Samples prepared for mass spectrometry analysis included 1 
biological replicate per time point (palmitic acid as time 0) for each condition (DMSO or 
1 µM HDFP). The sonicated homogenate was separated into soluble (S100) and 
insoluble (P100) fractions by ultracentrifugation at 100,000g for 45 min. 1 mg of the 
P100 fraction was incubated with the click chemistry reagents listed above, except 
Biotin PEG3 Azide (500 µM; Click Chemistry Tools) was substituted for TAMRA azide. 
After 1 hour, proteins were extracted with methanol and chloroform (4 eq. aqueous, 4 
eq. methanol, 1 eq. chloroform). The insoluble pellet was washed with methanol and 
resuspended in 6 M urea / 2% SDS in PBS. Protein concentrations normalized again 
across all samples. Samples were then incubated with 5 mM TCEP (pH 7) for 30 min, 
followed by addition of 20 mM iodoacetamide for 1 hour in dark. The samples were 
diluted 3-fold and the same amount of protein was added to 75 µL of pre-washed 
Streptavidin beads (Thermo) for 90 minutes. The beads were washed 5 times with PBS 
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containing 2 M urea and 0.2 % SDS and 5 more times in PBS. Finally, the beads were 
resuspended in 100 µL of 50 mM triethylammonium bicarbonate (TEAB) and 1.3 µg of 
mass spectrometry-grade Trypsin/Lys C mix (Promega). After overnight digestion at 37 
°C, the eluted peptides were incubated with TMT 6plex (Thermo) reagents according to 
the manufacturer’s protocols. The samples were mixed into 1 tube, desalted with an 
Oasis PRIME HLB µElution Plate (Waters), dried using a Thermo Savant SpeedVac, 
and stored at -80 °C. 
Serine Hydrolase Activity-based Profiling 
Cells were incubated with inhibitors in culture, the harvested and lysed by sonication. 
For fluorescent gel-based analysis, 50 µg of protein was incubated with 2 µM 
fluorophosphonate (FP)-TAMRA 161 for 30 minutes. For the proteomic analysis, 4 
biological replicates per condition (20 µM HDFP, 1 µM HDFP, DMSO) were used and 2 
of each condition was combined into 1 TMT 6plex run. 1 mg of whole cell lysate was 
incubated with 5 µM FP-biotin for 1 hour at room temperature. The streptavidin 
enrichment and mass spectrometry sample preparation procedures are identical to the 
17-ODYA enrichment sample preparation. 
Acyl-RAC 
The cell pellets were resuspended in Buffer 1 (50 mM HEPES pH 7.4, 1 mM EDTA, 100 
mM NaCl), sonicated, and fractionated by centrifugation at 100,000g for 45 minutes at 4 
°C. The insoluble fraction was resuspended in Buffer 2 (50 mM HEPES pH 7.4, 2 % 
SDS) and quantified with BCA protein assay kit. 1~2 mg of protein was diluted in 1 mL 
of Buffer 3 (50 mM HEPES pH 7.4, 6 M urea, 1 mM EDTA, 2 % SDS) and incubated 
with 10 mM TCEP for 30 minutes at room temperature, followed by 50 mM 
iodoacetamide for 1 hour in dark. The proteins were precipitated by chloroform / 
methanol extraction (as above) and resuspended in Buffer 2 and re-quantified. For the 
hydroxylamine-switch gel-based analysis, 0.5 M neutralized hydroxylamine was added 
to each sample and incubated for 15 minutes, followed by 1 µM Tetramethylrhodamine-
5-Iodoacetamide Dihydroiodide (5-TMRIA (noted IAM-TAMRA); Thermo) for 30 
minutes. For the enrichment analysis, the reduced and alkylated proteins (>1 mg) were 
added to the 100 µL of water-activated, pre-washed Thiopropyl-Sepharose 6B beads 
(Sigma) in Buffer 3, followed by the addition of 0.5 M hydroxylamine. The samples were 
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incubated for 2 hours at room temperature and washed 5 times with Buffer 2 and 
washed 5 more times in 50 mM HEPES. For the western-blot analysis, beads were 
resuspended in the 1X loading buffer (10% glycerol, 62.5 mM tris pH 6.8, 1% 2-
mercaptoethanol, 0.05% bromophenol blue, and 1% SDS) and heated for 5 minutes at 
90 °C. The supernatant analyzed by SDS-PAGE. For the proteomic analysis, 4 
biological replicates per condition (DMSO, +HDFP, +HDFP&17-ODYA) were used. Two 
of each condition were combined into one TMT 6plex run. The beads were resuspended 
in 50 mM TEAB and incubated with Trypsin/Lys C mix (Promega) at 37 °C overnight. 
The supernatants were TMT labeled and desalted as above. For the mouse brain 
samples, 3 experimental replicates per condition (WT or APTs KO) was combined into 
one TMT 6plex run. Tissue was washed in Buffer 1, then dounce homogenized at 4 °C. 
The lysate was briefly centrifuged at 1000g for 5 minutes to remove debris, fractionated 
and processed for the proteomic sample preparation as above.  
Western blot 
Gels were transferred to methanol-activated Immobilon-FL membrane (Millipore) in the 
transfer buffer (25 mM Tris-base,192 mM glycine, 10 % methanol) at 75 V for 2 hours. 
Proteins were probed with anti-alpha tubulin (1:1000; Sigma #T6074), anti-APT1 (1:500; 
Millipore; #MABS166), anti-APT2 (1:500; Thermo; #PA-527653), anti-Pan Ras (1:1000; 
Millipore; #05-516), or anti-Scrib (1:1000; Millipore; #MAB1820) for 16 hours at 4 °C and 
then incubated with secondary anti-mouse horseradish peroxidase (HRP;1:1000; 
Thermo; #32430) for 1 hour at room temperature. Blots were developed by West Pico 
Chemiluminescent Substrate (Thermo) and then the chemiluminescence was detected 
by Azure c600 imager (Azure Biosystems). 
Mass spectrometry and data analysis 
In order to obtain superior quantitation accuracy, multinotch-MS3 methods were used to 
reduce reporter ion interference162. Analysis was performed using an Orbitrap Fusion 
(Thermo Fisher Scientific) and RSLC Ultimate 3000 nano-UPLC (Dionex). Samples 
were resuspended in 9 l of 0.1% formic / acetonitrile and 2 l of each sample was 
resolved using a nano-capillary reverse phase column (Acclaim PepMap C18, 2 micron, 
75 m i.d. x 50 cm, Thermo Scientific). A 0.1% formic / acetonitrile gradient was used 
with 300 nl / min flow (2-22% acetonitrile in 150 min; 22-32% acetonitrile in 40 min; 20 
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min wash at 90% followed by 50 min re-equilibration) and directly sprayed on to 
Orbitrap Fusion using EasySpray source (ThermoFisher Scientific). The mass 
spectrometer was programmed to collect one MS1 scan (Orbitrap; 120K resolution; 
AGC target 2x105; max IT 100 ms) followed by data-dependent, “Top Speed” (3 
seconds) MS2 scans (collision induced dissociation; ion trap; NCD 35; AGC 5x103; max 
IT 100 ms). For multinotch-MS3, top 10 precursors from each MS2 were fragmented by 
HCD followed by Orbitrap analysis (NCE 55; 60K resolution; AGC 5x104; max IT 120 
ms, 100-500 m/z scan range). Proteome Discoverer (PDv2.1; Thermo Fisher) was used 
for data analysis, except in HAP1 dataset where the raw abundances were used. MS2 
spectra were searched against either Uniprot human protein database (release 
08/02/2017) or SwissProt mouse protein database (release 04/13/2016) using the 
following search parameters: MS1 and MS2 tolerance were set to 10 ppm and 0.6 Da, 
respectively; carbamidomethylation of cysteines (57.02146 Da) and TMT labeling of 
lysine and N-termini of peptides (229.16293 Da) were considered static modifications; 
oxidation of methionine (15.9949 Da) and deamidation of asparagine and glutamine 
(0.98401 Da) were considered variable; maximum missed cleavage was set to 2. During 
the search, parsimony principle (unique+razor peptides) was applied. Identified proteins 
and peptides were filtered to retain only those that passed ≤1% FDR threshold. 
Quantitation was performed using high-quality MS3 spectra (Average signal-to-noise 
ratio of 6 and <40% isolation interference). For all biotin-streptavidin enrichment 
samples, data are normalized to Pyruvate carboxylase, an endogenously biotinylated 
protein. For the acyl-RAC samples, data were normalized to all proteins using the 
PDv2.1. For the 17-ODYA time course data, threshold was set to >2 PSMs, >2-fold ratio 
enrichment during the last 3 time points (compared to the palmitic acid control) to be 
considered as significant. The hierarchical clustering was performed with Cluster 3.0,163 
with the averaged linkage method selecting the Pearson correlation coefficient as the 
similarity metric. For the acyl-RAC data, threshold was set to >2 PSMs, >2 fold change, 
and multiple identifications in the SwissPalm30 database. Statistical analysis was 
performed in Excel. Graphs were generated using the Graphpad Prism 7 (Graphpad 
Software), PyCharm (JetBrains), and Anaconda (Anaconda). 
Quantification and statistical analysis 
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All protein quantitation from the mass spectrometry experiments were performed by 
Proteome Discoverer v.2.1 (Thermo) and further processed by Excel, Graphpad Prism 
7, and PyCharm, as described above. Protein band densitometry analyses were 
quantified using ImageJ software (NIH). Statistical details of experiments and the 
sample size can be found in the figure legend and the supplemental tables. 
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Table 4.1 Temporal profiling of 17-ODYA labeling in 293T cells., related to figure 4.6 
 
Temporal profiling of 17-ODYA labeling in 293T cells. Cells were incubated with 
cycloheximide and HDFP or DMSO. Then incubated with 17-ODYA for varying amounts 
of time. Enriched proteins from each time point were labeled with 6plex TMT then 
combined into 1 sample. Protein abundances are normalized to pyruvate carboxylase. 
PSM= peptide spectrum matches. Ratio=relative enrichment compared to palmitic acid 
control (t=0) in each condition. Normalized ratio refers to the raw ratio normalized to the 
highest enrichment ratio across all time points and conditions (+/- HDFP), which was 
used in the paired-clustering analysis to generate cluster # as described in the main 
figure (Figure 2a). "17ODYA incorporation rate without HDFP" (related to Figure S3b) 
refers to the overall rate of 17ODYA incorporation within the DMSO conditions after a 
separate hierachical clustering analysis. 
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Table 4.2 Temporal profiling of 17-ODYA labeling in HAP1 cells, related to figure 4.7 
 
Representative proteins from each cluster are shown. 
Table 4.3 HDFP and 17-ODYA do not change steady-state S-palmitoylation in 293T cells, related to figure 4.8 
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Representative proteins are shown. HDFP and 17-ODYA do not change steady-state S-
palmitoylation levels in 293T cells. Cells are treated with HDFP or HDFP and 17-ODYA 
for 3 hours, followed by acyl-RAC enrichment and TMT quantitative proteomics.  All 
conditions are treated with hydroxylamine (HA). PSM= peptide spectrum matches, N=4 
biological replicates. 
Table 4.4 HAP1 cell steady-state S-palmitoylation, related to figure 4.9 
 
Representative proteins are shown. Cells are treated with HDFP for 3 hours in the 
indicated condition, and enriched by acyl-RAC methods. HA = 0.5 M hydroxylamine. 
N=4 biological replicates. In the vehicle conditions, no hydroxylamine (HA) was added 
during preparation. 
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Table 4.5 Steady-state S-palmitoylation profiling in APT1/APT2 knockout mouse brain, related to figure 4.10 
 
Representative proteins are shown. N=3, experimental replicates. All conditions are 
treated with hydroxylamine. 
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Chapter 5 : Conclusions and Future Directions 
 
Conclusions 
Protein depalmitoylases are hypothesized to distinguish between different 
substrates, which together impact the global S-palmitoylation cycle. To test this 
hypothesis, my dissertation focuses the structure and function of the annotated 
depalmitoylases, APT1 and APT2. In order to reveal the mechanism of APT1 and APT2 
orthogonality, I solved the co-crystal structures of these enzymes bound to their 
isoform-selective inhibitors. This analysis identified remarkably similar active sites while 
divergently conserved residues promoted inhibitor selectivity. Although the static crystal 
structures do not shed light on the molecular mechanism for the functional orthogonality 
of APT1 and APT2, we characterized acyl-binding channel to gain insight into their 
mode of action.103  
Since ML349 can attenuate MAPK signaling in cells, I sought to confirm that 
APT2 was indeed the major cellular target in cells. To accomplish this, I profiled ML349 
binding partners, and identified several low affinity-multimeric targets with no obvious 
biological significance to cellular growth signaling.84 Based on these experiments, 
ML349 is a robust inhibitor of APT2 for selective analysis of APT2 function in cells. This 
analysis also highlights how multimeric proteins can emerge from affinity proteomics 
studies through avidity-driven interactions. 
The development of alkynyl fatty acids coupled with advanced mass 
spectrometry have enabled proteome-wide analysis of S-palmitoylation. Despite our 
previous efforts,28, 43 S-palmitoylation regulation remains poorly understood. For 
example, there is no broad understanding of the substrates of either zDHHC protein 
acyl transferases or APT enzymes. This is complicated by potentially redundant 
functions of these enzymes, which may lead to compensation in germline knockout 
organisms. In profiling experiments, cells may reach a steady state level of S-
palmitoylation by the time of analysis, blinding the dynamic rate of turnover. 
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In order to profile enzymatic depalmitoylation, I developed a multiplexed 
proteomics analysis to assay hundreds of proteins over a series of timepoints following 
alkynyl fatty acid labeling. This analysis revealed different S-acylation kinetics across 
hundreds of proteins, and identified distinct acylation rates correlated with rapid 
depalmitoylation. Overall, this analysis confirms a significant role for protein 
depalmitoylases in regulating S-palmitoylation dynamics. Surprisingly, APTs had no 
significant impact in the overall steady-state S-palmitoylation in cells. Treatment with 
more selective inhibitors or analysis of APT1-/-APT2-/- double knockout mouse showed 
no major effects on steady-state S-palmitoylation, suggesting dynamics may be more 
challenging to analyze than previously imagined. Nonetheless, I established a new 
method to profile depalmitoylase-dependent dynamic changes in protein S-
palmitoylation. 
Although palmitoylation on proteins were discovered 40 years ago, the 
mechanistic understanding of this modification is just beginning to emerge. In my thesis, 
used structural biology, inhibitors, and chemical proteomic approaches to enhance 
understanding of the depalmitoylation events. While these efforts were mainly focused 
on APTs, other emerging depalmitoylases such as ABHD17s or other unidentified 
enzymes still require biochemical and cellular functional studies. 
 
Future directions to analyze APT function 
What would explain the differential functions of APTs? Some studies have 
proposed that their localization and expression levels may give a clue.75, 164 Although 
APT1 and APT2 show varying expression levels depending on the cell line or disease 
models,165 the most convincing explanation comes from the differential localization of 
APTs. For example, while previous studies reported golgi and cytoplasmic localization 
of APT1,20, 61 a recent report showed that APT1 is primarily localized and active in 
mitochondria while APT2 is mainly found in cytoplasm.164 However, it is unclear how 
cells deliver APT1 (and not APT2) to mitochondria, since there is no mitochondrial 
targeting sequence. 
Given this critical information, the next step would be to characterize 
mitochondrial function of APT1. Since mitochondria are enriched unique lipid classes, 
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APT1 could potentially regulate lipid homeostasis and also depalmitoylate proteins. To 
test this hypothesis, one could perform an in-depth metabolomics experiment with 
purified mitochondria after knockdown or knockout of APT1. Perhaps APT1 acts on 
palmitoyl carnitine, which cells use to transfer palmitoyl moieties from cytoplasm to the 
mitochondrial matrix. Since APT1 was originally identified as a lysophospholipase, it 
could easily be carrying out esterase activity with various substrates in mitochondria. 
Similarly, one could perform APT1 substrate profiling experiment with purified 
mitochondrial proteome. Nonetheless, it is intriguing to find that a number of 
mitochondrial proteins are constantly enriched in palmitoylome data sets. It would be 
interesting to study which enzymes, if any, catalyze palmitoylation in mitochondria, 
especially since there are no reported mitochondrial zDHHCs enzymes. Overall, APT1 
localization in mitochondria disputes numerous reports claiming that APT1 is a major 
depalmitoylase for a protein of interest. Perhaps the apparent depalmitoylase activity of 
APT1 could be due to altered lipid metabolic pathways induced from knockdown or 
inhibition of APT1. A series of future experiments mentioned above would address this 
hypothesis. 
Once any substrates of APT1 are identified in mitochondria, another series of 
future studies should address regulatory factors affecting the localization or activity of 
the APTs. In our affinity proteomics experiments (Chapter 3), we did not identify any 
stable APT interacting proteins, suggesting any mitochondrial import mechanism may 
occur through transient, low affinity interactions. To overcome this obstacle, I propose to 
employ unnatural amino acid photo-crosslinking strategies, followed by mass 
spectrometry to identify the interacting proteins upon perturbations. Here we could use 
the crystal structures as a guide to genetically engineer APTs to incorporate unnatural 
amino acids such as p-benzoyl-L-phenylalanine in proximity to the active sites or 
potential binding sites without affecting the catalytic activity. This may include b4-b5 
motif, which is proximal to both the active site and candidate substrate groove (Figure 
1.5 and 5.1). This motif is unique to APTs and shows a varying degree of conservation 
between the two enzymes. Furthermore, this motif is in proximity to the lipidated N-
terminus, thus potentially interacts with substrates near the membrane. A high 
throughput in vitro screening may be necessary to show that such modification does not 
 98 
significantly alter the activity of the enzyme. Another point of interest is the groove 
spanning from the active site of each enzyme (Figures 2.15 and 5.1), which may 
accommodate the peptide portion of acylated substrates. 
 
Figure 5.1 Proposed areas of unnatural amino acid incorporation for protein-protein interaction studies. 
The red boxes indicate potential sites of mutagenesis for the photo-crosslinking studies. 
 
It would also be useful to solve crystal structures of APTs bound to 16-carbon 
fluorophosphonate derivatives. This would confirm structural effects imparted by lipid 
engagement, and potentially help determine the exact site of protein-substrate binding. 
Additionally, it would be useful to get a better understanding of APT substrates. To 
accomplish this, I propose synthesis of acylfluorophosphonate derivatives linked to a 
series of different peptide sequences attached to the fluorophosphonate ethoxy group 
(Figure 1.3). Optimal sequences will react faster, and can be deconvoluted by mass 
spectrometry of purified APT enzyme. This would allow us to assay substrate selectivity 
across different enzymes. This library may include partial sequences of reported 
substrates of APTs such as Scrib or any other top hits from the photo-crosslinking 
enrichment assays. Alternatively, it may have C-terminus region of NRas as a negative 
control. Through activity-based high-throughput screening, we may also identify 
differential sequences preferred by APT1 and APT2, respectively. Overall, these 
strategies have potential to highlight molecular mechanism for distinct function of APT1 
and APT2. The photo-crosslinking method may also highlight how APT1 is transferred 
to mitochondria if we identify mitochondrial protein translocation machinery. 
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Furthermore, we cannot rule out the possibility that APTs may be regulated 
themselves by posttranslational modifications, including S-palmitoylation. For example, 
Cys2 of APTs have been reported to be palmitoylated.60 This modification likely 
enhances localization to the periphery of the membrane compartments to engage 
different substrates. If so, it would be interesting to study which zDHHCs catalyze APT 
S-palmitoylation and test if same zDHHCs process both APT1 and APT2. If different 
zDHHCs catalyze S-acylation on APT1 and APT2, it might suggest different lengths of 
acyl modifications, which might alter subcellular distribution and function. Also, one 
could address why only a fraction of APTs are S-palmitoylated. This N-terminally 
proximal S-palmitoylation is not critical for the catalytic activity, but may impart select 
localization that mediates responses to signaling events or potentially differentiates 
substrates. For instance, a number of studies suggest an increased level of 
depalmitoylation upon extracellular signaling activity.25, 48, 76 Although it is possible that 
this could be due to conformational change in the substrate (exposing thioester), such 
complexity is unlikely to rise if APTs were not regulated. 
To test this hypothesis, we could develop selective activity-based probes of 
APT1 and APT2. This approach maybe analogous to the proposed photo-crosslinking 
experiments, but it would enable precise localization studies. Through ML349 profiling 
experiment, I showed that isoform-selective APT inhibitors can be functionalized and 
optimized. Therefore, further development of functional and selective chemical probes 
of both APTs may help interrogate biological functions. This would enable the capture of 
APTs in situ upon various signaling changes as studies have suggested. For instance, 
one study saw APT activity increase upon EGF stimulation with the activity-based 
fluorescence probe.102 While this probe is useful to capture the live cell images, it is still 
promiscuous, especially with a fractional sensitivity to APT knockdowns. The next 
generation of probe could include a reactive carbamate group or triazole urea and with 
a clickable handle on the other end (methoxy group for ML349 and furanyl group for 
ML348) to be conjugated with a fluorescent moiety. The design of the probe could be 
structure guided, mimicking ML348/349 in order to increase the selectivity. If such probe 
could be made, it may answer the remaining questions such as where are the APTs 
activated? Are they constitutively active? How is APT1 transported to mitochondria? 
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Altogether, these probes could dissect the differential function of APTs through 
visualizing spatiotemporal localization of active APTs, which would also significantly 
corroborate protein-protein interaction study described above. 
Overall, any future studies of APTs should be directed towards investigating the 
cellular function of these enzymes. Clearly APTs have some functional effect in 
signaling pathway models (EGFR, Scrib etc.). The biochemical analysis is limited due to 
redundant functions of multiple serine hydrolases and it may be very time consuming to 
develop a probe that are only selective for the APTs. To get a big picture of the role of 
these enzymes, one could study protein-protein interaction experiments to characterize 
which proteins have affinity for APTs upon perturbations. This approach could 
potentially layout a cellular map of how these enzymes are able to respond to various 
cellular signaling events, if any, and the regulatory mechanism for their functional 
orthogonality. 
 
Future directions towards understanding dynamic S-palmitoylation 
In Chapter 4, I present a temporal pulse labeling strategy to reveal proteins with 
various rates of acylation. This data suggests some proteins are more efficiently S-
palmitoylated than others, presumably since they are better substrates for select 
zDHHC enzymes. Both acyl-RAC and 17-ODYA profiling have not yielded conclusive 
profiles of select zDHHC substrates, perhaps due to compensatory activity of other 
closely related DHHCs. Many reports identify 2 or more zDHHCs as candidate 
acyltransferases for a protein of interest.6, 142 Therefore, in single zDHHC knockout 
studies, temporal pulse labeling may overcome compensatory effects from other 
zDHHC enzymes, providing a kinetic approach to map select substrates. One caveat 
remains that DHHCs have different acyl chain length preferences4, which could bias the 
overall results. To overcome this, one would repeat the experiments with varying chain 
lengths of the alkynyl fatty acids. 
Alternatively, one could adapt strategies like bump-hole pairs to design a probe 
unique to an engineered zDHHC of interest.166 Then the probe would be incorporated 
into various substrates or interaction partners, which can be enriched and identified. 
This engineering process could be guided by the crystal structures of DHHCs as recent 
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crystal structure of zDHHC20 and zDHHC15 revealed determinant of acyl-chain length 
selectivity.166 Collectively, a future study could incorporate acyl-CoA probe with a photo-
crosslinking moiety that would selectively fit in the engineered zDHHC to profile and 
enrich novel interacting partners in an analogous fashion to the temporal pulse labeling 
strategy (Figure 5.2). For instance, bulky residues lining the acyl-channel such as 
W158, F174, or F220 in zDHHC20 could be replaced by alanine or glycine to 
accommodate diazirine moiety. One potential pitfall of this approach is that the designed 
probe could still be promiscuous. To increase selectivity, non-conserved residues could 
be mutated and the probe could include bulkier functional handles such as cyclooctyne 
derivatives or other polar handles to promote unique interaction with the soluble domain 
of the zDHHC. Any optimization would require an in vitro assay for zDHHC acyl 
transferase activity. This may include competitive enzymatic assay with a native 
substrate, palmitoyl-CoA, followed by a conjugation with a fluorescent dye upon 
denaturation of the enzyme. Overall, this strategy would not only identify substrates of 
zDHHCs but also reveal the molecular network of enzyme-substrate interactions. 
 
Figure 5.2 Schematic of temporal pulse labeling to profile substrates of zDHHCs 
Crystal structure of hDHHC20. The catalytic residues are highlighted in cyan and 2-bromopalmitate (black) is 
covalently linked to catalytic Cys156 to mimic palmitate binding. The structural zinc molecules are shown as pink 
spheres. Green circle indicates potential sites of mutagenesis to uniquely fit engineered Acyl-CoA probe with a photo-
crosslinking potential. Adapted from PDB:6BML 
 
In the current study, we did not address which enzymes are responsible for the 
significant boost in S-acylation levels in the HDFP treated cells. The most likely 
candidates are ABHD17 enzymes since they are highly potent targets of HDFP and 
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multiple inhibition of other serine hydrolases did not reproduce HDFP-dependent 
results. However, since there are no selective inhibitors of ABHD17s we could not test 
this hypothesis. ABHD17s are worth deeper investigation, because they are more likely 
to be the major depalmitoylases than APTs for two major reasons. First, unlike APTs, 
these are known to be predominantly plasma membrane associated just like the 
majority of palmitoylated substrates. Second, genetic knockout of these enzymes has 
been reported to reduce the viability of cancer cells, indicating that they are likely to 
participate in regulation of key pathways for survival. Since these enzymes are reported 
to be Ras depalmitoylases, developing selective inhibitors would be therapeutically 
valuable in addition to studying the overall function.  
However, any effort to develop ABHD17 inhibitors will be hampered in the 
absence of any structure. Thus, to gain deeper mechanistic understanding of these 
enzymes, a future study could solve crystal structures of ABHD17s bound to HDFP. Not 
only would these structures highlight acyl-binding channel but also residues or motifs 
critical for the activity. Since ABHD17 enzymes harbor multiple S-palmitoylation sites in 
their N-terminal domain, they are challenging to express in bacterial recombinant 
expression systems. In order to purify fully S-palmitoylated enzyme, it might be better to 
optimize expression in the eukaryotic cell lines with detergents. Nonetheless, it is 
unclear whether the palmitoylated N-terminus region is critical for the overall function of 
the enzyme. One could validate this by purifying the truncated versions or alanine 
mutants within the cysteine-rich domain. Meanwhile, activity-based high-throughput 
screening assays against a library of compounds would enable search for the lead 
inhibitors. Altogether, studying molecular details of ABHD17s would provide direct 
evidence for the substrate preferences as well as an opportunity to chemically modulate 
the activity of the enzyme. 
To unravel global contribution of ABHD17s as depalmitoylases, a future study 
might use an inducible knock-down system to target ABHD17s, followed by temporal 
metabolic pulse profiling with 17-ODYA. However, one issue of temporal profiling 
analysis is that the method heavily relies on isobaric tag labeling and lacks biological 
replicates of samples. Therefore, a significant number of kinetic profiles are prone to 
human errors and instrumental errors due to increased complexity. To overcome these, 
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a future study should validate kinetic profiles of interest with [3H]-palmitate temporal 
pulse labeling. If ABHD17 knock-down experiment mimics the results from the HDFP 
treated cells, it is a possibility that these enzymes could be regulating acyl-CoA levels in 
cells, thus globally contributing to the overall S-acylation status. To test this hypothesis, 
a future study could purify ABHD17s and carry out an in vitro enzymatic assay with 
palmitoyl-CoA. This study could build up to a metabolomics experiment, where we test 
the global level of palmitoyl-CoA upon knock-down of ABHD17s over a time course. 
Furthermore, it would be worthy to identify DHHC enzymes that palmitoylate ABHD17s. 
It may identify potential regulatory or trafficking mechanism of these major 
depalmitoylating enzymes, completing an overall picture of how cells establish dynamic 
S-acylation and S-deacylation cycle. 
Ultimately, what fraction of proteins in the palmitoylome are actually 
palmitoylated at a given time? If there are multiple palmitoylation in a single protein, are 
they all dynamically regulated? If these questions can be addressed, it would provide 
the most detailed global map of regulatory dynamic S-palmitoylation. Any future study 
should focus on profiling the exact sites of S-palmitoylation. However, the reported sites 
of labeling methods rely on acyl-RAC, where cleaved thioesters are captured on bead 
and eluted from the beads after washing out the majority tryptic peptides. This method 
may lead to a significant number of false positives and any dynamic changes could be 
hindered by abundant steady state pool of palmitoylated sites. To overcome these 
difficulties, one could first label cells with 17-ODYA, then click with azido-diazo-biotin to 
enrich proteins with 17-ODYA incorporation. The captured peptides would be eluted by 
cleavage of the diazo moiety33, leaving unique signatures on the captured peptides, 
which would represent the dynamic sites of palmitoylation. However, there would be a 
lot of steps involved in the procedure and the recovery or the coverage in the proteome 
could be very poor. Ultimately, it would be beneficial to develop liquid chromatography 
and mass spectrometry techniques to directly detect palmitoylation. The challenge here 
is that most of the hydrophobic peptides are lost during the sample purification 
procedure and the standard columns coupled to mass spectrometer are not optimized 
for the separation of hydrophobic moieties. Furthermore, since palmitoylation represents 
only minor fraction of proteome, in-depth software analyses are needed to precisely 
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quantify modifications. If these difficulties can be overcome, this approach would directly 
bypass chemical labeling procedures, which could potentially perturb native biological 
environment, as well as any loss of proteins during long procedures of sample 
preparation. Our lab is currently developing this technique and it would be beneficial to 
the field. 
Overall, temporal pulse labeling revealed dynamic acylation rate of various 
proteins. The acylation rate is amplified following thioesterase inhibition, and highlights 
proteins with accelerated dynamics. This pulse-labeling approach has potential for 
direct analysis of acylation kinetic profiles following selective knockout or through 
incorporation of unique acyl-CoA derivatives. These approaches overcome inherent 
limitations in previous methods to identify the most likely physiological substrates. 
Similarly, gaining mechanistic insight of ABHD17s and their substrate profiles would 
provide a detailed molecular map of how cells modulate S-palmitoylation to regulate 
essential biological processes. Collectively, proposed future studies here will establish 
the most quantitative profiles of dynamic S-palmitoylation and identify potential 
therapeutic targets implicated in disease models.  
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 106 
Appendix A: Synthesis and Purification Procedure of Chemicals Presented in 
Chapter 2 
 
General chemical synthesis and purification procedure. 
Compounds were purified by normal phase silica-gel flash column chromatography or 
Waters High Performance Liquid Chromatography system using a 1525 Binary Pump 
coupled to an Atlantis T13 C18 column and 2988 Photodiode Array detector. NMR 
spectra were acquired on a Varian 400 MHz instrument and processed using 
Mestrenova software. High-resolution mass spectrometry (HRMS) analysis was 
performed using Agilent Q-TOF mass spectrometer. Synthetic schemes are shown in 
Figure A.1 and A.2. 
Synthesis of ML348. N-(2-chloro-5-(trifluoromethyl)phenyl)-2-(4-(furan-2-
carbonyl)piperazin-1-yl)acetamide. Synthesized as described previously83. 250 mg, 
86% yield. 1H NMR (400 MHz, Chloroform-d) δ 9.99 (s, 1H), 8.75 (s, 1H), 7.42 (t, J = 4.2 
Hz, 2H), 7.21 (d, J = 8.2 Hz, 1H), 6.94 (d, J = 3.5 Hz, 1H), 6.41 (dd, J = 3.5, 1.8 Hz, 1H), 
3.84 (s, 4H), 3.19 (s, 2H), 2.66 (s, 4H). HRMS (ESI positive): Calculated m/z [M+H] + = 
416.0983, observed m/z [M+H] += 416.0989 
Synthesis of ML349, ML349-sulfoxide, ML349-thioether.  
 107 
 
Figure A.1 General synthetic scheme of ML349 derivatives 
Synthesized as described previously with modifications83, 167. (a) Phosphorous oxychloride (POCl3), dimethylformide 
(DMF), 30 min 5 °C then 2 hours at 80 °C, sodium acetate. (b) sodium ethanolate, ethanol, 0 °C then room 
temperature 16 hours. (c) Sodium hydroxide, methanol, 60 °C, 16 hours. (d) m-CPBA, dichloromethane (DCM), room 
temperature, 3 hours. (e) peracetic acid, 1 hour. (f) 1-(4-methoxyphenyl)piperazine, HBTU, DIPEA, DCM, 16 hours, 
room temperature. 
 
Synthesis of ML349-thioether. (4-(4-methoxyphenyl)piperazin-1-yl)(4H-thieno[3,2-
c]thiochromen-2-yl)methanone. POCl3 (0.8 mL, 1.14 eq.) was added drop-wise to ice-
cold anhydrous DMF (5 mL), followed by drop-wise addition of 1 (0.8 mL, 1 eq.). The 
reaction mixture was stirred for 30 minutes on ice, heated to 80 °C for 2 hours, and 
quenched with 3 mL of ice-cold aqueous sodium acetate (25%). The crude sample was 
extracted twice with diethyl ether, and the organic fractions were pooled, washed with 
brine, dried over sodium sulfate, and concentrated to yield compound 2 (brown oily 
liquid). This compound was slowly added to a mixture of ice-cold ethylthioglycolate (0.2 
mL, 1 eq.), sodium ethoxide (1.5 mL, 2 eq.) and anhydrous ethanol. The reaction 
mixture was stirred for 16 hours at room temperature and then heated to 80 °C for 2 
hours. The crude sample was extracted with ethyl acetate several times, washed with 
brine, and dried over sodium sulfate. The crude mixture was purified by flash column 
chromatography (20% ethyl acetate : 80% hexanes), yielding compound 3 (300 mg, 
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54% yield). Next, compound 3 (92 mg, 1 eq.) was saponified with sodium hydroxide (24 
mg, 2 eq.) in methanol overnight at 60 °C. After removing the solvent with a rotary 
evaporator, the concentrate was extracted with ethyl acetate to remove any starting 
material. 6 N HCl was then added to the aqueous mixture, precipitating a white solid. 
The solid was extracted with ethyl acetate, washed with brine, dried under sodium 
sulfate, and concentrated using a rotary evaporator to yield compound 4 (60 mg, 81% 
yield). Compound 4 (20 mg, 1 eq.) was mixed with HBTU (100 mg, 3 eq.), DIPEA (0.03 
mL, 2 eq.), 1-(4-methoxyphenyl)piperazine (Sigma, 14 mg, 1 eq.) in DCM for 16 hours 
at room temperature. The solvent was evaporated and the crude mixture was extracted 
with dichloromethane (DCM). The organic portion was pooled, washed with brine and 
dried under sodium sulfate. The sample was purified using flash column 
chromatography (5% methanol: 95% DCM) to yield ML349-thioether (25 mg, 69% 
yield). 1H NMR (401 MHz, Chloroform-d) δ 7.46 – 7.41 (m, 1H), 7.35 – 7.32 (m, 1H), 
7.17 – 7.13 (m, 2H), 7.11 (s, 1H), 6.94 (d, J = 8.6 Hz, 2H), 6.87 – 6.82 (m, 2H), 3.93 (d, 
J = 9.6 Hz, 6H), 3.76 (s, 3H), 3.12 (t, J = 5.0 Hz, 4H). HRMS (ESI positive): Calculated 
m/z [M+H]+ 423.1195, observed m/z  [M+H]+= 423.1194 
Synthesis of ML349-sulfoxide. (4-(4-methoxyphenyl)piperazin-1-yl)(5-oxido-4H-
thieno[3,2-c]thiochromen-2-yl)methanone. Compound 3 (90 mg, 1 eq.) from ML349-
thioether synthesis was treated with m-CPBA (1 eq. 78 mg) in 20 mL of DCM and 
stirred for 3 hours at room temperature. The reaction mixture was extracted with DCM, 
the organic layer was pooled, treated with similar procedures as above, and purified by 
flash column chromatography (5% methanol: 95 % DCM) to yield compound 5 (105 mg, 
80% yield). This compound was saponified to yield compound 6 (20 mg, 23% yield) and 
coupled with 1-(4-methoxyphenyl)piperazine as described above to yield ML349-
sulfoxide (11 mg, 37% yield). 1H NMR (400 MHz, Chloroform-d) δ 7.45 – 7.24 (m, 4H), 
7.18 – 7.07 (m, 1H), 6.95 – 6.78 (m, 4H), 3.90 (d, J = 6.2 Hz, 3H), 3.73 (s, 4H), 3.53 (s, 
2H), 3.09 (t, J = 5.1 Hz, 4H). HRMS (ESI positive): Calculated m/z [M+H] + = 438.1072, 
observed m/z [M+H] += 438.1010. 
Synthesis of ML349. (5,5-dioxido-4H-thieno[3,2-c]thiochromen-2-yl)(4-(4-
methoxyphenyl)piperazin-1-yl)methanone. Compound 3 (90 mg, 1 eq.) from ML349-
thioether synthesis was treated with peracetic acid (0.7 mL, 1 eq.) in 10 mL of DCM for 
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1 hour at room temperature. The reaction mixture was quenched with dimethyl sulfide in 
drop-wise fashion. The crude mixture was extracted with DCM. The organic portion was 
pooled and purified using flash column chromatography (5% methanol: 95% DCM) to 
yield compound 7 (70 mg, 70% yield). This compound was saponified to yield 
compound 8 (27 mg, 42% yield) and coupled with 1-(4-methoxyphenyl)piperazine as 
described above to yield the final product, ML349 (28 mg, 68% yield). 1H NMR (400 
MHz, Chloroform-d) δ 8.03 – 7.99 (m, 1H), 7.62 (dtd, J = 15.4, 7.8, 1.4 Hz, 2H), 7.55 – 
7.47 (m, 1H), 7.20 (s, 1H), 6.92 (d, J = 9.0 Hz, 2H), 6.87 – 6.81 (m, 2H), 4.42 (s, 2H), 
3.91 (t, J = 5.1 Hz, 3H), 3.11 (t, J = 5.1 Hz, 8H). 13C NMR (100 MHz, CDCl3) δ 162.11, 
154.66, 137.27, 136.19, 133.93, 133.55, 130.02, 129.86, 129.23, 127.85, 125.82, 
124.20, 119.09, 114.56, 55.54, 51.27, 51.15. HRMS (ESI positive): Calculated m/z 
[M+H] + = 455.1094, observed m/z [M+H] += 455.1097. 
Synthesis of ML349-FL. 4-((2-(2-(2-(2-(4-((4-(4-(5,5-dioxido-4H-thieno[3,2-
c]thiochromene-2-carbonyl)piperazin-1-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-2-(6-hydroxy-3-oxo-9,9a-dihydro-3H-
xanthen-9-yl)benzoic acid. Compound 9 (900 mg, 1 eq) was treated with di-tert-butyl 
dicarbamate (1.1 mL, 1 eq.) in methanol for 12 hours. The contents were extracted with 
ethyl acetate, washed with brine, and dried over sodium sulfate. The samples were 
concentrated under vacuum to yield compound 10 (1.3 g, 95% yield). Compound 10 
(250 mg, 1eq.) was treated with propargyl bromide (0.2 mL, 2 eq.) and potassium 
carbonate (300 mg, 2 eq.) in dimethylformamide (DMF). The mixture was stirred for 16 
hours at room temperature. The crude mixture was extracted with ethyl acetate several 
times before washing with brine and drying over sodium sulfate. The sample was further 
purified by flash column chromatography (1:1 ethyl acetate/hexanes) to yield compound 
11 (250 mg, 88% yield). Compound 11 (250 mg, 1 eq.) was treated with trifluoroacetic 
acid (TFA, 2.5 eq.) in dichloromethane (DCM) for 5 hours at 60º C reflux. The residual 
TFA was boiled off and the sample was dried at high-vacuum and proceeded without 
further purification. The Boc-deprotected compound 11 was coupled with compound 8 
(220 mg, 1 eq.) in the mixture of HBTU (910 mg, 3 eq.), DIPEA (0.1 mL, 2 eq.) in DCM 
for 16 hours. The crude reaction mixture was extracted with DCM several times and 
purified with flash column chromatography (3% methanol: 97% DCM to yield compound 
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12 (300 mg, 78% yield). This compound was conjugated with 11-azido-3,6,9-
triozaunderdecan (Sigma, 0.013 mL, 1 eq.) in the presence of sodium ascorbate (3 mg, 
0.2 eq.) and catalytic amount of CuSO4 in DMSO for 16 hours. The crude mixture was 
subjected to HPLC to isolate compound 13 (100 mg, 22% yield). 1H NMR (401 MHz, 
Methanol-d4) δ 8.08 (s, 1H), 8.02 (d, J = 7.8 Hz, 1H), 7.80 – 7.74 (m, 2H), 7.63 (ddd, J = 
8.3, 6.3, 2.4 Hz, 1H), 7.48 (s, 1H), 7.02 – 6.94 (m, 4H), 5.13 (s, 2H), 4.67 (d, J = 7.7 Hz, 
2H), 4.61 (t, J = 5.0 Hz, 2H), 3.93 (dt, J = 13.3, 4.9 Hz, 6H), 3.68 – 3.56 (m, 12H), 3.16 
(t, J = 5.2 Hz, 4H), 3.09 (t, J = 5.1 Hz, 2H). Compound 13 (20 mg, 1 eq.) was coupled 
with NHS-Fluorescein (Thermo) (13 mg, 1 eq.) in the mixture of DMSO and a few drops 
of DIPEA. The mixture was stirred for 3 hours and purified by HPLC to yield ML349-FL 
(10 mg, 31% yield). HRMS (ESI negative): Calculated m/z [M-H] - = 1053.3034, 
observed m/z [M-H] -= 1053.2781 
 
Figure A.2 Synthetic scheme of ML349-FL 
(a) di-tert-butyl dicarbamate, methanol, 12 hours, room temperature. (b) propargyl bromide, potassium carbonate, 
DMF, 16 hours, room temperature. (c-1) TFA, DCM, 5 hours, 60 °C. (c-2) HBTU, DIPEA, DCM, 16 hours, room 
temperature. (d) 11-azido-3,6,9-triozaunderdecan, sodium ascorbate, CuSO4, DMSO, 16 hours, room temperature. 
(e) NHS-Fluorescein, DMSO, DIPEA, room temperature, 3 hours. 
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Appendix B: Synthesis and Purification Procedure of Chemicals Presented in 
Chapter 3 
 
General chemical synthesis and purification procedures. All compounds were 
purchased from Sigma-Aldrich, unless otherwise noted and were of the highest purity 
available. NMR analysis was performed using a Varian 400 MHz NMR instrument. NMR 
integrations and coupling constants were computed using MestreNova. Small molecule 
high-resolution mass spectrometry was performed using an electrospray Agilent Q-TOF 
mass spectrometer (accuracy 1-5 ppm) and analyzed using the Agilent MassHunter 
software suite. Low-resolution mass spectrometry was performed using an electrospray 
Micromass LCT time-of-flight mass coupled to a HPLC pump with a rheodyne loop 
injector. Compounds were purified by normal phase flash silica-gel column 
chromatography or by semi-prep High-Performance Column Chromatography (HPLC). 
HPLC purifications were performed using a Waters semi-preparative 1525 binary pump 
system coupled to a photodiode array detector, an autosampler, and an automatic 
fraction collector. Separations were carried out on using the Waters Atlantis prep T3 
C18 column (10 x 250 mm), in 95/5 water/acetonitrile 0.1% formic acid for 2 minutes, 
followed by a 40 min gradient increasing the mobile phase to 5/95 water/acetonitrile with 
0.1% formic acid. Data were analyzed using the Waters Empower software. Resulting 
HPLC fractions were lyophilized using a Labconco FreeZone2.5-Plus freeze-drying 
system. In-gel fluorescence was imaged using the GE Typhoon scanner. General 
synthetic scheme is shown in Figure B.1. 
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Figure B.1 ML349-Biotin synthesis scheme 
(a) Di-tert-butyl dicarbonate, methanol, 12 hours, room temperature. 90-95% yield. (b) propargyl bromide, potassium 
carbonate, DMF, 16 hours, room temperature. 80-92% yield. (c) TFA, DCM, 5 hours, 60 °C. 60-90% yield. (d) 
Compound 5, HBTU, DIPEA, DCM, 16 hours, room temperature. 40-54% yield. (e) 11-Azido-3,6,9-trioxaunderdecan-
1-amine, sodium ascorbate, CuSO4, DMSO, 16 hours, room temperature. (f) NHS-Biotin, DMSO, DIPEA, room 
temperature, 3 hours. 52%- 60% yield. 
 
Synthesis of ML349-biotin. N-(2-(2-(2-(2-(4-((4-(4-(5,5-dioxido-4H-thieno[3,2-
c]thiochromene-2-carbonyl)piperazin-1-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide. Compound 1 (Sigma, 900 mg, 1 eq) was treated with di-tert-butyl 
dicarbamate (1 eq.) in methanol for 12 hours. The contents were extracted with ethyl 
acetate, washed with brine, and then dried over sodium sulfate. The samples were 
concentrated under vacuum to yield compound 2, tert-butyl 4-(4-
hydroxyphenyl)piperazine-1-carboxylate (1.3 g, 95 % yield) . 1H NMR (400 MHz, CDCl3) 
δ 6.82 (ddd, J = 36.0, 9.8, 3.0 Hz, 4H), 3.74 – 3.48 (m, 4H), 3.07 – 2.95 (m, 4H), 1.48 (s, 
9H). 13C NMR (100 MHz, CDCl3) δ 155.0, 151.0, 119.4, 116.1, 80.3, 77.5, 77.2, 76.9, 
51.4, 28.6. Compound 2 (125 mg) was treated with propargyl bromide (2 eq.) and 
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potassium carbonate (2 eq.) in dimethylformamide (DMF). The mixture was stirred for 
16 hours at room temperature. The crude mixture was extracted with ethyl acetate 
several times before washing with brine and drying over sodium sulfate. The sample 
was further purified by flash column chromatography (1:1 ethyl acetate/hexanes) to 
yield compound 3, tert-butyl 4-(4-(prop-2-yn-1-yloxy)phenyl)piperazine-1-carboxylate 
(130 mg, 92 % yield) 1H NMR (400 MHz, CDCl3) δ 6.83 – 6.73 (m, 4H), 4.50 (d, J = 2.5 
Hz, 2H), 3.50 – 3.42 (m, 4H), 2.93 – 2.85 (m, 4H), 2.47 (t, J = 2.4 Hz, 1H), 1.39 (s, 9H). 
13C NMR (100 MHz, CDCl3) δ 154.2, 151.7, 146.0, 118.2, 115.4, 79.3, 56.0, 50.2, 28.1. 
The compound 3 (1 eq.) was treated with trifluoroacetic acid (TFA, 2.5 eq.) in 
dichloromethane (DCM) for 5 hours at 60 ºC reflux. The residual TFA was boiled off and 
the sample was dried at high-vacuum to yield compound 4 (87 mg, 90 % yield) and 
continued without further purification. Synthesis of compound 5 was previously 
described103, and an aliquot of the characterized product was used here. Compound 4 
(50 mg, 1 eq.) was coupled with compound 5 (1 eq.) by using HBTU (Sigma, 3 eq.), 
DIPEA (Sigma, 2 eq.), and DMF as solvent. The reaction mixture was stirred for 16 
hours at room temperature and the crude mixture was extracted with DCM several 
times, followed by a brine wash and sodium sulfate treatment to remove excess polar 
materials. The sample was further purified by flash column chromatography (40 % ethyl 
acetate: 60 % hexanes) to yield compound 6, (5,5-dioxido-4H-thieno[3,2-c]thiochromen-
2-yl)(4-(4-(prop-2-yn-1-yloxy)phenyl)piperazin-1-yl)methanone (46 mg, 54 % yield) 1H 
NMR (400 MHz, CDCl3) δ 8.05 (d, J = 7.8 Hz, 1H), 7.72 – 7.49 (m, 3H), 7.23 (s, 1H), 
6.97 (t, J = 10.9 Hz, 4H), 4.66 (d, J = 2.4 Hz, 2H), 4.45 (s, 2H), 3.99 (s, 4H), 3.19 (s, 
4H), 2.52 (t, J = 2.4 Hz, 1H). 13C NMR (100 MHz, CDCl3) δ 162.2, 134.0, 133.6, 130.0, 
129.3, 127.9, 125.8, 124.2, 115.9, 56.3, 51.2. The alkynyl portion of compound 6 (30 
mg, 1 eq.) was conjugated with 11-Azido-3,6,9-trioxaundecan-1-amine (Sigma, 1 eq.) 
via Copper(I)-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) with CuSO4 (catalytic 
amount) and sodium ascorbate (0.2 eq.) in DMSO for 16 hours at 50 °C. The crude 
mixture was purified by HPLC and then lyophilized to yield the intermediate product with 
free amine at the end of the linker, (4-(4-((1-(2-(2-(2-(2-
aminoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)piperazin-1-
yl)(5,5-dioxido-4H-thieno[3,2-c]thiochromen-2-yl)methanone, (31 mg, 70% yield) 1H 
 114 
NMR (401 MHz, Methanol-d4) δ 8.08 (s, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.80 – 7.73 (m, 
2H), 7.62 (ddd, J = 8.3, 6.3, 2.4 Hz, 1H), 7.47 (s, 1H), 7.04 – 6.92 (m, 4H), 5.12 (s, 2H), 
4.67 (d, J = 7.7 Hz, 2H), 4.60 (t, J = 5.0 Hz, 2H), 3.92 (dt, J = 13.3, 4.9 Hz, 5H), 3.71 – 
3.54 (m, 11H), 3.12 (dt, J = 24.8, 5.1 Hz, 6H). This product was treated with Biotin-NHS 
ester (15 mg, Click Chemistry Tools), DIPEA (2 eq.) in DMSO for 16 hours at room 
temperature. The resulting crude mixture was purified by HPLC to yield ML349-biotin 
(22 mg, 52 % yield).  
Final Product (Figure B.2): 1H NMR (400 MHz, Chloroform-d) δ 8.02 (d, J = 7.8 Hz, 
1H), 7.85 (s, 1H), 7.64 (dt, J = 15.7, 7.6 Hz, 2H), 7.53 (t, J = 7.5 Hz, 1H), 7.28 (s, 1H), 
6.94 (s, 4H), 5.14 (s, 2H), 4.54 (t, J = 4.9 Hz, 2H), 4.47 (s, 2H), 4.26 (d, J = 6.1 Hz, 1H), 
4.02 – 3.82 (m, 6H), 3.67 – 3.45 (m, 11H), 3.37 (q, J = 5.2 Hz, 2H), 3.12 (d, J = 20.1 Hz, 
5H), 2.91 – 2.78 (m, 1H), 2.16 (t, J = 7.5 Hz, 2H), 1.58 (ddt, J = 31.9, 11.7, 6.5 Hz, 5H), 
1.40 (dt, J = 15.0, 7.0 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 173.3, 164.1, 162.2, 
136.3, 134.0, 133.6, 130.1, 130.1, 130.1, 129.3, 128.1, 125.9, 124.2, 115.7, 77.2, 70.5, 
70.4, 70.1, 69.9, 69.4, 62.4, 61.8, 60.2, 55.6, 51.2, 50.4, 40.6, 39.1, 35.9, 28.3, 28.1, 
25.6. C43H54N8O9S3, HRMS (ESI positive), [M+H] predicted m/z: 923.3249, found 
923.3232. HPLC purity: 99% (Figure B.3). 
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Figure B.2 1H NMR of Ml349-Biotin 
 
Figure B.3 HPLC analysis of ML349-Biotin 
Synthesis of ortho-ML349-biotin. N-(2-(2-(2-(2-(4-(2-(4-(5,5-dioxido-4H-thieno[3,2-
c]thiochromene-2-carbonyl)piperazin-1-yl)phenoxy)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)-5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide. Synthesized as described above but used 2-(piperazin-1-yl)phenol (50 
mg) during step (a). Intermediate compound 2, tert-butyl 4-(2-hydroxyphenyl)piperazine-
1-carboxylate, (60 mg, 90% yield) 1H NMR (400 MHz, CDCl3) δ 7.10 – 6.96 (m, 2H), 
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6.89 (dd, J = 8.0, 1.5 Hz, 1H), 6.78 (td, J = 7.6, 1.5 Hz, 1H), 3.52 (t, J = 5.0 Hz, 4H), 
2.75 (t, J = 5.0 Hz, 4H), 1.45 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 154.6, 151.2, 138.7, 
126.3, 121.1, 120.0, 114.4, 79.8, 52.2, 44.3, 28.4. Intermediate compound 3, tert-butyl 
4-(2-(prop-2-yn-1-yloxy)phenyl)piperazine-1-carboxylate, (20 mg, 60% yield) 1H NMR 
(400 MHz, CDCl3) δ 6.99 – 6.87 (m, 4H), 4.72 (d, J = 2.4 Hz, 2H), 3.57 (t, J = 5.0 Hz, 
4H), 2.98 (t, J = 5.0 Hz, 4H), 2.50 (t, J = 2.4 Hz, 1H), 1.46 (s, 9H). Intermediate 
compound 6, (5,5-dioxido-4H-thieno[3,2-c]thiochromen-2-yl)(4-(2-(prop-2-yn-1-
yloxy)phenyl)piperazin-1-yl)methanone,(13 mg, 40% yield)1H NMR (400 MHz, CDCl3) δ 
8.04 (dt, J = 8.2, 2.4 Hz, 1H), 7.65 (dtd, J = 15.0, 7.8, 1.3 Hz, 2H), 7.54 (td, J = 7.6, 1.5 
Hz, 1H), 7.23 (s, 1H), 7.15 – 6.97 (m, 4H), 4.79 (d, J = 2.4 Hz, 2H), 4.44 (d, J = 5.2 Hz, 
2H), 4.14 – 3.91 (m, 4H), 3.25 (d, J = 23.1 Hz, 4H), 2.54 (t, J = 2.4 Hz, 1H). 
Intermediate compound before coupling with NHS-biotin, (4-(2-((1-(2-(2-(2-(2-
aminoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)phenyl)piperazin-1-
yl)(5,5-dioxido-4H-thieno[3,2-c]thiochromen-2-yl)methanone, (12 mg, 65% yield) 1H 
NMR (400 MHz, Methanol-d4) δ 8.03 (t, J = 8.0 Hz, 1H), 7.94 (s, 1H), 7.70 – 7.59 (m, 
2H), 7.52 (t, J = 7.2 Hz, 1H), 7.31 (s, 1H), 7.09 – 6.88 (m, 4H), 5.26 (d, J = 3.7 Hz, 2H), 
4.69 – 4.43 (m, 4H), 3.91 (p, J = 5.0 Hz, 6H), 3.79 – 3.46 (m, 9H), 3.37 (p, J = 5.1 Hz, 
2H), 3.14 (d, J = 5.8 Hz, 5H).  
Final product (Figure B.4): (9 mg, 60% yield). 1H NMR (400 MHz, Chloroform-d) δ 
8.18 – 7.98 (m, 2H), 7.85 (m, J = 20.2 Hz, 1H), 7.72 – 7.51 (m, 3H), 7.05 (m, J = 34.3 
Hz, 4H), 5.28 (s, 2H), 4.67 – 4.21 (m, 6H), 3.93 (m, J = 36.5 Hz, 6H), 3.71 – 3.06 (m, 
17H), 2.93 – 2.58 (m, 3H), 2.17 (s, 1H), 1.53 (d, J = 90.0 Hz, 6H). C43H54N8O9S3, HRMS 
(ESI positive), [M+H] predicted m/z: 923.3249, found 923.3242. HPLC purity: 99% 
(Figure B.5). 
 117 
 
Figure B.4 1H NMR analysis of ortho-ML349-biotin 
 
Figure B.5 HPLC analysis of ortho-ML349-biotin 
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